var title_f4_63_5104="Hemodynamics in cirrhosis";
var content_f4_63_5104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pathogenic mechanisms responsible for the activation of vasoactive systems and hyperdynamic circulation in cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 616px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5104=[""].join("\n");
var outline_f4_63_5104=null;
var title_f4_63_5105="Halometasone: International drug information";
var content_f4_63_5105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Halometasone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Sicorten (AT, BE, CH, CZ, DE, ES, HU, LU, NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of steroid responsive skin disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Cream: 0.05% (10 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Ointment, topical: 0.05% (30 g)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10390 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-F17749F6BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5105=[""].join("\n");
var outline_f4_63_5105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323399\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978953\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978956\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978952\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821059\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978955\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10390\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10390|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_63_5106="Patient information: Dermatomyositis (The Basics)";
var content_f4_63_5106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"27\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/47/30450\">",
"         Patient information: Polymyositis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/11/26804\">",
"         Patient information: Myositis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dermatomyositis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dermatomyositis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12382112\">",
"      <span class=\"h1\">",
"       What is dermatomyositis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dermatomyositis (DM) is a condition that causes muscle weakness and skin rashes. In DM, the muscles and skin get inflamed. Doctors don&rsquo;t know what causes DM.",
"     </p>",
"     <p>",
"      DM is more common in adults, but it can also happen in children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12382127\">",
"      <span class=\"h1\">",
"       What are the symptoms of dermatomyositis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;DM causes:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Muscle weakness &ndash; The weakness affects both sides of the body and usually happens slowly over time. It involves muscles closest to the trunk of the body, such as those in the neck, shoulders, hips, and thighs. Depending on the muscles involved, people with DM can have trouble climbing stairs, lifting things overhead, or swallowing.",
"       </li>",
"       <li>",
"        Skin rashes &ndash; DM causes different kinds of skin rashes on different parts of the body. The rashes are red, sometimes scaly, and usually very itchy. Sunlight usually makes the rashes worse. People can get rashes on their:",
"       </li>",
"       <li>",
"        Fingers, including on the backs of the finger joints and around the finger nails",
"       </li>",
"       <li>",
"        Elbows and knees",
"       </li>",
"       <li>",
"        Upper eyelids",
"       </li>",
"       <li>",
"        Neck, upper chest, or upper back",
"       </li>",
"       <li>",
"        Scalp",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12382142\">",
"      <span class=\"h1\">",
"       Is there a test for dermatomyositis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will order 1 or more of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Electromyography, or &ldquo;EMG&rdquo; &ndash; This test shows whether your muscles are responding to the nerves&rsquo; electrical signals in the correct way.",
"       </li>",
"       <li>",
"        Muscle biopsy &ndash; For this test, the doctor takes a small sample of tissue from a muscle that is weak. Then another doctor looks at the sample under a microscope.",
"       </li>",
"       <li>",
"        Skin biopsy &ndash; For this test, the doctor takes a small sample of skin from your skin rash. Then another doctor looks at the sample under a microscope.",
"       </li>",
"       <li>",
"        An imaging test called an MRI scan &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12382157\">",
"      <span class=\"h1\">",
"       How is dermatomyositis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for DM involves different parts.",
"     </p>",
"     <p>",
"      The main treatment for DM includes medicines called steroids. Steroids help reduce inflammation. These steroids are different from the ones athletes take to build muscle.",
"     </p>",
"     <p>",
"      People with DM usually need to take steroids for a long time. But steroids have side effects of their own. They can make your bones weak and increase your chances of getting an infection. To avoid these side effects as much as possible, your doctor will slowly lower (or &ldquo;taper&rdquo;) your dose over time.",
"     </p>",
"     <p>",
"      If you can&rsquo;t take steroids, the steroids don&rsquo;t help enough, or your symptoms come back, your doctor can treat you with other medicines. These include medicines that calm your immune (infection-fighting) system.",
"     </p>",
"     <p>",
"      Your doctor will also give you medicines to help your skin symptoms and itching. Some of these medicines go on the skin. Others come as a pill.",
"     </p>",
"     <p>",
"      Other treatment for DM involves keeping your body as strong as possible and preventing further problems. This usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Working with a physical therapist (exercise expert) to learn exercises to strengthen your muscles",
"       </li>",
"       <li>",
"        Avoiding sunlight by wearing sunscreen, a wide-brimmed hat, long-sleeved shirt, and long pants",
"       </li>",
"       <li>",
"        Changing what and how you eat, if you have trouble swallowing or choke easily on your food",
"       </li>",
"       <li>",
"        Taking medicines to prevent side effects from the steroids",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12382172\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse. He or she will work with you to get your DM under control before you get pregnant. Plus, he or she will make sure your medicines are safe to take during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12382187\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your individual situation. Some people with DM have only mild symptoms. But many people have more bothersome symptoms that last years.",
"     </p>",
"     <p>",
"      DM can also cause other types of long-term medical problems. These include lung and heart problems, and a higher chance of getting cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12382202\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=see_link\">",
"       Patient information: Polymyositis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"       Patient information: Myositis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/63/5106?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82977 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5106=[""].join("\n");
var outline_f4_63_5106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12382112\">",
"      What is dermatomyositis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12382127\">",
"      What are the symptoms of dermatomyositis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12382142\">",
"      Is there a test for dermatomyositis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12382157\">",
"      How is dermatomyositis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12382172\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12382187\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12382202\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=related_link\">",
"      Patient information: Polymyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_63_5107="TTE vs TEE abscess aortic root";
var content_f4_63_5107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Aortic root abscess and mitral valve vegetations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis precordial view (panel A) from a transthoracic echocardiogram in a patient with clinical endocarditis and acute severe aortic regurgitation shows a deformed posterior aortic root and thickend anterior mitral leaflet (arrow), which are nonspecific. The transesophageal echocardiographic views (panels B and C) show a vegetation of the mitral valve (arrow panel B) and a large abscess cavity of the aortic root (arrow, panel C).",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5107=[""].join("\n");
var outline_f4_63_5107=null;
var title_f4_63_5108="Secondary C cell hyperplasia";
var content_f4_63_5108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F85628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F85628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Secondary C cell hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3eyil07ThG+ZsNgsSfWoL7xJb6Qxjuijyu4VEjGXbPTipvEupPbalBZxp/rzjI7e9ZeoLDHqBvby2A+zr5gkC5z9amMVJ3mty3sdDdacdWtYzOzJHwwTHNMTTrqG4TZIjW+OAw+atq2KrbqVOQQGH0NVmaVr1QwxD2wO9ZKT26AlfUw7u6aTUhp0bILkDeRg/dqpqekPfxJA0x8pcszE4ya6m+t7dJftLqokCFfMxyox61ymlrBDGbWK5eRbiQld3Udq1py0vDoLqZ8sRsJE/sO3ErbghfGRnvXfWSMkaswwSAcVh6Fp08OoyO8i/ZEyEjFdKCCwJH4Uq072Q0Slhxio5VBcNSkcjFP6gViGxFICJFx0xUgGV96U9OaTOCMDrQAnQ9aRkJlBHApHVm+6cH1p54HPagCKXdgq2fZgM0OeFA5GKcsgdcrzzg04Y5J5oDYav3MU4LgjPSmPIi5Y9Koy6gk8cscEi+YBj1waNWBflnigDNK6oo5JJxWXqerG2Nq0ab4ZnKlx0UetYhtTLZNbarcGV2bON2OKe00M0UMVoQ8SqVCZ6jpWypq/cHoR3WuGy1CJzcNPDO/l7EGdp9/zrplu4/L3NgEDr6VxE9pqFpp1xdRW6OoIaPcvIGe9Tx3N3dWTreW7QqY/vKe1a1KUWk0C8zo7wWWpW+G2Sr2PXFctqhXTnhsQ5eNgck/w+hq74dET6a4sHLBT1YdTWfq0Ij1eO7ucvDjZ8p6HuKKcbTcXsPzNXTddl05YrfU0LRtws6glD6c9q3P7VU3scAVyj/dkx8ufQ1zeoC7lkis7WEC3ePPmEZxjtW2be1s9LSO42tNs5bvurnqWVnbcFqX7zU7axCteOIlJxubpRPqtmLXzxcoYgNxKnORXMW8UN04tpbkyyOCY0lYdPYVVt/DuqTXUkIYwWqnAfI5HsKlRi1qx8vc3rbxJa3MLS24YRLxuddo/WqWp+I9kQdJFSM9DuABqxpfhG3s97Xlw90hz8j8KKujw5pRkJeIOowwRj8q/Sk+RPQacUc/Y6qJ5l8yRWY8gAk4FJrGsTwWsrxW7unTcvB9K6aPSNNQER26jH93IqWOwt1OBEMD15pbyv0HdHAaf4Sn1uD7XNPJDFIvyqSdwyOprQ/wCECEFp5dlfMsxILO/ORXdLx8o4A9KaRVc8r3Fzt6GQNAjGi/YTId5UZkHr61zs+j3VrMlpGzOiKW849GOa7fJHSoZIElkDSqWI6Ascfl0qWrppgm0cJfzGytgkqRxqXwz7ck5/z+lYzr51yiwMVE4JjlTOFYds+lem6to0d9FGFAGDkg9DXNp4dvbCwukgdJZAS0K7f51kqUYq8XqWqlzidd1G4fRRYXErm6gYGMjB3k+/bvWjper3UNxEk4BthGFcdfm/xrSm0a0NislzCEuGUAq38Detc5Np8vhpmnnkM0LuGZf7wyDx+Fc3N7O8EbrlmjsNDnW6lnKx7FDfKCMEcVPb2NtLYXCKCpd2DFTjn3qr4emg1Oc3lpHJCJCSsZ6BeBk/lWzDaJaxuspBWV/pnP8AWnSipbmc5WOWsNPt7FUtLdy5J3HLcjPpWzpOnJC0ouirOk/y564PI/nU1xoVvBqqzhpCHGMAcJgZ5omRbWY3BJaCLLkDnc3QVqoKdTRic/dNvS9ISHV5NRWUtvj2BOyjOa2yOBjtVfTnWWzjlUYDDIGMcVOrAiutt9TnYE7lPPFOUAD60o9qKESLRRSGqAOtFFHekAMMgjmgcDjtRRTAAcjIoNFI3TNF9AFpiqEXCgAUqmlP6VIAuQOTmgjPWgUpoAa4BGCM1n3wkgKyRHGD0rRHPNVNRXfaOpHJHSiL1KTLEUodc4I/CiqOmzFFEcjZbFFPmtoJxMDV7W4bUpbueMbITmH1PFZeh6lca1HcW2oWphUAjk9R9a6LU/EOnrcQ2yuk08knlqo5571nwzf2pozTNELbzt0R45XBxWib5feQXOn0/wAtrOMRnKqoUHPapJNkWC3Q9zWPHdwaLpkLSSkwIBEWYYye1Vb24ubnVEkLbLGKHecH7xPr+FZct35AjQvLkTblC/Lgg5qpYaHuuVupAo7qB2pPDtislis3nmdXYvu9cmujTBQADj0qr8mkRtkawRJGwCj5uvvQo+agkl+vGaeeorMAx8uM96FIPFIxwpPpTIXV8gHJBoAlXGMDtQoGaZjJAyeOp9akACjigQHGabJ0pQw3YJGfSlA59qAIgvGQvWh2C9etSSOEQsewzXEHxFNqGtLbWUJktQG3zdACO1VGDne3Qd+5p6xNcRarHLnbYRxFn9zWZoltLc6p9q0//jykYtIW7n0FbNsj3USiRhIDwxHQ1prBHaWyxwIET0XitFPljy9Qa1M+78O2898t2Xk3r0XPFWLHQ7S1CMEy69D6Vfik3rzTpWIAAIqOeVuW4WGxojxsjAFehBFRvaReWEVAB0p8WRnBpQx3dahgVbextrCORYY1Xedxx3NZltpCR3VzIDvimIcxsMgN6ityf5sAimMwWHPRR1NUpSV/Ma2OX1u6uVuoLfTGClTmRSOCKy9dvCy3MLE+aI/MU+wPSrv2tl1C7abb9nUqsTepPbNQTbJ7i3LqDLK4iBx2J/8ArVM5JTjGxcVpc0PCGhrHb22p3qlrwx4Gf4c+1dSHYg05VCoiAcAYpAOSBQ5c2rI3In3MOTxTUGVxU+MK/HaoIu9AD4VwaeBg0J1NDHB9DRcGIxxkjk9hRyYwzDB7j3pq553HJp55TFAiHvTlGSKYwO7PGKfH95R70DuW+1VNVmNtYzTDPyKWOKtAHcTnjHSor0qLWTeAV2nINJko8jN3DqksuoSSvHHM/lGFj37Go/EWo6fM9m0ZYSRnyXVuVUgcGsaIb9Ynwd0CT/IV6dfSrl5p2+wvnRGZwyszY6A5BP8AKuXGU3Cd0dtO2lxNJ8QOb2aS2224jRVCA4EmOpz+Natr4uivryOK63QxxsHWTqG9q463sCPs8ccxMkmWYA8gUs8Bt5njZJEVWG3I4A/rXEpSg7RNnCMtz1y01SDULoqkm4NxkHpVu5ltdPFvBcJuWZtoGK818JSuvia3CFllYFpExgKD0H1r1G0Md3qRhng3GJQyMwrvwmvvSOWulDRG9GoSNFUYUDFOIUDnAoOfwoI+Wuk5hwoFMQ5GKfVITDvTWLbSVGWA4B4yaU0tADN+2INKApxyAcgH60JIrkBcnIznHFLIgeMqehpsCCNMCmPSxJR2owM5ooERwSrOjMm7aGIyRjOO49qkIyKOlLQBHkDqcU+opU37fY1IB2pDYEUmDyO3rTqaWO8ALwec9qBAgCoFHQDFNkTeKf60fWgDnbhbq31BjsBgAyjDr9KK1bxl8+JD1Y5xRVc2iujVGRaafZytHKsCB4iwQ45XnBNO1iOIWDmUOFiBdQncjmtm3t447cBB1+b8+aryqrRsCMjHelzXdyF2MuOW21HSoRNFmK6QMsb9QRVU289x9ptHQxwsvlJg5JGOta+mQJJcLMVGYU2J6DJ5/kKlEbR6opJG0g0J2egIsaZbJZWEEEYwsahae4wxI6VY7UxgCOKm93dghoGR0xQST0HFOXpinYGMUAZUV8H1J7U5zirVtE8bknoad9mjW588KPMxjNWT602+wXGkkHBpSeKbK21eaargjcTge9IB23ndjmquoXsVsPnkCHGeT2q8SAM9q524NrqnmMNsiZMZ9vWmld6gtSN9UR4IpLKQXCTSeWzKeFHeq8mnrFG8VhAQJn+facEA9Tmq2gWzRarNp9raMlkg3NKe7e34V1lraraqQpLFjySa0lam/dFcTToI7WBYo1CqowBU10AY/wCVBHNEgzGOc1k9xkcBweanfkVAnBAzU5NDGxg4PNJIcEGlP3uabOPkBHOKQkD81U1OTbZFFHLfKKsKciq18AIWLHgDPSmhpHDa7YzWmlWqwfOiS5bjPPb9ak8J3C6jqdqGJZomLEdlIBGP1ratrxJ3e1lTiVmVSe+OTTY7QWviezexhSOBlbzAox2qWuaT5t9TTmsrHW/x0mfnpJDhqaW7ihGRMMEGqMTYlI9DVuIkg1ktI63uNvGcZoQ4o0pd23MdKMkDNIT+7GKE6Z9KOghxGFpqHJIpxbKkVHEGDZJ4pgIRSIwVwSe9PbqRUL9fahDRoVFdKGgcHkYNOhwI1+lLMN0bD1FS9iTwI3Kw+JJbe0TEImKOrDoc5yK3m83Tvt0s4P2OdcKxHTNclrcraf4qn86Ixl5mY/ma72PfquiW0Uiny8bi39KrFqMVFvqdKuzlrWA2E/8AaMCo7rlgH7gHj9Kj8Q61Nq0tlcNAqzRApIF6YGMZ9e/51a1q7tZLsW6bvLH7raOPxqv4f0lJb+WzkEm9CQXxyDngmvK9hNvnOlTjvLc2/BMEYvJtUvVZCp2Zbr2Fem6V5z3M0siqIjjyyO4rl9IitxcHS5LWQJHgmTHDGu5gQJEqqMADAFepCPJHbc4qs+Z3H96U9KSl7VSMSCBw2eeRU9VbePypHUnJJJFTuGIwrbTkc0+pUh5poJBHFONIKRI7tTCuRjOKdRVMAHFHegCg0AB4pAeKG+6ajibORSHbQl70lLSc5PpQIWigUUAFIaWigDN1cLGsdyxx5JJyB2IwaKt3UayRMrDIIwRRVRktmUhbWRZYFdTlSMg1DKm0sTjk9KxtF1RhqFzZTosaIf3eO471r3ksYIO4E1MouLsCKmkRi1dogWIdiRn65q5dqBcxOTjjFZP25be4DOcKATitHUbqGK0juXYCMkEMenPShp39R7Mul/lxSc7QRzTQVYKw6EU4EhTgZ9BSECMe4Io8z5iAeRQfvVX2t9pLfw4prUZYPIpyk8ZpucZoAxQIWRc00R7kKsAUPBBFSKvGainl8mMkkDvzUgNu5RFAwB5I4FctpiP9on8lAkZzgeretOnk1N76acMr25AWKP39TWrY2kpmjC7VijHzED7x9K2S5F6gWtDtJrS1xcyb5WOSfT2q/IcITTJA20AHpTOSvP41k3fVisLy6+n0pQNoI7daagwuM049KQyMfeqZT8tRDk1ICM9abARufrSg5BBoPWmn2oAiJAYiqmpQNPaSoDgsOtWHX5896eRvjp3tqM4XxDepHZST6cFNxAuVz2YEAj8s1f0fU2v5rCdYyisAGB4xUsemWkst0kkZ2ly7c96zobsQTqYFBCc7B1xWM7KVkaLVHdznBBx1pqkbSaZDKt5ZJJGc5GRTFY7eO1UtjKxLBIfO244IqG7UCbOODzU1qcMaLxcspquo1uKnzR4p+PkYe1MiGAM1OMc/SkxFWI9qdz1qFG+c49an/hwKY2Nc/N9ajl9Kc1NfmmhFu3bdGuD061ISCDVS1kCkqe9SX0pitZHUZKjOKlgzy34meEnutYg1OJso37t19qiS8NtosljasRKi4xn2roZdet76GaIOryRk7oyeVIrzeKaVNQuZSGMjZlSMnqKwquUvcl9k6aa0Oi0bw558BnmXDBgTnrXRRxKuoqttsVgp8w98nvVLwtrySWVokygO/wB9V6KAepp4vJLjxVO0BwjOqDHTAUk0UlzSs+hM2zqvD9ldR3Ny14wdC+YyD/CegroQMVFagCMY7gVL/EK6HLmdznBjgU4dKZJ0zREcrzTW4dBnWXOKlqJv9dUtIbAHmlqvFuEjZJIzVimJqwUU3BzTxTQgFFJRTuAHkVBEm2Rm9anpAMGgaYtFJSLnJzSEKByaWiigApr52nbjd2zTqKAIJ3Kx5PWimX4ZraQJ97Bxn1opxVy0Z93p8M12s6HbIgKDHbNY9vYy6ZcRwu890s0hy7c7M9BWJPrV3Lro8gtHbxjMuenNdJo99dTalJ5xQ24TBx6+tauE6a12sTuUfFulym3ae0kfcibio74OcVbJt73TBp8m8Bdv/AT1xUVpqcN1e31qrlngfgHup9KjFnP9tNy0oiG8BvRl6fnQ7pKMug99TpLK4hlj2QuGMfykZ6VbRhng9K52ysYdL1C6uUcgXByVJ4z61qWE9vNGXtihDMSxT19TWTXVbAXV64Jz70MMmopIy53BiCKkiztAPPvSGOPB/wAaD6Dml9AaVVBUEUCuKqnb835Vy3iBTqNwscN40PkyYIBwGPYV08rlVPTPauO1uWKzDTNGXdH3bVPUnvV0tZabi6E2myO9wkTne0AJduxOK6ez+SBA3UjNYelxhLQS7CpmG87upzW0hEsY4xjpSqfEPoTyPtXgZzUO880/nyWAxmoo+nJ4rMB60/AppHy4BwfWnE8igBoGBigkbgD1oY4PvQDnHH40wHE8ZpppWpmaEBG4pY+VIp0g4qtNL5cbds8UPVAc1o99JdyXxeIoFmaMZ/iHrXNao02m+KLqWEF4cjcM9OBXczQxfYX+cLIxOMd64rUt91rLo2YxIoXPHzVhUqL2jaWhvCN0b/hTU2ima0cEICWXI6r2xXXsuG3Doa83t47lNjzsYriN9qsOjD0rrtD1qK5QW8zBZAduG459KIvqiJrqbMRAb1qWYBlHPSq0h8uRQT97p71KJARWpmDuI1BNSo2QDng0yRFkjwai3CNcUAAjxOxHc0/NOhG4EmolbLHFFwB+D9aa2MVKOWFMmGGxx14p3AgYZ4xkd6sySeZbSALnAqq+TkL1qlc3sllpkszjLIpJA74qZj3PNNMlkN7qga32zbmYue9Ylnan7ck7Of3iEAegziuk07Xba9vgkiBJJwSVA9/WrK6VafbGieQxI0QUc9Md81zYuonUbtY6qfuoydAvoNP8QzxSlTEtsxUjpuxk5/KtrwfPnTJL24TMoIUdzjt/OvPtS0290rU1a4VLiOYt+8U/eHc+3FesaO9tZ2DXzwCGCYq3lj5to4FGHVnprewVrWudnp5YWqev8qt5OajgRQuUPyMMinjrjNdRyBK4C8nrTLZyWdT26U6dFKZbtTIgA2RTWwdB7580Hp7VMOlMZcsKeOKYmyA/K5PapVIIyOlDKCDnoaFAUYHSgG7it0zSikPIxQOBTEKelIKXqKBTAO9FB60dqAA0U053DHTvTqVwCkHNIqBTnkn1Jp1ABSGg1HK4UdaQ0RXb4jPNFczfa8HvnsYVZpsccdaK1jSdtSk7Fz7NAyODEvzDnjrUel+VE0kMqgByR6cYq6UG7pxWPqiJHqttMZdhH8J/ippc3ug9gu7Kx0OWERq0aSyCNWUZOW759quzyTQ28UUsMt3vbHmKmO/U4p/iJVm0uO6iVZGhYPg9q2bV0W1jORjaOahy0UnqyTE8SaTJcWYeByJF6Lmsfw6qaTBIS0hJOGB7V2dyBNEB2JzWbFbI87q3XHaqhVfK4PYduoWOqx3Fx5IBDYyD2IrVUiuYSG8sJ5GkXfGvIKjqKtz65FZ2qSSBmDNjCjJolC79wDVnn8qSBGVnMjbcr0XirgZdvBGBWfbXsblDnAcd6fdSrGjlcfyrLW9g3MbxDqU0V7a2sKFmlJy2cbV/x5p1lZRWMga4ZppJsAZGdoFclMZ9e1FpILsqEk2qF7Yr0i1SN4EzhyBjNdFRKlFL7ySCQeZsaMgrnDD2punSqxljJ+ZTjmrXkrFbts69aznKxSrKE2iTkj3PWsN9CjTQgbh29aao5xSw42fWnd6QA445oz8v0pzEYqAjaCc5B5waEAMw35oDbWPJwT37VBEG5Lc5qVec9z70wEa7hEyxeYvmNyFzzUpHGfWqqWkC3Rn8tfOIxuxzVxvuGh26AiHJOc/drD8UeabOOGCQpNJIu0jrxyf5Vtqw3gHpXL+IdZgl1F7a1ZWuoNqDPQO5wBQnZ37AJeyCytIWurgGWBBu9jjkmsrUIReXsE0eGDAE444zyRWdrcM0189kGDT5USuhzuOM7v16e9cxa65qFteyaZdo26JzHlThlrz+dSk2dUYPl0PZFtYhEI/9YjDILcmuQ8T6esFwJ4X2XCkMOfve9VfDusXwlKy5aFc9edv41s3YjvhFcod0kXb1HpWkZ8trMjlcXqdF4c1SLUbFA5HmqMEHr9avzDy2A7GvLtVuJLLU/tVojJJCobAONwPtXdeHteg1y2UMGjmXqpH8q1T5UmRKFtVsbsbbkGarTdTVhVKIRVefkGtEzMs2hzHiqAYrcMvPU81Ys3wcGkfBuDj1oWjGOiODyafL81QSHZKcZxTy3y0eYhu3hm6YBrj7xrltP1CS8kxHG+AR0x/k1qeIdYj07TJZ5m2gt5agdSTXP6omfDyLLLkT/vduecelTJXjd9y47nEafYldZnv5MLGi/u1Jxj0xU+qXV1em3iix5pbBdcjI7DP1ren05DpqLOG/dATA8Dpn8+Kp6XGZ2n+zheoZCRyMVz1Wnr1OhO7uc5PdPHNFbX5aQtkEk/c5/wA8V6naGIaBbi4X9yEAb8K4+w0V7/U0e9jUvGeQOOK37rVVgnaxaNTahSJCDyAcD+ZoknRcbik1NWR2lpqVv9pt7JSQ235R7dq02XZg1wsU32T7PMq+dJEyru77T3ruA/mwqeMkc11aWTj1OVqxNgOvI6imAYbFLH90UoABpoBwNLSHjmhW3ZxTQhQeKKah5xRvG7APPegLDm4FLQOaWmkISlppzkUppgBpCwzjvUcTMSd4xint24oHYRgcZHWlUnbz1FLmikFxA2TQSFBJpOBUMkoAJzSHYe71Vu2zC+PQ1BbX8N1u8lg204OKg1C6jhgZmOBiqs72H0Ob8KTNcapLHcRqZY5CA+OozxRWz4StYRE1zGCWlctk0VWIknPQRqyLiud1zSY9Uu7cyFlERzx3rp2GVrG1JG+1QOkhUqeQP4qcG07oOg2ynh8qbT8/Oi45PUVTj1pDCIlwJi/lqp7ntWi9shmDsv73swrB0+GC41S8lhxIsLKVb0cdRTiou7YPQ6VLt7aBJL4FB3OCQKpatq6232a5jAkjkcKWU9ATjNb7sJIQQAwI5FYOsaYrhZkHlyAdVHDD0IqIcreotTTluEKiNiu/G7r2rN2NFqgkkAa12dx0NVNKFpev58DMssRMTqeOR25rTnVEU+Y/DHGDRpHQa2KWq20V9LZ3Ec7gW8hcLGcbvY0p+1X85gRTFH/E7HJ/ClFzFDcCBFy7cDA4qxYi5haaW5Me0k7QP7tHM0gsZ+iaOdJt7yQoFbdwRyT6GofN1Hw9Cko33trLJuf+8gPpVsTXzaxLna1jKmAO6nFayRhtP8iQksOBkVbqu95a3DlLUN2jQIxPBGcd6xfEmoLYw2m6N2kmlESgdge9UNU0y4naKe0neKeE8pu4celVpLvUp9btbeaxPlBSS5IIU+uamMY7piOo0y6MiFJCA6nt3FaG7nNcrdtd2jZW3ZivzAg9R6Ve0XXRfTNFcwSQP1Ut0YfX+lRa65kNqx0BIIqEinBgzEL0psgKn2pIQEDH0oRQGPuKQ+1AOelMBp61MPmBX2qIp82AMAU2SYQKXJpMZUvZmt4zxluwFeceIIV1CaRrSRbaSK43M2dpdwOufatfWPEMwhvJLpBASSlsmfmb3NeXWt5e3Gpl5cTENjrkZ7fzrnrTa0T1OijTv7x2OleXpuvNcTzNIsUJZyTne3BJ+uT+lY2twSDVre9EpD6gvnkYwQcnt+FadzbS/Zo/NiEhkXJGcHp1+lSHSpdZitxKWEsSgKw4wvTrWEcPJ+9I1U0nc2bBPI02fYFzKS2M9DWKHli055IHkMisSBXRzgWlkgaJiUUIcdx61m3Vle3txbvZBVtnUq4GPlz3NNUJJXI9okT6BqFvrNmwkVftMQ53YziseC+vdD1giIebZynaMckGuZvJH0fXbpYLjyZUbGADhhXVaDqI1h1hlTZeoufNA4akrxd0U429Du9C8T214xtpnCzrwVPWuhEsKxlmZdg6nNeQTaRdXVyt1t8m6jfDYO0H3FX7rWrmC3utMe3kkLp8rhvvcc1vezsYSgn8J6XDLaykGKVTnphhSS27+aGU5zXi9mp0f7HdB5/KD5IY4zXWa94ouWtLJtMnAaR8OevHatHKKa5XuTySTO/KAA+bjOOuaxL7UDGZ41cJsXIPXcfQCuF13VdXkud9ncu0SICyr3Penrr1xd6Z5Js3ilb5Sx7D1zWdS6jdMqMH1Odn164u9bmh1El4d2I4cZVT64+tdfqYSfSolgCm9RNi5PQd64y0s7ddeZ2kzu5POT+VeoaTptpHZLJkSSEfeNJ1lNq3Q0nFROA1W5u4bWaHJklCASF+OB2FbXgjVLS/tBBDGFlUncD/AAirviKK2gjvbi4hDCNPlIHLMeAK5XwXb29lJIFLNcSgndtyF9s1nUcXeTHHWJ6NZweTFcOyr5rrtU+3rXlevSzx30jZPnIxb685r0G0+0zzFpJQUxtCjv71zNzYB/EcCXYXyXYgk9ORisqzctiqNk22M0TXbq41UklcRRnco/jAPOPfHNeiaFc3G6XznDxth4mHcV5fqEB0uSa1i2pPG2EZejKa6rw7Mb2wgdJjFNbtwexHpWuFnyrlexNaF1zI9NjYPEGTnIpUBPJrDj1eG2uLeGSUBpuFHY1rW95FPJIiOpeMgMoPIrr2OQsMMimQqVLZPBNSUCqTAQD5jTWKI3PU0+jAPUUwAZ3e1LRRnii4gopAaU0wGEYahzgUrVHJnGT0pFIeCCKZn5sGkhYFOTWRruoGxh3qAV/iI6imk5OyGXL+5EOQWAHeqQk3oCjZBHY1g2N3c6hLi42+SRhSe9SWElyNXaJlxbKMKfWtHScdHuCZd0UNFJMJNiAsSAoxS6tYPe3EeJMQDqB3p2pWjzRfuXMZBzkVUimkVPKMm5l6mlq3zJ6hY6PSoo4YVjiwFUUVhaTqXkylHYkeporOcJJiaNw4yM9QK5jXlkg1qxvV3mGNW3rXT5rJ1qaO3h/f9HOwD1J7VrTdpC3L9tOJYgR3HFUbeCG0uLkpHgSkM5HTNJbT/YNOY4aVkXp3IplteG/giYRmNn5IYVDTs7bDRHBd39trEcarG9g4+fn5lPrXQXaLJbOA2MjK81yDCbVJtQt7SQpJbMoLKefXFJYX2oz30OnvbyHaCTKemO1V7NyV1ug6jvMfS7G4dEM0iOWbjlhVdpbnU7+ynLtFaSL80RHzA89q6VLML5nn5y3QEcVais8MjqFCJyDjJNQqtne2o2kY2n2t5dX8zMgit0bEZI+Zh610UdpHFGPOO7HrThLHGokdwNwB9OtYvirXbfTbVTITvJGFHVqnmc3ZCNl5IYomdQpIrF1LxJZadCXnZQ5J+XPOKyVSeWQv5rpG6hsY5rjtb0GS68VxRST+XbSADLN19vzqIwvK0maKOhq3njmC4f8A0dXUo38I60ul+JXvLl4i74HfHH0rpovB1jHAFjjRnXHJFUJPDUBuGNqRArcOMdCDUPlV3FFXi0Sx3V2ZT5jhoGwB7Gq9/rsFoo8xc8nJXtjqagvxPp1jdRiUl+iseB0rkNKv2XU5bhnMshX5kAypGOeK5alVrVGkadz0az1d3WJ7Z0khODye31rbt9Wt7n5N22XONrcGvAbzV9Q0C9BtlcWTMTEmfXqK7TTfEo1e3igULOzJuYxHDIRz+BGK6IVb25jOdFrVHqasrKMNzTs+WQTjFcFp1zMumTLp160k2/h5zu2n0xU11qTSaQYb2+Mdxs+aWIcD6CtuaLdkzHlZ2M10m47D06msTVdTU2pZV27ckk1zOj6jBbWUkaXEspznfLnLfTPauY1HV5NQu59szx2yK2V28yYOMD86wrVVFuK6GtOk5asyb66vZ9RlmupFkXaTtP3QD2qxo+mma5t3slZvOk+cEfKo7mtXw7pdrqsstr+8WUwkqrn5i2Ov0xXUeGtDe1tLe3lQpJEclh+NTGLb5nubzmkuVGlcaNJd3BliO0JF5QXHDVd0mxkjg2TJiRQMEVsQDCgDqBjNTALXWn7vKzjvqZr2Ym8wOOo6GsYWL6f5nlsct90H1rq8YwSKgvYI5WV9vzL3pWXXYfMeTav4YN9r0cu4oZgfNyOhx/KnCwfw3Mp3li5GCSQD9Pzr0TVLZnt5XgCicxsFY9QcVx+sWl3P4eitbk7riJxMjlh0HaoqxTV0awqS+F7GjPqCz2bRK2LkDOBXOy3MjzbLjbDMcqhboaTTLOZtRlklfHHIz3qS/jE9jJIy+a0UwyAMlVrjcde5qtNCvcNMdO8i9EaWUch2c7inGcfSqOnWEt3Zrbh/LWUBwVOcLmtjw9Zya7AIJ7dGjjByxypAzgZ/CqUNja6T4gWyicgE4YCQjjHSs2pQTuVdbLc6Xw3NZ6Y01uxjk3KGDuR29c1LqNvGml3DWzoTMwbco5x0JFee+IvLh1K4aJpBErYK7i2D3H06VOutTXVvCkEjIYUwpYbQcdqppyXOieR3vc0GsotLQTyup2D7zHk0un+K/MvhbR5iskUsDjkmsqzeXWcpOFlLLgOxwB+dSX0DWLhAiFj8oVWBOfU1Ki27Pct2e5p3upS3jbZ2M+CCBjaoPYY71s6HpivdwrHnco5NYmkC3MCqqHImG9j2z1r0O3+zxamzoVGVBJB9qtpJkSdlZGHqEU+k6ih+9DIcDnpTdSSCeOG586ON0bcN3Gai1+9+3a7HErK0ABHB461h6tplwmrwl+bRv3e3PAz3qnpJNExV1qdHcafa3rteJ5ZhcZBHPbFZmnRT21ugEJNu7FQdvJ5xj8q6bwnpyQWZttpeMksM9AD2rohpiPGqOSUX7o9K15VLVEc/LozgRb3MMUgULdQAboieWjYdBXFeGfFN7p3iS6n1iaXzCx3BRjvxkelev3Ph8WrPc2RbftOY8/KTWFc+DLO/ujc3sJDN8wAOCD/UV2xat72xCaO20nU4NRtw8L5OOR6VdGe9colrNptytxaui2wH71a6WyvIrtN0TBsdalpJXWxmWaUVGjAg4PFPU5oTAG6UL0oPSkyFBJ4AouIjBIc56ZqTIBFVry9htghlPDHAIqJjL9rAUgwFc596Cty/kYzUUzqYnAYE4qlJLKwZOmfSsLT7G8s7iYq7zIzbi0h4+gqoxUk9RWsadpdGWZ4wDtU8kjio9ZtIrqI+Y2FJ5+gp1tHcGUvIUEfYKKq6nchF8twSHyOKa+PQrcgura2FkjQtgRn5TVCGeaOPLMHkY5AHpU0iibTzFIDFEvqetQaZBEXe4j3SCIYwOa1TSTuT5nQ2Mm5B5mOnNVriKGOYupyG9Kit72C5bylYq7A/KRg1na1eQ2NsLVWYSOCEwMtn6Vg01Kxa12H6tCnk4icIxPBBoqtpuki5tY0u4LhjGdwdz1zRXRGooq1xWZ2ANZPiZIhbxvMGcRyKwC9c54rXWNnGAeap6pGXgdABvIKqG6bgOD+tYxlZokj0vEwfjpUmo2v2mymt4mEMhHyuOxrM0C6aEW8GolY7ybKbezEf5zW7Ki5GOg9KJJqQJ3OZ0aX7Dqm9Akiyt5dwyDlWA6126Imd4AyR1xXGT2kWmXcs9jB5hupd0wJ6H1FdXpk3m2y56rxRV1tJCLLoGXB9KqyTBItyD7vHWrhrktRvRbSy2z5DFiRj+lYT0RUVcq3YuL7V438wiGP5lQ9Gb3q1BpUOo3kN1OC5iJ2g9M1W0q7gvZpwhIaMDPbaxrZ0R1S3CrhcknBPXJrOnUdzSSsi3LBGxClRk8Z9K5fxJoZvtRsnDlBCSXx1x7V1ckigkfxdaytSLPcCeJuMbCDWvM1qiUXdE1FLm2CmQM65G7pu96cbcSXEpU5ye/rWJLp7WbJFbyAs4JU9MGm6X4lEU72998rJ0Y9z71g5FKPVFfxbp0ht3OSVK4JHVfevLbbTtS06/fyt0THKbicDBB7/AEr1XWddhdfNgy0bJwQK5/V3ttVa3t/NQNLGSCh5VvQ1m/e2NYTa0Zm6d4baTSfNuCst1GSyKfmBwOhrJ0XTWfXo4Vh2/vSxWBsA5HOCO1aFrNJp+oQ4upp0tiRJEM4I9j3q9cXrQ3UGpWSt9mRs/dwV5wQaJR1unccZS2ZVn0K5g8SXcFhcSCykJYruJIOORmoddvrqxtoZIo2aMnDqw4Ar1DSIba8tVvVGWlG5v61B4itbaew2GBW3Nt6Dj3q1rZvoQqiTszyLUb8TQxz+Uw3Hhl6danurfYLK5UlYSjSvt7ckH+Qq9rmmLb6GRF8xSThfrTrXybjTLlR87NCIowG/1eetc9RJNPzN1LS6Oo+H+mWbyf2nAzNKVwc/zrq1AjZ+OpziuO+H+oCG4isQjIhjxhhzuFd06qsjhvrXe1Y45PV3Gwn1q3CikEtzVWPGRUyZ56gdKroSI3HOeKjlztNSOoK4IyKaRmmBXwCv0HesDXFjjjVpNpG4AA9DXSFAOaydb06C+hCTAgKdwIOMGlyp77DTsYb2iW18xQhFYAgdhkZrFgZ4dZ8u0jMgmk/fDso7mrPi6GWC9juYnZkSNVC5PQdKk0lFhkEwXLXDgFc85rBLk21ua7q50mitbwvLAihAozjHHPvXnHiPw3fxeIZ9RtyZomfIHXA9q7/RrGcW9wkszNI7EAkcL9K17eyCWoiYhsDBY9TWigkn5kKbi7nj8NneWWuvHf2/mwTHeCR94HmmeJo7AXijTn8gYBKgd69aTTYVly+dozt77TXmHjqwjh1giNC1quPMMZwwJzxn8KylCzsuxtCakyTS1tRAixyR7TkttGSW+lLFDBqDqsLNvlbbvIxgj2qh4duY7GG2EdvlzKP3jjII9D616T4W0a1aVr8qCiH5F7bu5xWdCCTbkOpLlKEPhpNN0ppXbLkZfNYF072cEwspGZpDuyW424x/OvTdfZP7Ny/3W4x9a4PdZRXirKUxjaSx5FKtGTdyacu5j+GUOoXasH4j+UjOcnOa7HUred7y0txb742GWfuDWPo9ta2uttcW5ykvAwOCa77S5GknkSRf9W2Acda2oxXxNE1Za6FqwtUtLZUUcY5qxyM4pzEYxUZcBwpPNapW2Mdw3jaVNNNuHixnrzTHOSakifC4INVYDKu4iqukoDJ0PHWsmO8fT7mGGNEjtGPLf/Xrb1XzWAdPuA5cf7OOa5bVLKRJPPWU+UD91uRiqTtvsUrM6MPPHf3F0Zl+xbA2M9DV621O3lVWWRdrdCDwawrZJVtZlutj2zpjI44xXmeu3+t2QkhsLQpYpITHIMk4zQ1fqEYOTse1S6lbxtsaQZLbcn1pl04HmKWJyBXh2iT+JNTu3E7+ZbuwPK4KEeleqaLcXHmSwXbBnjAGT1JxS5Wut2OUOXcuXTOyACLzCSMKegq/bhxF84Akxisqxvbi41CVGh2Qpxk/zp2oa3DE6iLEp3bCV7VcoyfupEXJLDT5hqst1cXDtu4SIH5QK6AoCm09K57Qr6V5pvP/ANUPusa2xeRZxu5PaobblZg12Kt7iADH4CshUa9vFXy2O059q6JrdJGEknzH9KdlEJCKAapSsFzP/shHIMjnGPujpWfc2N3p8xNiN0LcsO4rejdwTv5FOb51KnpQm1uGpztpcQ3TtLFbN9oX5emDSt4ahudVh1G9JaSL7iDoPrXQJGiHKqAT14p+evvSvZ3iFwVF2bcDFFIp54PFFSxFWB/3ORWdrcSz2kkJk8sMCC/pmtAxusJqhfRLNBsIyGODVx3uBi2umxtLAJZmle3kEitnngV1LgFht6Y61wulSi71S+mtJPkVjEVbjBGOa3tCj1KG3dbt/NbedpH93tWtVPdsSJriMSvIhO1x2Her2hPvEo5wOOahFpM0wkYElegp1hIYL3YwwG4OfWsW7ovc2JWEULOx+VQSTXnug6hbar4gvg03mAk7M/0r0KYboXUjggivFbBJbbxbdizzvRm4x26kVDd00VCN02XNc1a90bXrtbGBZrRsKSOCjcZP0rqpLZLj7KGkeP5Q4Kn1FUdV1e0gsZJjaoZbiMCQH171kLLNGsN+0zKka9+Bj0rNNRaktLfiVZyWp3t8pj0yeeB/NkSMlQe5ArnfDurPe6ez3iCOXdg+hrGn8Sva25ck7XXdtBzXHah4lvJLlWHyWx5+UY9s1j9ZVnC2pcaDZ6/ckTrGrt8yHcu3uKzNX8NzX9vNPbttk+8uOD9Ko+Gr1tRurbzDkRquWzwwruBcwQ5BdcegNVFppMh3g7Hlvhu9eTXY7PUYsQxqcBxwHxwf0rS8R6lYT31usUWzUF4f5SoAPQ/y/OrOsyQtr0ptmgIlhwQ2Me9YM0Vu0ly9vIDMkDuHBydwGB/Os6rSd12NF7zuLoKzXEN40SxsMgs3vn1/CtLxJAy6abi2cK7Lh4z0b3FYPhq6ntdMSOJgYnYiRTywPf8ASti2tZNQgmurp2a3B/doOAAKxprld2y57m94T1f7LpccUykjGPpUWsa2UnECRnB5HtXLQXsUNxJPEJAArfu2PBNVLO+u7u+SJypkROcD/PFbKT3ZDp6mjqV5ENyO3lgg5XI+924rnNMYbpAjOgZC4bHIKnr+VWZGtjqs32qMqAdrMRnHHWsu++0tqVsLHLL9wIMgHPWsXCcmbxSSsdx4C1y0upVGF81G4c8Z7Z/GvTZsOykcjGa8H0m0a01qSJV2pLGXUJ3717J4f1KLUtPgliYtxtPqCOua7aW10ctZWd0aiDHSnk4NL2pprdGAucqRSLyKaeBxSrQAjYBxVTUI827Y64q1/FmodQO22c9eO1EtgPNvEF3KwuIVyWLDCdeBxiu10LTki06AsPnK5DEciuM01IrjxK6vk4Pc+telQjbCo6AcVCSskaz00EhiWFdsYwOuakXkGndFOOtMU81aMiOQYzjrXLa7oFtfTT+fuV5FDZU45FdY5xyazbqaE3iRO6hn4WlJOWiKi7O5wOtWtroccYbLKy4RjyF9a67wBfQ3XhsRxuGZCc4PXJzWV4w0+3mmt7dyhuCSUQk4bjBHFclo8mq+GtQZYYkVSpJjc/KwHv61iocsL/M1f7xeZ6vrk0aaaGc4AINebWxsNc1qd2wcjCehPvVbxT45mu7OFEt/LBPzruyce1U/BUlve6i626lQvGDwVPrWPtWk/M0hTaV2eh6ZpiobdflURnPFdhFgoD371gXcDtawJA4D4HIPfNbtucIBnJFdFP4Uc83dlheaCgJBI5oFJmrJIpkO8c4p64C9aZdyBVyWAx1zVATs7n5iF6ZqlqBelaMnYSDuByKotbRXMPlsoMQAH0qlLZRwWl3NbM73ckZAkZs4zR4evEnso1i3ExAIzMOp7miUG1dAmWpzbsgsZyMTKVwOpFU7vTvIgitbKPenmKpL9hnmtc2UL3sM+ws6gjcDwKtiRQm6TC88VPYdzJh0+HS7W6uJNpwpbAHQCs/QbRpDNeOd8kh3BQenpV3U3e4aUE4tyuGz6VFoMENjbySxy7t3U9q2irRfdkt6kWvG5sdIeaMKs5cYA9zXE61eQaLaOplxPNiR89vau9vLq3vLUmVj8pyp9a8um8PX3i3xFI0rlLWM4TA4Iz1ohNu6eiW5pCCerNLStdvvENxbWmjxmK2UAPKw5P0r1DTNNFqi+axd/U1S8L6HbaFaeVCuXxy2K21be3sKz0fw7Ck+iFkbjA61EiHPSpSOaceBxTJI0jx15pxFOpGGaAGO4DKpBy3TigGnSD5TUQNAD84NFRuwUUVLAh84+QGJB471zVzq4RZ5plZYYvbr9K3kGV5B2isjX50gtUCwLJukCkbcjFbU0r2sSzN0qC3+1fbrIgQTguR6se9a8+pi0hVnzktsCjqTWZpMirqUljEoWOEBhjsT2rVMUb3CyMoPl5Iz2NOpvqNPQls9WSSdoCwEgGSM84qDUr+OB5JQS4QZyBXEXWpNal9VhiLNJJ5cinsFOOK1NF1gayJI3hKoB1PIPPrXNUahOzNYwdrnoVhcC6sopgCA6g4NeZatbS2+tyCCJcRlp/Mzg/NkYPtxXpWnqqWKBBwBxXnXia9MOpG3ztM8bYkPGMc/1pS1TsFPcwb22NzIz7yFdtp56N1p2pXNmdKksRPiRk2sM5wauaI6XW53id49nAI5z3/XpVO60SOytLmdI83UrbgX6D6VjBJu0jeTfQwoo2t7Y24mied+hfjC98f4ViWOlfadSaOI+eiA5Y5AXnp/n1rooUhaJ/Oi/ePGykMOQ3XIpZlisbmMWzl1fDuBwAB1/GsFD33pqa3dtDVSafT7SGHa0MhOA/sK1ESeS2DxvvY9eTzWXcXQuWinuYsoOYyRkD60/wAP399fXskNpEFgyTuIwBXRGjU5bpWMXJE93bi4jkjn5I4Qjg/TiufjtZNMQi1VwGYgk854wava5PJayzHznaVWwFVeMcd6kt9Re6eGJow53Ak4/UVlySWj2Kv1KLWrCJHsw0USnc5/HBz+OPzrvNKiij0MMk28bc5B6msK8SCWZLeeMhXBb5eMN3z654rUt9LZNIS3tZCJFbd1rWEU42ZnOT3OcU/2i7JbxhRE/Oep+taXhc2817NK8ASeP5CfUVAsM1vrU1t5W2EgEuPXH+NWhEtjOZIn3OxyVFKrGMHZdUO/MjpJdDsriVZ3jUqcHGO9ZXjuwt7SKyuLWHa/mhfkGARg9aWTXj9kRIxtnOflb2rDj8T3Gq6ZepdQRiOFN6jJJBH9KmM9LvoTaVzZurC2meG/jCpOg2fL/L61J4Y1Szt7xrYMqTSOdyjpkf1rD8LXMtxb77wEeY4GRxz2Jp+s6dc2+q2l9ZxqUiY7gvBbJ/pVUlZ2bHJXVmeqggikNZ2m38c0cYLgsRmtDOa6Yu6Od6C4pm0AkjvUgFN7+lUIb1x/OqupMBaSlvTmrRPFYfi26+z6HdsDghCBz60mr6AtTmfBcLy6lcPgNGX+Vu/evQgMDHauW8B24h06Bjg/LnPqa6kZIzQ0uZlzd2KvzKy9+tRcginocODStimQVbmTahPoDWZoMkepxvcNaFZI2Khn9PUVqhFe4AbkEVaiVIxsjAUe1O9l5jKcmmxTzrPIqtMnKsR0rn9X0U3SXC3PzFiTGwOMZ7V12cA7TVe7j8yI7TzjrUvXRgm07ni2v+D7thEbRGldlwwx9wjvS+B9C1Cz8RKbuIxBY9p4wG9K9b0ieWEiC9KsxPBxU+o6eJJQ0XXrWTjy+6zf2zasyFbZ44lbcGA6YrOs55rG9mllmDW0nO0nlT/hWklykVu0UvXGMd81kx6RNqE4kLnygMbSOCc04XirMyavub41OHCZb74496S91SGzi3zEgHocVlXugRpPbXEj4e34QKxAx6YpLm6W4eO2mhLq3A44quXm+ESXcjn1KHX7We3tJMFSNx9s1eFpNLaOkblXxgMKsWelwxYeNFTH8KjGa2LdQIxgAVabWiB26FTTrfyrRI5vmcDk+tKYIViKxhVPUgVdccZFVREodm/iNG+okY817NZ6lawDOx2yx9R0x/Wte+jVnjLHGKZcQqy7ioLDpntTA/2uJXVx8jc1UrO1gKl8hu7KSOBTkjaecVmf2U8GkSW7zsm5s5BzxXRRiRpZY3iCxKoKsO9czrNvPDHcRwylvNPyKT0z1pxk0uVMErsy7lZdYm/s3Tw2yPaHlPAxXb6bp6WFqiIoBVcEgVHoOnR6bYKNv7wjLN3JrRLZj4PWok7vTYpy6IbGMjJp8abQeMc5pIh+VS0WJbG0c7felPWkPPSgQdcUmeaAaQmgYS/dqA5KkA4z3qVssvNIo+X3pAU33RxKrtvYDlumTRT7hQQRRSsUhhI8ncR17e9YGs2rXtpcQxSlHYfKwPQ1vtkl+gGOlcd4hkma5it4pRGJsjg88VtSV5aEMtaRafZ75ppm3Fwu4j+8AB/StlGRZgWGBnIJrntEuxukikcbg+xMn72AM4qxeag09jcfbY/s6o+xWXqwoqpqXvAvIr+KbICF4bKIZdixA6cjmuZ0i4l0/UIYCGEbnYeOprU1K5n1PTJbnTpmiitThiWwzEf05pmm6hIlxBFqscbvIu6KULg8eorgqPmkdMNI6no2jn/QlGc4ry74kwCTVreEvt3SABf7wPX8uK9O0OTzLXgcdq5L4h6XHcSx3hbZLbkSKfUdxW60M4O0jmrHWLa0vPsbRlPKAIxzurZE6X7yW8lsWjBxuHSuf0K/gubhriWJd7NtwBkmus0CGae6uPMg8uEkFDjrSpU1rdbF1HYq6RHDfzyQS2JjWE/I7DJNbFx4Ztp4CvlgsxySw610NjBGgDMo346+lSXaMVJjYBu2aqVr3irGXMznbnw7HNbRRZAVCPujinHSVtYT9jQI5xkqOp9a24JWIKuMSY59KfGMzMWXKjpimpvZiueea5aGNCfLD3LgsQo5PqP51y0Gp29ncRMbeRWPygEdOteu6rZRXCmVV/eJ0I6ivPdY0UKL5Vi3iWPdGT1VyR0P51lUhzu5tTmrWZpWN3YXg2SAGUDIz1GatJcxOkkVqxaRMDPofeuI03R7o30UgLKyD5ie4HatDR3On6pNN5itbudrAtjHr1rC3I2i3FPVG7d2V/KS8TAJjnPf3rEvNN1C4AeMskyjkdK9K0i5t7qxR4Njr904qDVLFDIzqNrbetWrbmaqdDyYamYrmO2v13tkDzB79iK6g6JBMqmCUxSOMYUY3A9j+Fc9qtnZi6LzZSQuc7TnBFS33iVtPs0FvCXdAMHPtWDsmuU3ak9jqIdOl0gMHjBgboOuKhv47/AjYBI+qup/nUOj+KZdU0Z2uoSpVDu7/jXM61r+qXN2baJjHbKOMD5iPWrc3TZnGEpPU6C0u90YTdJAysyuw7MD0/GvQNNn822jbduO0c+teWaaxhX94QQ4G44yNw45ro7DxCLOKGO4ARA2wN7VtCsqnwkTptHfd80pPFZFhrNpeDMEyPg44OcVomdAuSwxW/MYD26VyPizF+6aepI3nLn2re1W+SysZZ2Bwi5+tcxZ3i3NwJ5UKyugyD/DQ217yKjudJo9usNrHEgwqYrVz82RwKxTcSQ2sbRDd+8AP0rXVgVGTQu5L3BuvFQs5aQKBzT55FReSBUWn/vpS2eM8VXQZZWEIc9xTIIjGzMzZzVl/lbFRP0OOKSuIUZyc9KqyK4lAT7ncVYimUSBW607b8xNUtBo5nxRE0CRahCSHtjkj+8vcVr6fqgurhUX/nmG/Op7uCOWJ0lAKMMEGsDSrgW18oZMDds4+tEvejbsCR0M0KTXBUqMiraBbaEk4VQM0/y03eZ3rKvrj7UpjQ/Kcis0rhuQvcf2hOREQyKcGtWG1RFHGW9ayvDOiJpEE3ztK80hdi1bnetJJJ2jsFxcDFRRyOJ2XHy1NjI601mCEcHmkgJM7hUbcHinsemKYeRTsCGPyOa44m/0r7THbnfGo3n2yx/piusuDtiYjsKzNMmg1L+04SpDr8jkj1HUVcXy3dtBNEWn6lJbWsSX0u+WZgI/Xnt/OoH3XPiSzjRxsVSzr61g6nfwWGhLPG5lniUwwsR0JNbPgWGK5b7e3mG42eU2/se/603ZNyGk0rnYScRmoo+Y/alu5Nq49aSzj2W4UsWOScmsw6Ey8LSqc0oGBUUZ+c0CHSHHekzlTSy/dzSJ0IpAhAeKRslTjj3oyMEihSAMc0mMZghMZP1zzSQkjggkepPNIsyF9o57Z96TgtkdaYCSDvRTnHr0opgZ97KqxuckHoK5nSrSZ2abUyskkcrGMjqoParj6naXF08IlWSROoU9D71V0+9WW5uc4WOJipJ71tFSinoTuXLvRbSSe0vC3lvASV5xuzWN4okmJiMaqyQ5kYEZzxjP5nNbGr2seqaeFVys0XzRsD/EOlcp4lurpNKtpomQzr8shHTPcVjW5nC9zSkveLmgabE+nySl2/ejkAdfWpbzy3e3YqCyHG3+4QeM1H4K1Rr7TriO4G2eGUgqOwPPFN1dTe68i2pJjiiUv2ycnP17VxL337zNdnY7vw+2YGHbgioPFVstxaFT0PBqbQFKw9hkDpV3Ubfz7dh/EBkVutjK9pHkVvpbWmpq6TBREwCK4+8e4z9K9Usvmto2ZQGI7V5f44jezaG5Qtu3YGOx9TXf+GLs3Oh2sr5JKUcrXvMuprZm5AobdnrTWGH+b7tLAQr89DViQbgfSqZiUZ2EMTN1HrU2nyiSEYzkdcjBrE1e9a2uYLcqfLkPLf3TUunS3AuGMgB4wMfxD1qWmtSrXRrSFVkIPO7rWXeaeskm7IK9x61df94Scc0xFxj3p3BaHP32mmJg0e4rjBI6iuV1zw/d3DH7FJmAjITgYPevTJVXBBAP9aqy2ayL8g2j0ApStuilNo8n0W/vPDpO5y26Q7oyc59TXS614xjGmJcWqtLkZbtVjX/DIu5opoz5c0ZyGHevPtd0280xpoLYOY2BIHOMd6icFa63NklUZ0ukwQ6tcLcEgvKu9ox296wtWjgg18LJAyWocDewxn+nWovCGo3OnHYsZeQAnDdh7VpeJLu+lsmhvdO8tp1BRw44J9a5dp2Zp7ydjcnZY7ZohGsQePIKDtXN6XAJbaS4dAxhB3Fm6/lV9b5k0KISJ/pcSeXsPJbmm2NzHZ2s9vdWoR7oDyyP7x9Kia59hRvFFW5dobaIRIVdxuPOc5q5HA9vYwjUVBtpsFHPY1Z0mxTUrSZ1Gz7Oo4P8ZrpW0sXfhH7MRkxjcoI5GK3pwULLzInM5KS6XSpDJaIQZQBlQCG+tauoyS3mkrG08iSOA3y8Ec9K54hij2sfLJgpzyPWut0O1a40wT3B25U7QfUVr7Rx1XQmUUlqVL/V9R1ERWsUf2dIgC7uM76sadA39oXDPhgoB4PHTmuc1C9utKS1umz5Fwxyuc7R7VqrqVsbCSRJtke3eNvVmPas51m1toHJbY1JtQtze20Ml4I5Ac+Wp6/Wuinv4re2MmWfHZea8hls11KLUNQMzJLbJvAHVj2ArQ8M63NuKXU5ZAQMMeelWqy5VbpuDonoOoQ/2h9nnSaULHh/LXjJ961tBieG0DS/fbkg9qydGnV7QYycnOfWtaS+jhdF6Fz2rpjJzVkYNWND9c02ONjKdx+Sk8wBdzGplPT3oEQyxBXDN2qxJt2cU26I8vntUKNlRzx2p7oZT1V2S2coMtt4FY3h60kPlG8O+UsWJ9PStjUyoicvwuOtV9GlDTqOOmRRKTURo0dRuGiQpGMnGeKisLYM8bFcHGSPQ03xDJJb2/mwpuOQCPap9PkwAeq0o6RuI0GUAcU0HAouH/cNt644qlpzSkN5mSPU00tBWNAHIpSAR0pinnFOY0ANfqKO3NK33c0mARzTGVL3IhOKSzEcKSsVCrtyxx1ps8qm4SHcN7c474q80SiIrjtilLRAeU6/pgntXexZplnmE4DHG3J9PpXd+CvLOjJ5S7drMp+oNefeK55LGW8+ykpGCF2qSCAB2P1JNegeCWX+xIAFKsVDsD1yeaTlzXNJJqCNm6Xc6Adc1OMAAVCTuuB7VIepqkZkgqJR+9NSfTpSEc5ouJCtyKYvy9aVskrtIAzzkdRSOQDS3ARhwcVDvJ+7yalPI9KjRCpO0D3zQMQRJvLkfORjimqAJCoz61IQSR2HtTlUAYPWgCNj7UUScUUxHnumWkMFzJ5EbbDHvkcjkk9B/OtPTNNs9Q0lYQroHfLFuuat2ZisUiS4fIzgs/UmtRHgyyqwPpW06jeqEivbWEMcYt0BDIAo9xisC80e0WzbTyD+9dnXPUHrWxf3v2SOa5XBCepxUNpuu4Y7mZV805PHbNZO9m3sUtDzbSTcaLrc0ePldNrntntVq3ttRtp5WeUySSHchHZT1rs9T03Tb+ZFmkWK77EMAT+FSwabbhsM7NNs2E57Vz8ttlubOabua/hmZZbddjZAXHHqK25WCqSxwK53RI4tPCwx8LntW3fDfbPjqRV6dDF7nB+M4zJCyLgxs/OB25qx8NLprjSJI2AxFIUX6cU/xFbbbSdC2A0TYb0OKi+GMRj0UsQoJfJx3ouuVmj+E7poRs4PNQq8mVUc81Z8z7o2sd3cdvrVeT93NuApmRHc2qsQxUEj15pYIw+ABgLxVhpUKZz+FV7cuszAYK9qVhjnj2MQxG3FVgpLtjOBVi6kJYArge9KdoY7AOnbvSYFeMAkhjjAqMFlAGSfUnv7024Z1kYIM8YIqeKWNlAkXBxtpDGPskGcDNZ2pabFdw4dQccZ71efargLkqKkh2lyCeCKLDTtqed6rpUVt5lxaQMkyfKB2P8A9asKztb3Xr5IZLoiNSoKOPuhT0r0zV7HzIZFQ/Ng4OM15hPdzWmstGkRhnRc7s8PWfs9bo3jO6Ol1jw/5DATDc7D5HX19K5jUrPVra8t/NtybZfulfmwfWutt9fa4iiMsiuVGM47+opda1DbZP5ZIK85/pUc9txJyRR8LarbwSSwXYEbMQcetdfb3KvL5cTL5b5Uc14vdSMupyuWZhkZR+CPXHpzmtnTvEJt73eC5QAbSOoP0rNq2xUqd9UV7Pf/AGndxOcXAmK9euDzXqFq8EOhwvMyiMId3OByK8umnjur25niiCu8oYAnpnqfzzWzqN4z6UllHcYkYfMo54pXk3dFTjew+9W31RbSxmbcLaYsSOjJj1965y5njt0lt7fdtLA7f5flWrbrILB5LWEJJvEYDdW65P6VmXli9m7i4GyQnOOuT2FOSWqHAn0TUo9Gm33SmRZQVcFcgfUVPoVhbTalKlliUP8AvC4+6opbuzgSygd5CZ5mYFGwMMP6Yqbw7N/ZE9yLdN4dcK34+lRGKUb9Qb6o7mADTYkErBU6AmtLZE6pLKQxHK49K4RteTUEkkn3qFPAx1q/b+J7eRBbRli4GCMdq6o1VFLuc8qcmdpFfQtIUUg+vNXpVM0SeW2Oc15xcapDZFF3ne57dRWpZeLI7W3VbttsmM4PWrU9dCXTdtDu5MFADzVC+u4bKHzpsADjNctb+NUlvvI8mTyyOJOxqj4u8RWrWYUkOu9cgfWtdYtKSJUW9DptW26nY+VG5CyAcj0q5bwrZwJI+ERRxmuf8PanHduicKMAqPatvWblJYFTGcHIGfvVHtOb3UNxtoaD3cdzbyAHJTrxUeiTRXcDNGehI/KsHQtRFxDMyxuDu24IxnFbOiRJAJI40KqWLc9ya0UeVNMlo0pCUAwM5qO0nMkkkbDGOlOgn3yMpGMVOkaqSVAyab00YDEAjYjd19amOSKqyxM8mcnAqxu2RjIZug4Ge+KGAOeMCkjO44qO5Yqvy9aiacw27ufvBTge9HQCo1qF1lrktnC7B7U+/wBYFsJo/LJnRNwX+99KrWzT29lB5haSe4c5P61He3Kre2cc0D+a+V3Y4qnFt66iOR8Tob6zSVYxub5mXp81dv4YQppFozqFlKBW9eOK4LxTMbfVfssgAFzIixt6DByPzrrvAcm7SRaSSiWW3cq5655yK51HqbSfupHRqD5wI4554qQt+9IwcAA57UhXDipOprZMxYo6Uj9KHOAKaTlDSAZGcnrS3HGDTY1BNPuB8op9QEQ5UmjuTmkj+7igZBpDFNPXpnvVe483A8oLknkk9KmTp1oEQyjrRRNnGKKYzn9X0+HUYgkhOM7gy8EGoLextbW7DhpBLjH3iR9SPWorO6h06dNNuZZZJGOUc8j86sTWJ/tcXizsUdcGLsD61d2ly30JM+LRGkjuUvLmSYSvlRnhQK0bd3sbsRrGPsojCIcd885/StCOKVbzcADCB0759arape2llD5t1KIoydo3HvUym3vqUiDUrKCSaOSWFGcHKsR0pI7UR3LTrktIAD7AVxXirxVdxXkMWmxrKF+dsn7y+nt9a6vwtrUOt2EcsZ2t0YHqrdwa51UfyNHBpXZqi0/0jKMw8zHHYVZnnktEETnJPf2p0Qw8ZJzg1Lq9ustuz4+YDirvcnqeVeN/FObz7DE42t+7A9M9fxr0DwpZiw0W1hVcAIOtefa7otnPqVncBVCM2S3v1r1aAFbeMcbQoxSlZJJFztZJE6uUBx9aY75O4nrSfeU9enSjyRFCi8kY78mgyHwsu7LY9OaVYnaRpEO0ds01MKc4zinxz/eDcAdPemBGdzSESY47UCGYMSu0DtUluN8jSH8KskcUxFZoWzk4Y1DJAGcg8VdbODjrUTwmRgScYpWC5TMALYFTQQK8ZOOQeCKaUZJCGOFPIq6ihEAHSi1h3KE9uUBY4YZrz7xjDHZSm7ljdlDAYVeMc9T9a9NugGgcE44rC1GyS6h2TICD60WT3Ki7Hl8l6NKkVtmVm+5tXOM965O71G+lu3S7lYR7sgY/KvQbu2Mt49vc2wAhfap7YpuqWGlhFWeMKzHAIOK5K0OWVmdVOcbXZlpYQajHHdYEk6r5kg9QKpT26HUUudqC23DoOij2rpHsVsRBPaufKUYI9Qay7lLR7WVbfLHGSPT2rCKaWhSldk1zPBc+XPY26ko20YT79DoourabUImiEoCEhfukHr9Kz9C1DyL4xojHIwARwCP/AK9dDpmoLd3P2i5gDmJiPLkGQPXHvXTCDpxs0ZT3Mi1juIdWnikJ8qBix9/SrfiKFb3SZXUq11uEiEfeOD0/I1Feal9tubt7KAobhcDdzg+36UzSWuI4jZ3yKZSBz3AJqKl4zUrdioq6EFl9va1uJBKZIolYjHJb2Fbvh60N5pF9PHGoudrqikfXFVNdgm0+wRrdJQ8pXZIOhqtZareWFlKi7Y5HXDBh0J9+x5qXt5MTTa0MOxsbudWSUneeinjNU9XhvLA29yke1S5Qtnkn0rrdMmDR+fdIiHZtjKn25NQWdkuuW/2UyiSEMSTjlWxWji3NytoUp9zMmukT7N5sZkkb72T71ZutNspLhZpZAQ4BIJ6ewrUh8OwWEIF0Gk2ZZSD29KbbzWk995bwpsVMgHnFax6KPQzbXQqXVramw2W4kV0HyYOAT71lJDHNG0kqfd4IzwDXby6Mk9mJLeXDth0ya5MaPci+MdzNlGbIVR3o504tNjjvoQw3U2iSxzSxHDkAEdh6V6DptvFqUdjqMhbcpOBnjmuO1WKVB9lkjzFKpHXOCOnWtu11q203RdPtnyJDnK/Q4rOlPRW3/QKqudpPCluI9igIxpba7VbgRqAW74PSqcl3Df31uYHDxrGXO05HPSobCzW116SZGJWfqvvXVStJO5zvRHR+SGORxUyjAFM3quASBnpTwCOCetUSBPWnpgADPJ5pu3B5oEkfUkZHQmlcGJOgb5vSsW+klkR1gQuy9F9TTG1+K41Ge1gDbYfleQjC59AabpkN22pTSOwW1UYQd2PrW0YtasEzYjTZBAkpUSAfr3xU0sUcseSqlhyDjoaQxq20soLKcqSOn0oIwuBWe4zz34g6b50Ed6AfNtQXGB3GD/jVb4VagZdRuQRnz1EvBzg9MfpXUalHMy6p5wzD5XyA98jBrifhFKkV3cI4xIQMZHuahpxTNU7waPXpM7c0kZOMk8USn93xTYzVIx6D5eUJHamJynNSnlTUaAkUwQIME0svKdKZu+anKWZX3AAZ457UgYR9qHGPxpVHFKelAyCUuCgRdwY4bnG0etOU4JzTj0phAbhsEGgRHclhGxUZYDgetFOlGRRQM4XQ9Z0/XG3QENMnQkV0NuFyPMYADqa4H4caJJGBcbWjHO0EYyK7WezumnLRyIIsYwRyPenGPS5U7J2Q+51ZYnmZUclBleOGqPxBZw6towzEW3YZeeRVey06ePIaUyBiTk9vaq813eWF1IJRm0HQ4rT2aekdyE2tTnToWo2+so4gDWbJs2sc7RjrVfRbptL1ea2WDYrNk4H6mu9XU4JrdFdh865XPesa6W2lkfyY99wVIBX/ABrkn7t7o2UuZWZds9WE0yJBIhKn5w3JxXWW8i3NuM89jXgOmX93Z+LALlGjBcq2RXuHh5t1uxDZB6VMLrcKsOU5rxXpEXk3ATKhULDH55rd0O5N1pduWkDEKASO5FS+I4T9lMiqGboR6isHwY6x3d1Zbv3fEiD07EfyrV6q5O8bnWIu3J6j1pXcvwelSSqEj4PSoeg3UbmY31yMHNSRRB/mzxTSM06CQRgr29aEBJbAAyJ3VqnqG3yd74+8eKlJ2jJpgNbJOBSikRg43Kcg04YoAayhhyAad0FKKWgCo+/dluFqvfNtRHAyK0HAK1h6uxQFVYhcevek2NHI+NNVgtSLZXxcTjK//XrkIrabUxJBKXEqnckndab4muYoNZk+07XcsG4GWHoK1NCnZuJC2ZAedvQD3rCcXpJI6o+6h1o00FhDZCTzWRSCx79af4J0pJLyZ5ny56x54K1d0+2hhS4MZyZQSobqKPC6RJMWdyHjc9fSteeFmjJ3R1p0GwKhhbxhwOCBXF+INPlg1RlR2EUvZeMHFeiQzAjaSCcZHvXHeIL2CW8dJvk2NgN604tte6TF66mWLeHSltixZ0D8y9NprHm1WO41KfzQEuJpFKHI5AyMVt6nbk6RGFbe/mDbu7rnp+tc/Jog3ibDK6jl2/pWE6V/fkbQaNjV/F0Z8O3MUiFZofLEI7k8c1jQST6lJCbkgS3CA4UYAHPX3rMmtR5qSSZck7dhHBINdVawIVjkVVUxjbgHpWM0qaRaSWw+8K2MMZVRKkAJC9m9q09D1GFbuOZbcW1ndKXRSAMEda5q61W3+xyuGO1ZggOPvVS1W/v2k8tYyLeILsIH3a1otyuiJRudn431h4bS2gso9z3RK7+wFZOhSwpYSy3CL9oTAAPGR0qLS7acaOlxqBeaKOT5OckbqVPlnjYgeWxPDdx2o5mvcQRiramrFNL9keTdxGCdo7j0rOkv52uIJZEVEDAZzy1dNeva2mipPFGu84BA7mufv7iCaGAzJsLHK4GAKtJWu0StXoaFw8N5A1wCh8jJUZ65xXJajqNq1rHBMhe6jmOD0+UknB/E10haCzsJN6/uJV24I5z2ri7S3M2pSxFjvL5jZhwVzzXO1FP3TWmu56F4NtpYrHzRgFm3Y9q7OMqki71GccNXK+ErG4tLNjM+VY/LzwBWxdfbGuraGCIGGQ5eQnoK76a5nucs92POtSDWEtWtXaE8iccqDU8mvwpqQtSH3nocHB/GnDRoxatH5su9uS5bmobjw8ssUA+0TDy+pB5b610L2b3M9S/PesSNgA9axbq6me+jjAZ9x4RBn862hZoqBctjGOTU9jbRWvEaAe/eoi1HUooPpEdxt+0LtAbeVXjd9a1I0CqNowB2qWQg4pAcZpczYhR0pCOKCcd6QnFAzM1aDzIpFOPLZCDnseoNcHpGnvY+NFljUiyl2hD2weT+td7r3njT5Ps65kOOPbPNed/2lcP4ytdMlKxWsTjYT1LY9aat1LjfWx604+TAqKLg4NSRPuz7U5gNwNRHVXM/Id2pFGKWkpiKrtiUip1AK4PQ9qqyLi6cjPQVaj6Ch7FDsAcUw9adIcLmo05BqRC9TSED05oHWg8A89KYyG5DEfL1op0h4oppgcn4VuDKrXcsRjVziMf7IromTztzICFI/Oud8N31tqQIt1KRxNswR0NdTGCqFc8dBVVNJbWEhsdooAIP0qpe2sbRNFcJujNaUattG05xUcxMgYbSCOhNQmwOJ1zTdnl+RGfKgXgA9e+K8z1rVZdC1iG/s9wh3fNET+f9a9s1yy3w/eZR146V5v430CO/hSdUJj+6wXrn1oqe/FI2pWT12M/TNXtvEeqGXaqTKoJX19/rXqfhe5UxqoOO2K+fbC2uNB1Y3Xlv5MTbQ3TNey+Fb2O/gN3buA3G9M9D61zKm6bs9i6u2h3l6nmWsi+o4rxoarLonisyTOxRpNrDHYivZbaQT2wJ7jBry3xdp8Q1dI2jLNI+RjqMelddFxu1PYxjezSPSVlMkKtnqM09PujNU9GuEn0+3kT7rIOtXcZzjisUSNZvTrQ/HA6dqUpxTijMm7FMCWJsRg9RTzhxj1qqhKnHrViNxnpTEPRdqhfSnd6PpTQTvxj5fWgAb36ZpwORSMMrj1qHmJMM/FACXcoSNsVxWtap526KAkSIpI962fEF4YNNuJo2BIHXPTnmuA1S+E6F7Ip57R5LZ/QUNe65FwV2Zus2yXEkc9xGvA+aQd61/DscMyO0QyEXaCPSsUieSzjWZwSy7QCO/vV/w1HcWqb7mURgZUqAMGuaE7p3Z0TVkbC2U1xAZY22+XnC461xt3LdXWrC2iLxzQNk7eOK6a71WZEVbfaFc4xnBNJB4euJZjcxkCWT7x7kVpCyu38iVdLUksdbbT7t4r2YsWXKVVv9W0+8lNtcMI52OV75/Gq6+RNfPDdpi6gz1PUA1z13HbXF/I0JYuDgP0C02+R66MUYKT0PSLBfMjdJYvliYbCRnNS6osbxllQKAM0vhmQSaVErFfMx0znNa0ttFJCGZQcHODWKlz7k/CzgLi0e41BTDChMY8zaR976flWDI7h2eJnjkDcjsTmuv1qeLTdWgOGy42jb0Fc9OjgTlAGBYAY785rnn7rOiLuZ2qRL/YkpiIxuEjx9y3qK1PC91HJpMkwR3ZxtlVz0x0NUYIJ5L6IK4J2B5AO3qCPWtu1RIYJFjUCNxlsDHOKVJc0eUqdka2mW0k2LQunkS7XUEnj6VW1Wzhs9R8mRgW5IHQDjNJ4V1RLqR4ZQgaFR5Tj0pmtWs8t/580haPI5XqK66S5JWkzCV2zWLxvYRZTfEQGOKzdQWHVI/s6Ky4HyEDpio9HguLdzHI7NAMiMmti108qFZOZAeo7g1TstCVpqc3qE8k0KxzNsCjAPTIArC064Q6rb+S2MS7Vf1rs/GdpEmlNMOqEEj07GuMiu7Se00+SGIxhZdrlR1NRGCSukbQlc9jsgTpe6QYwN2BWhpxaaNXIwAMAGqumgSafEin5SvJPpV7T4StuU8wtjvW1H4TkkWQM4NSrnb7VEg2gCp06VqSRMvzc0Rjk0shOaRfU0xkpAxUMob+Gpuq0EdMUIBmOBnrigU7g8UjCmBFNkg4615b4w0y4ttbt9TX7iOPMHXof8K9UxkYNc94jsjdabdwoB5mCy5557VMtNTSm7Ms+DdQk1PTFuJUCMSePat8jnNcJ8N9Rc2n2W4UoYyyqcYDYPOK7vIIoWjsRNWYUlLSUySKRQXyKfHQw4pE44oGPk+4agiPJxVhhlT9KqQ/fzxSEiV+D70gyTTpOaRev0o6DI5OnrRSydwOtFOwHnNlv0TWUjjCvZygfPjB3AdTXdw3McgjZTweoqjregQahbMhX3BHBB9RWL9pudH4uld4UUfvFXOfqK3latZrcnbY7YOoXIxjrSPIphLZGMVkaRqFvqcO+CYMvYCrWSoZCMg1g42dnuNFmSSOZRGcEuOAazbvTo1UpIMIw5xVu0wsq7u3SrV0jSBQmPXmltoM4LXtFS+Is3izan+McEHHBrh/C5k0DxHdrNOgso2MbAtycHGce1etXm6FmIBOBkj2rya+0CbUtTvWSQRSI5dWJ6g9qiT3behtDVWZ7DoV/FOg8pw8bDcrA8HNcz47sriXUbeS1+VlO4H8qi8CQy2umRwsw/dMcH/ZPIFdP4it5LjThNBjzVANNNJ6ELRmF4P1VEkOk3Eg+1Rcj/AGgea64E7uDXkV811HPFqsMJE9rJiTHGR716bpGoLewZPyyLwynqDUvTVBONmabuCuBT7dpDCvnhFfJ4QkjGeOfpiq46465qUQOwGWIppEMZIQHbb0FWNoMYI9KryxsoPpToZwqbX6etMRNDIGBHcVJnqewqr5gModB25qyrbsY6UAOByAazdYcCFvpWiTxXO6r5rGZWPBB2n04qXsNbnO3x8y0kgJZ45eSfSuYijVJBDCvzox+b0BpxutSR51kQlFbcAOuP8Kq2VytxcSvYrJ5+MupXAH50Tvyu7NoKxDqKDTJFjkdpFkbk/wB0+tbnkW8+m+W+5RMuN47Vn6vYTXWlvLtDHhlyMZ5oluom0q3spm8uaVM89ua4YqzTN5aqyEW3sbKeGG6kfao+WXqD3r0fQRbSWkcsU6yoRkEV55aaNNNarBNIsgORnrj0rKNlq3hy7JsZ5SM8hDlfxFdDm6krJmTp3WjNvxXYz3esTizQpKh3A929q5ZbO4uUk2IEmU5PvXoVhfy6iEkWEC52fvMjHNV7XQ5pdS87mJi+4gdMVpJynZS6BB8qMnRLi7t7iGNoiYc5LL1U/Su8lmP2fIOeOg71UuNPaISYIRnH3xUcNncJBHiUMVb5iT1WqdNcvMtDOUrs5LxPcJc2ZZhmdflB9DVrQ4orvQljUgXII3Z/h5rX1TSYL3cCpXdgnHrWfbaedP0G5u9y/vJNvIwcA/8A6645QU9PM25rR0Me5d7HVZUJRndSqcYyf85/Kus0rS5ViuDMA8eBsB+lc1rlzbzQabZXEixXvmb42K9VJ4zXUWmqeVpoSVgZMbTjoSPStIJQWhM25JM4GGxmtdZufJJRVOB/StjQZbqbU2SfLwk4JarssUsiSSqqeY2WTHcg1kW909m8qSMRnnryWzmo55TbSNHqjpZ5rdLhdpKohyRVjTddVY5JFgdo0PzMB0pdJ0/+0rAzTgDI4I5IArmIpGVp0tzJEJDwO5q1db9DPlUtEdD4r1GDUbZbaFN0Un+scdh7VwaaE0F7AFLCAsG6d61oGlivn88gQKOnbp1rvNHtra7tOVUlFyM9q1VRQatsC9xE9hKbSxZuWwvT1roLJSIFIBGRmsS28ue5EcY+QDn0rqEAVAB0ArSC5VYwkyEVIhpCACaaWC85qxBMAxwRSIMcCndeaVOtMBkLMxYMMAHipQPlwKKUUCEFD9KUUEZ60AR44qvcpiJpMZxVsjimcGN1PQilJXQ7nnUaNZeL4PLjYQzOXVgeBwdw/lXpSAFBXE+JJG07TUu41G5HwM84ya6zS5/tFjDKOjoD+lO2ifyKnrqWqKTGPc0o6UiBCKbjApVOadimAinIqCNcPTzneMEY70EY5pDHNz2oC/LSA8ipO1DEUJGy1FMmOJD6A0Uxl0YAAzUN1bRzowdQc8U6GUSd+alXIPOMVIjj59Jk0m/W7syFgJ/eJ0B9/rW5peoQapZebEQQuQfY1pXEKywsrDOa5J420fVoZLZcWlwxSZB2PY1rf2is9w8zcRweCRnORWjBIGXHcdagt4EIWRcdKtRoq8gVk2mBka/M1jbzXCRmXCE7B34r52mvbwXM8gaWN5JCzBWOBzX0rq8Pn2hQHGSBmuBTwrarrBEqkCY4C9j3pcikjalNRTuU/AM1xB4fkluFkk2sSAeWIrv9Ovo57XY5AyOAe4qilvFbMbZMbVGCq9qrQ7YrlrUnhcNE/cD0oUbpkyd3c4rxNK+jeKWMxc2NzGSUx8rH/OK0op49EeC/a43Q3A+7nIxxjH4V0+u6VBq1iYp0DOoJRvQ15DO1zJq66XcM5t4WJhBHKH0J9Ke9n239CrcyPdtJuYryKKaFg6Ou4EVp15l4F1kWzrZyAJGf9WC3THB/WvS43V0BU5BqEzOSadmJN8y7R1NZ5QxP831rTwM571XuYyxBFUSiJFLYI4pxBgAPJz2qWLgKncVMRkYoAqSXSqjEkcCuE1vVzLqqwxMQpB5HY5rpdcKRxSljtRVJJ7cV5jKjya2lzbShoCOFHPak0rNs0hHUc+oT22uMkkrFWHyqwGMVcZYrW0Lonzynk9PrVPV7q1t4RJKu6SNvlIH6VGmpwTRxlnBDNyCO39K4m3JJpHQkXdK1MuGhcbh2z2P0qvr9k91Zx3cSjzkJ3Y46ciiysbkXrCFP9HPO4d63YbWT7HOykjIO1TWjhyyTRPMjB8PX0sk0KsHwCF5GMiu/gsotuFQc9a47Vr2bSbWBLW3Te7YVT0UV2XhH7bc2CS6giRluVUenvW0KVryIqTvqiKKGSLU/LEWI8cSD+VT29xs1B4ipBTnJ6EGuhNsjJwOaz7q1EokVBtcjr3zWy5X0Mbjby3gu4xGzEoeuDTF0uGO1eOJnBA4bOap6dFdW0LCdgzKT1Paq1zeX9wkkdmpQqclvanyP4U9AMS+up7WTY2DtOGNP1GbzNAltpYwwV9ysDzjOcgVO2kXEc7T3TLJ5pUnj2waqamrkShELKuRgda5sRZP3TaGu5yRVLjWftE8qpIoVUEgGQvpjsau6xN59/bpv2eXu496qx6bLe6rFNKmzBB5HXFbus2UDy+e+1SmGJqI+5qzWVm7FIai32KSSJfnt3Gc9xnGKXXYLe4t0uoMBmwSAOvemRafJAwjlkUxyn5yTwQeatm1+wrFGQWUsQuentTguVpoltNm94c11W0OJ5QElX5CuOK5F9ahvNemgiiMeQVUju1bNnAxu5w3EBXG0dKzb/SBFqULwcsxLZA6GqqRjFvzFTSuT3MMa2Em/O9lwQe59a6TwrKGhudhIQKAPr3rndVhl+1WyOfnl647V1OgRJDZOQMFjj261jGDshzehq6ZDskkKn72WNdBFINoDdRXPaU8ktzeJjCqQEPtwa3Vrua7nM9WPLZJqKaLzMHOMVKKUCmA2IFVAY5NSCkUU49KQEbvsZBhjuOMjt9akpGztOBzTYGLLlhg0xDxS9qB3oNADScioTxkCpXHHtUQ54pjMbxJAk+iXKFN20E49an8LXKS6PCU6AYx6VYvELQyjGSVyB7is3w7PGs5t8Ku0EYH1yP51D2K3VjpOtNY4BpwpuM5oIQyMjNTVWU4kx2qxjJHPHpVAyu7YkxU68jPrVW44n4q1GfkFIb2IWOHNT+lQT/f/AK1MhyuaGIoXCjzicUVNcL85NFNFGd88Th8EZ9a1In8xQ3FMuEWSMj06VmtJJaSB1OY84YUtxbm0OlYOsSLHOYOjSDcpI71twyLKgZTkEVU1WzjuEjkYfPGcqaI2vqJGf4au52hMN7gTKxHHcVsXDsqqVO3JxzXJeIppNPEF7EwWJXAl4/Cuqsys1pHIx3bgGBqprafcNhyK8sTBj1rK1LyYYWnlU7ofmBXrWvFKpUjOMEiqLIkpkjl5VwQQe9ShmFpd/HqN3cSxqwwAd571bCLLOsjKNy9DUSJFplqREhMcfUDk7fWiWL7dbSrbTBS6fK1aSs3eOw9i28jW6FmXKAj8q5jxXplvBcjUI487lIYqM5yOK6G+0q6k0+zgS6ZHiIMkmM7vappYYnie1chlxwPUVEkkroItnj0F35+m3Ebq8c0LGS1kPGD3WvTfh3rT6jpyi4bMgA61zGt2cKpNabYjE778g4ZT3rJguJtGnt72xSX7IzAbscHtWKfK3Ha+xtKKmrrc9yHSmF1JIzyKyPD2tQ6raK6HDdCPetghRzxVJ3OexHINhDAHinNKoXdmnMQFOelYt7cxwKz7gMcgmhjWpjePp0j0SYgne7BcCuKitWt9Ot7hCVIXPHetvVtTTUdKuZiodYyTjOQQK5JNWuZNOjT5EDNtjB/SpqySp8nmbUk90QJBcObzAE6Pgru4wT3H8qn0XTCxb90smwglge1TadDdSaokV1hTjcdo4rodMsZYtQkFrF8knB9BXEk3szolKxf0VwsckSOCv8I9Knl82CaCCCPdvPzMTwtJotibdn8xQGBxW3aWLTXiuSNidBXZSprqc0nYyLHS5r7UpDeRfuIzgZ/irqdojACcADgCpjhH6Yz1pjDJ4HWtUr6mTbZZikBQc1Ul5lYr60u3BFAWmlYRA4BBDDk01FWNMBRgVM60bvkZSOKb2GY13cFohFs2uGPX0rF8RX6aVZfbQgds7Sp75ravImaYFfvAfzrB8X6U13YIu47VPIHeuasrNGsEr6kFmseq2lrewMuQCyqDkjHXNUtZlSRHDoxZmCkdvaqXhbRJ7C+hlsZStvclkO7naas6hoJF8trcXDkMQVb0NQ4K25ovdYzY0YHBCBcOM5xjoRV6eKS7sIprR/NiVOo7HrzWMZit/PZnc+z5c9CxxW14buraC3ktEDJuJGGPelBuCCavZlSCbFqVaQqRyOetVIdX83UYwH2hRgL61s2qW/8AaRtzBkLkMxHFUZtH0+61GX7O7JLE2SmOT9KfLe/MPmSZCB9u1E3EchduiqPyNd08bwaJttlAkICqMd6x/B+joL9iY9iAZ6cn611WoP8AZmkWQRraxxhlfd827JyCPTGOfetaas0Z1JLZD9IiZbZtw+YryfU1asXZ4/nGCDS6QySWiunKtyKn2hZjitm9XcxHrzTgMGkHrTqADvRR9aSmIaxbzFx0704UGlFAxRQaAMCmhsnFAhsbM6HcjIfRsf0qugIc56GrJcq4XGQaibAkxnn0oGhrg8Y6iuVvrL7H4lhvN+yNm2sPWutJ5rH161e8iKRjDFcqfRh0q4O0h3sbyY2il7mszw9cST6cn2hdsy/KwPqK0s/Nioas7ElZziX3zVpQAOBjNV5x+8qdDwKQ2V7sYdTz+FTQMGQYOaJ13KPaiLp70w6DZ1yQadEcLzTnGRUeOh9KBCTUU2Tnrg0UDF8oHIzWfeoqv5ZJORnFace4liVxzgc5yKbNCkgywBYdDSvqIpafJscRE8dRV+Rd6kVzzzEO3BR42zW9ay+ZArZ6jNElYfmUr2wivIZbadQ0bjBBrKk1WPRJraznV/Lf5V4JAxW8wZ3JU9KiubWK4C+co3LyDjkU4yS0lsJ6lU6lb+c208P95fQ46/0rnNT1+3luXhtbpEmtzucE4xVm50O2aee9mnnUOuG+bHArkm0KG81KKbTHElpIOcnk845/GrtCKuhxjd2ZePiaG58Uw2sNx50cybSAOA2OcVenW6tbvyLR/wB5KcqmOAq9R+tQ3Hg+K3MModo54cYk/oK7CazS5tbWfH7+E5DDr0waITjGzHNLZGtbN5lvGTjlRmsfVoDFOsyNtUHJHrVvTrg58sqQB0NS6pF5towAyetZJ2Ylocp4o8Prqqw3lkwSbGGA/iyK8pudQ1bR4X0q8if7OHyg7A5zXrtreNDcLHITsDZwa0r3SLPVkDPGjN6kUTt8M1dGkZcu5554Qnl06USBiILhg23shNekW2qxOcs4IHXFcn4g0JrOFhhjAw2nAyB6VyZW50SZ54HaeNhwpJI5p8ilrcTXNqj1DUdcg8t0tpEkkA5UHpXDaxr6z3QsyjeVP8rMO1VLe3jCNcoxXzUwwY42E1R01FtpgZZ1nTJ6nJFRzQT06FRpst288GnWF5bbmkDg7QR94muU1ya5kFnHbpsROV2/eB4zXcJZNdiK5WD9ycjAH61s2fhiGa4FxMA0nbjAA9K54pylzSNVKMDktHvJ2tXdU/0k4Tc3JNdnoFw3lh2GWQ4cgd6mt7BYdYa1+yjytm/zPer15LHY2E37o7SMjYOc1p7JLRLcylPm2EiPm3BzgO5JAratI/LXkfN3rktFuJm12KORNyqnzOR1JrtnAYjaQDW8o8lkZN3IpWyenOKaTxSyxODuHIphbacNxnpQhC/jQT+VIcUN0oAGG4daiwQOalXhaY/emMzL9xbzLIR8p4NY+oy3Dy4jXdG38u9bt8MqNw4NVbS3Et3GP4R2rOpYtHO+Frz7Fcmx1GPy5JpC0TY+U+1bHi3TN9v9oi/1iDdx3xVnWNLVdzFcjIZWx90iqmpanJJp7x27I8ka5ye9YSdtSr3d0cHfTKL+2ZAxmbr269K3BpF3cFZZ4BGVIbcvUiq+gW9vqurSCSM+Yqq3B4U5r0VYwgxjPGKtKytbUqU9dDho2e9tZZLR2W4jYgfw7iO3Nc1pvidIZ3bUott2jEZA+9XYaxc2TNdwW8TRTq+WA+XcfUVx1rpo1TV4YYrZ/mcgs49+tOEG21bQcbNXZ6n4QxLam4AOHGcn3rJ8cq01u0AlKtMAiDvnNdXa20em6YkUYACKBWFbWY1K/M9zuKxv+7Fb0Goy5uiMHqbvh+3+x6PawN1RADU00gScA/xVLJEfLUIcYqFYg7Bm5YUr8zcmJFhTxTs0xRTsUAO7UCmg4wMk0bvn2+2aBDqRmCkZIGeBmjvQBzzQA8UYpKjd2CsVU5HSmFiWmMgLbj1qGKSUoCy8k1ZxxTDYrMcHFKoyCDjBp7JzTSMHNJlI5zULu8sQ00EJYo+HX2zya6Kzk82JZM/eANJcQieMDjPeuaGryabq4trgAW8vCP8A3T6Ghu+iWoW5jqpE3dKWMYGKWJw6Bgcg06haom4jDIIpqjGfWnZ4oFIBCwHXvTeCOOfpSyBtjbCA2OCRxmoHSbylVJE8wYDOy5B9eARQA5qKJOOtFMY5VdQMMG9c05gSvbORTh9aZPv2fusbveoEZWs2yiGSZVIY4ztPWn6dP5aKjA4I6elaCxEwbJjuJ6mqd1GIQGQABT0p3urMaJpGycDg9jVgLlcEk59aoLcRTkDcFk9M1PtderGpCxHPbpPE0bgE4I5rldP0+WwujCYliRG3q6n39K6wBgeRkkc1n3CB7zexOcYxWkJWTXcEinrGsQxQ+Vd4Rsbgx6EVoaLdBolXcrRvyjA8GqWpWFvfwmKePeCCoJHK5rl7bR77T7yyEdxIUtWPygnay5/nQoRta9hvY7W8d7a/gSP7kr81p3CM8RCYye1Yk2o294UWKVWnTnaOordt3EkKkHqKl3srk+aOB1U3ltr0a+Tutm6kDpXU2iyxASwjKHkqP6Vb1SzWeBmC/vF5BqhoE2RJCz/Mn8OeRVSfNFPsU3dGkbiGdCjDdnqMVg+IPC1vqFuxiBSQcjb61sARWwDgfKTye9TRX0MjsgYbl6is72fugm1seaXWi3Jsza7sP0O7v71z82iPp8kMkkbKxYK2OQ1es6zpP26SO5tpCs0fOOzD0NQWzWV7cNYSqv2mNQzIy/r71cbL3vvL9q7FaxsxHEmRgccVrRSKOMY9Kka1YqNoHFIlqQMvwB2qVyom99xJX2sFJwCOo61iwW88QuEmk8xGbKZ7CtfWoZW09zZvtnUZT61i315Nb6RLO8RlnVASi9zQpaaEjtIurddSSzJBnEYZiB17V05QKwYZzXLaVDbw3KXsibJinJJ6CuoeUSxKYyDu6Gqna+gEiyCTIU1BNEFUFsNtPB9KfZxlN3PBNLdk7QoGSTip66CIAMijoM0uCBg9RQvJqrgJnnimyHjI6U5iNwHekkVgvNK4yvqRU2qdODTdFTLySHrwBWVrklwj24hGVMgD/StLSZTCdsmAjDcD60pKyGtjUvYTPayRjqykCvGdUttV026vQRhwMkdmHtXtqncvB61javpQvRv4MgG1uPvVOlmn1HCVmeY/D7ULdLyRGJS5I+Ysf0Fdxd6/aw28jCQSPH1ROTTNL8IWkczu8Cgt1zzWxH4X06OV5Fi+Zxgn1p8sOa7uVNps461WXxHqKzrb+QE5JI5Y46mu+07SoLTa4AaTH3sVJp2nW9grC3TG7qTVw8KcCqk03psQ5XMTxLNMIoorfhmOSfapLRSkcQUDd3q9cwhwS3XGB7VV0nEmSTkocUJ6B0NNSduTx61CrruOAw+oIqZjhSahQkKTjrQiSTpTu1M5NOHSmMYVPmA+lP8AfvS0UMAoFHrRikIXNNYMSMHvzTqB1qgFpaKKaENNROGLjHSpTTTQNEeSpzisjxHpsV7aEbeW/iHVT61tnntUbqSpUHGRUtdSk+pzXg+/ljSWxv5AZoTtBJ6iuqRw/KnNcd/wj1x9raWWUlwfldeMj0NXtPhu9MmeWaUyQEfc/u/SqcddGOST1R0bKDj25pfemxuJEDDoaeRSMxKRh7UtITQMil4FFI7blBZCpPUHHFFCGTD09qbFIsi7kYMMkfiDilHGBkmjqOKgQ6oZ4RKCD0qQcd6UcCgDDntFLqOVdT8rCrhMyKvmFSMdR3qHWo7kGKS0UOA2HTuRUgLbFDEH+lU72THcto6hQWBGfanGCNzuK8jvTbOTzIvmAyDipHcRt8x4NQIq3FusYLqPriohZw3dpJG4yr9avmRe+Kpi4WIsVXC56U7sZhJ4eFldRz2+7aisGLHJOemKZa6rcwatHbrEz24+WTHVCeh+ldDDceYXDEbSPyqFbW3mYORiVRgMODitPaX+PUTRbvZ1htJJGIwFzXP6RDG18LxW5YYOO9TauhntJbFySkny5B5AqLQNPNpamOFm8tRtXcck+9StIvXUexc1dZCR5JJwQ3FQ29mgmaYMRLIAGUnpWlFBIYypPPfNVHi8uYyOrcccCpu7WHc0Ix5O3njGDWLqGoWMGpqWaNLhhtBPXFVVvLiSaZJFdFjPysW4YVxHiy0M95HdBWkRSQ4XJyM/4VElKLsXCKk9T0tdZgijG58g9DXKa/43YCa30+2kebJQP2B9ax/DOjX17bGSS5dU6BGOTiun03w/HFIomIZgME7etQlrqVyxjuYOhaxrk04XU/8AUBCwO3GcVleJPGFxHKItOhKADlpBy30FdvNNawakLEkCbbkACsrxLpKX0SEQxu44H8JArRQ95OSEnFvYk8P3R1HRY5bvCs68kdjXRaDeQmBNsodR8pPvXMWtlexWaqixJgcgZOKTTJgk7RojCR252g7SfWrjqmiGjv8A7QiSckBWp7yLwcjk1xt3pVzqEib7iWJU6BW60kj6zYyLECs0Axhm+8PrRyJ7PUmzOznAKk1XmmihtzM+EVRk544rlrnxd5StF9lnMw9uDWNrx13XdP8AJt3SGCTG7H3iPSoUW3Z6FcjLn/CTyalrT2+lBJEj+8Sa2n1l4gIryMxueQ3Y/jWR4H8KpocbPMxeaU5ZjXT3Vmk58sDOB3ptxUrLYbscfqWtCbVbaKCYFJARtA711mk2ckukx+d98MxGfTPFUT4Ug+3xXEaKjJ37108IKqEUfKOKqck0kiXboNsi3kgP1HpTpJlXGMEmnPhI2CjtWYkySHD4Rx2NQlcRqBxtyOagkkdnXbwAaSO5jUBSwJqdWV8EYKmhOwCxswUs3SmzTiOMuQSoqQsAOvFYniW+e0tUMKB9zhSPQGmlzOyA2EZZ4wQeDzxXNRCbStcuCX/0WY7uex71uaRkW+Cfeq+v2jXEeI/vFSKuDs2nsw8i3bXK3cYeMjYehqbODisnwvbPa2fkTEMU6c9u1bLqByKGkm0tgG5pw6cVXkcrjFPimDHB4oAmoxRn8qQuAwHc0gFHWlPUdaO9LQIQDGT688mlHTmilzTELSUUVQAaaadRUgNNNNPPSmnkcimNDHXIqN41kUg+lSEgDnp701iQuVUmgozfPuLS5RRHvgbqc9K14pBImRVeSPdVSSKaJxJEeR78Gn8QNXNNnxxUZbceKzkvbuSbYsUZAPJzzWTc32t/b2WKwQW+cBi/OKXK72FY6SVwBRWQkepPhnRAp5IznFFC9SkbmcgHjmlChc89eeTTE+63+8f50/0qCAyMZzxS9fpUTgbAMDGRxUo+8fpQAyOLyy/zFgzbsE9KhuYcgsvUdasmlNALQy7WQiV1zgZ6elXGi80fPzVVwA3Sp4CfKPJofcbMfUYdQgeI2I8xGcB1Y/dHc1e2DaVcKXxkqDyBWinVqrW3zby3J8xhz6ZpuV9ARVW3MisY+D6U1ZBFOsI3eaU3ZxwOa1IlAZsACql/w5I4O2lvoO5UW2FxdpLNwyjaMGtaKCOMfKKqwfeh/GrQ6GhiY4YyWzwaG5YfrSL/AKtac3SkIo3VhHIjBQFYnishtInNx/pDobfHCgc59a6QgHrTXGVOad9LDTZiadoFtbXLzRySbz1+bj8q0DYsr7xLk+9Fr/rGq0/3TScmFzJuNNE1x57JH5w6PjnFTParJCqSEdecUrM2W5PbvUEjNtHJ/Opcm9Bol+wsjCSKTgcFT6VWOkwy3ouVeRXB6DhfyrVtiTGKrk/6Uw7U4t9BXuT/AGddykHgdajuoAy44OR37CrKdKa3IGaQXMj+zrZptuwFzWhFZQwL8qjOKyNKZjrN0CSRv9a6Bv8AV/hTkraA22Yt/fpHP5caSSMOoRc7R71d0hnaJmlGGJ9e1QEARSEAAnrVnThi349aNA6F/iopZ0jHLAd+aU/drlNfZv7UgG4454zVQjzOwmbFtqceoMxtmyqEq31qO+skuY8PkHOcqcGqfhhVXT1KqASecD3rY/iNXJckrIEzltXjvLWEfY1LHsaltdTuoNMilm3biBkAc5rcm6mqMI5cdsNVcyas0XYv2d6t5aKxODQbQSKA+XUHvWRCSEGCRyOldBGT9lznnFZTXLsLZk9qqIuQetVdYuzbpHImGCsN4z0B71Vt2YxnJJ/GqeqE/bVGeDAc+/NTHcXU0bW7jW8UAgeYMCtgkY5rkzxLYEddy8/hXSSk5X6VbWwPcay7gaIE28nrT060p++PpTAcGoyM59KZSGkBODTgaYv3acfu0AxaQcZyc0o6Uf40xBSDgc80o70nakAd6dUSk7hUlMBTUZ4P61Iagk+8Pof6UAhSwKZAzmkzxmhfuindhQMQetIwzzTm603+H8qBkBjG/cMDjtVN4ZkuGdLgtEf4COlaD96hl+6KYipa3zpdGGTaSRnriiqNsoOrPkA8CipqRVxtH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Secondary C cell hyperplasia. The follicular boundaries are intact.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5108=[""].join("\n");
var outline_f4_63_5108=null;
var title_f4_63_5109="Calculator: Newborn hyperbilirubinemia assessment";
var content_f4_63_5109=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"NewbornHyperbili_form\" name=\"NewbornHyperbili_form\" onkeydown=\"clrResults();\" onkeypress=\"return validNumberField(event);\" onkeyup=\"NewbornHyperbili_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Newborn hyperbilirubinemia assessment",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <span class=\"medCalcFontIO\">",
"       Input:",
"      </span>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Infant Age",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Infant_Age_param\" onblur=\"NewbornHyperbili_fx(); minMaxCheck();\" onchange=\"NewbornHyperbili_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Infant_Age_unit\" onchange=\"NewbornHyperbili_fx();\" style=\"width:105px;\">",
"          <option value=\"24|0|Days\">",
"           Days",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|Hours\">",
"           Hours",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Total Bilirubin",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Total_Bilirubin_param\" onblur=\"NewbornHyperbili_fx(); minMaxCheck();\" onchange=\"NewbornHyperbili_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Total_Bilirubin_unit\" onchange=\"NewbornHyperbili_fx();\" style=\"width:105px;\">",
"          <option value=\"0.0584795321637427|0|mcmol/L_Bili\">",
"           mcmol/L",
"          </option>",
"          <option value=\"1|0|mg%_Bili\">",
"           mg%",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|mg/dL_Bili\">",
"           mg/dL",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" valign=\"top\">",
"         <span class=\"medCalcFontOneBold\">",
"          Clinical Risk Group",
"         </span>",
"        </td>",
"        <td align=\"left\" colspan=\"2\">",
"         <span class=\"medCalcFontOne\">",
"          <input checked=\"checked\" name=\"Clinical_Risk_Group_radio\" onclick=\"NewbornHyperbili_fx();\" type=\"radio\" value=\"Group 1: Gestation &gt;=38 weeks and medically well|1\"/>",
"          Group 1: Gestation &gt;=38 weeks and medically well",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" colspan=\"2\">",
"         <span class=\"medCalcFontOne\">",
"          <input name=\"Clinical_Risk_Group_radio\" onclick=\"NewbornHyperbili_fx();\" type=\"radio\" value=\"Group 2: Gestation &gt;=38 weeks and clinical risk factors|2\"/>",
"          Group 2: Gestation &gt;=38 weeks and clinical risk factors",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" colspan=\"2\">",
"         <span class=\"medCalcFontOne\">",
"          <input name=\"Clinical_Risk_Group_radio\" onclick=\"NewbornHyperbili_fx();\" type=\"radio\" value=\" Group 2: Gestation 35 to 37.9 weeks and medically well|2\"/>",
"          Group 2: Gestation 35 to 37.9 weeks and medically well",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" colspan=\"2\">",
"         <span class=\"medCalcFontOne\">",
"          <input name=\"Clinical_Risk_Group_radio\" onclick=\"NewbornHyperbili_fx();\" type=\"radio\" value=\"Group 3: Gestation 35 to 37.9 weeks and clinical risk factors|3\"/>",
"          Group 3: Gestation 35 to 37.9 weeks and clinical risk factors",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <span class=\"medCalcFontIO\">",
"       Results:",
"      </span>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td colspan=\"2\">",
"         &nbsp;",
"         <br/>",
"         <table border=\"1\" cellpadding=\"4\" summary=\"tt\" width=\"285\">",
"          <tr>",
"           <td align=\"left\" bgcolor=\"#ffffff\" height=\"250\" valign=\"top\">",
"            <div class=\"medCalcFontOneBold\" id=\"ttxt\">",
"            </div>",
"           </td>",
"          </tr>",
"         </table>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td colspan=\"3\">",
"         &nbsp;",
"         <br/>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <span class=\"medCalcFontOne\">",
"       <input name=\"reset\" onclick=\"clrResults();\" type=\"reset\" value=\"Reset form\"/>",
"      </span>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Age Limitation",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOne\">",
"      Results are not available for infants greater than 6 days of age or newborns less than 12 hours of age.",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Clinical Risk Groups",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOne\">",
"      The risk for severe hyperbilirubinemia and the threshold for",
"intervention are based upon the hour-specific bilirubin value as well as the presence of other",
"clinical risk factors. The gestational age and presence or absence of the following risk factors are used to assign a",
"      <b>",
"       Clinical Risk Group",
"      </b>",
"      category.",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       Isoimmune hemolytic disease or G6PD deficiency",
"      </li>",
"      <li>",
"       Asphyxia or lethargy",
"      </li>",
"      <li>",
"       Unstable temperature, sepsis or acidosis",
"      </li>",
"      <li>",
"       Hypoalbuminemia (less than 3 gm/L, a risk factor when considering phototherapy, not transfusion)",
"      </li>",
"     </ul>",
"     <span class=\"medCalcFontOneBold\">",
"      Sources",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOne\">",
"      The American Academy of Pediatric (AAP) Practice Guideline nomograms [1] are used in",
"determining when exchange transfusion and phototherapy should be initiated. When phototherapy is",
"used, the AAP recommends the use of intensive phototherapy, defined as irradiance in the blue",
"green spectrum (wavelength between 430 and 490 nM) greater than or equal to 30 microW/cm2 per",
"nm.",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      For bilirubin levels below the phototherapy thresholds, this assessment tool uses a nomogram",
"from the Bhutani study [2], which predicts the likelihood that subsequent serum bilirubin values",
"will rise above the 95th percentile. This study only included infants born at or greater than 35",
"weeks gestation with birth weights at or greater than 2000 grams, so the results should only be",
"used in infants of 35 weeks gestation or greater. This nomogram should NOT be used to predict",
"the natural history of hyperbilirubinemia.",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia  in the newborn infant 35 or more weeks of gestation.",
"        <i>",
"         Pediatrics",
"        </i>",
"        . 2004 Jul; 114:297-316.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin  for subsequent significant hyperbilirubinemia in healthy term and near-term newborns.",
"        <i>",
"         Pediatrics",
"        </i>",
"        . 1999 Jan; 103:6-14.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5109=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(){",
"alert('This field is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"",
"function validNumberField(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"var val = field.value;",
"var charCode = event.charCode;",
"var key = String.fromCharCode(charCode);",
"",
"if(charCode == 0) {",
"return true;",
"}",
"",
"if(key == ' ') {",
"alert('Numeric field cannot contain spaces.');",
"return false;",
"}	",
"		",
"if(val.length == 0) {",
"if(key == '+') { return true; }",
"if(key == '-') { return true; }	",
"if(key == '.') { return true; }",
"}",
"		",
"if(key == '.') { return validFloat(val, key); }",
"",
"if(isNaN(parseInt(key))) {",
"alertNaN();",
"return false;",
"}",
"	",
"return validFloat(val, key);",
"}",
"return true;",
"}",
"",
"",
"function validFloat(val, key) {",
"var currentVal = parseFloat(val + key);",
"if(isNaN(val + key) || isNaN(currentVal)) {",
"alertNaN();",
"}",
"return true;",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function NewbornHyperbili_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.NewbornHyperbili_form){",
"",
"",
"doCalc = true;",
"param_value = parseFloat(Infant_Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Infant_Age_unit.options[Infant_Age_unit.selectedIndex].value.split('|');",
"Infant_Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Total_Bilirubin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Total_Bilirubin_unit.options[Total_Bilirubin_unit.selectedIndex].value.split('|');",
"Total_Bilirubin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Clinical_Risk_Group_radio[0].checked){ Clinical_Risk_Group = 1; }",
"if (Clinical_Risk_Group_radio[1].checked){ Clinical_Risk_Group = 2; }",
"if (Clinical_Risk_Group_radio[2].checked){ Clinical_Risk_Group = 2; }",
"if (Clinical_Risk_Group_radio[3].checked){ Clinical_Risk_Group = 3; }",
"dp = 1;",
"p40th = interpN1(n1_40th, Infant_Age);",
"p75th = interpN1(n1_75th, Infant_Age);",
"p95th = interpN1(n1_95th, Infant_Age);",
"plow = interpN2(n2_low, Infant_Age);",
"pmed = interpN2(n2_med, Infant_Age);",
"phigh = interpN2(n2_high, Infant_Age);",
"tlow = interpN3(n3_low, Infant_Age);",
"tmed = interpN3(n3_med, Infant_Age);",
"thigh = interpN3(n3_high, Infant_Age);",
"tlow5 = tlow + 5;",
"tmed5 = tmed + 5;",
"thigh5 = thigh + 5;",
"p40th_txt = fixDP(p40th,2);",
"p75th_txt = fixDP(p75th,2);",
"p95th_txt = fixDP(p95th,2);",
"plow_txt = fixDP(plow,2);",
"pmed_txt = fixDP(pmed,2);",
"phigh_txt = fixDP(phigh,2);",
"tlow_txt = fixDP(tlow,2);",
"tmed_txt = fixDP(tmed,2);",
"thigh_txt = fixDP(thigh,2);",
"tlow5_txt = fixDP(tlow5,2);",
"tmed5_txt = fixDP(tmed5,2);",
"thigh5_txt = fixDP(thigh5,2);",
"document.getElementById('ttxt').innerHTML = '';",
"if(doCalc){",
"if(Total_Bilirubin >= 25){ document.getElementById('ttxt').innerHTML = \"The subject's bilirubin is greater or equal to 25 mg/dL. <br />&nbsp;<br />The AAP guidelines recommend EXCHANGE TRANSFUSION for patients in this group.\";}",
"else if((Clinical_Risk_Group == 1) && (Total_Bilirubin >= tlow5)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is greater than 5 mg/dL above the hour-specific threshold for exchange transfusion for this clinical risk group (risk group 1 threshold for exchange transfusion: \" +  tlow_txt + \" mg/dL).<br />&nbsp;<br />The AAP guidelines recommend EXCHANGE TRANSFUSION for patients in this group.\";}",
"else if((Clinical_Risk_Group == 2) && (Total_Bilirubin >= tmed5)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is greater than 5 mg/dL above the hour-specific threshold for exchange transfusion for this clinical risk group (risk group 2 threshold for exchange transfusion: \" + tmed_txt + \" mg/dL).<br />&nbsp;<br />The AAP guidelines recommend EXCHANGE TRANSFUSION for patients in this group.\";}",
"else if((Clinical_Risk_Group == 3) && (Total_Bilirubin >= thigh5)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is greater than 5 mg/dL above the hour-specific threshold for exchange transfusion for this clinical risk group (risk group 3 threshold for exchange transfusion: \" + thigh_txt + \" mg/dL).<br />&nbsp;<br />The AAP guidelines recommend EXCHANGE TRANSFUSION for patients in this group.\";}",
"else if((Clinical_Risk_Group == 1) && (Total_Bilirubin >= tlow)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is above the hour-specific threshold for exchange transfusion, and the patient has no additional clinical risk factors (risk group 1 threshold for exchange transfusion: \" + tlow_txt + \" mg/dL). <br />&nbsp;<br />The AAP guidelines recommend PHOTOTHERAPY and rechecking of serum bilirubin within 2 to 3 hours. If the subsequent bilirubin level remains above this threshold despite phototherapy, EXCHANGE TRANSFUSION is recommended.\";}",
"else if((Clinical_Risk_Group == 2) && (Total_Bilirubin >= tmed)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is above the hour-specific threshold for exchange transfusion, and the patient has additional clinical risk factors (risk group 2 threshold for exchange transfusion: \" + tmed_txt + \" mg/dL). <br />&nbsp;<br />The AAP guidelines recommend EXCHANGE TRANSFUSION for patients in this group.\";}",
"else if((Clinical_Risk_Group == 3) && (Total_Bilirubin >= thigh)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is above the hour-specific threshold for exchange transfusion, and the patient has additional clinical risk factors (risk group 3 threshold for exchange transfusion: \" + thigh_txt + \" mg/dL). <br />&nbsp;<br />The AAP guidelines recommend EXCHANGE TRANSFUSION for patients in this group.\";}",
"else if((Clinical_Risk_Group == 1) && (Total_Bilirubin >= plow)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is in the HIGH risk zone; other clinical risk factors are low (risk group 1 threshold for phototherapy: \" + plow_txt + \" mg/dL). <br />&nbsp;<br />The AAP guidelines recommend PHOTOTHERAPY for patients in this group, with repeat measurements of serum bilirubin after the start of therapy.\";}",
"else if((Clinical_Risk_Group == 2) && (Total_Bilirubin >= pmed)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is in the HIGH risk zone, and the patient has other clinical risk factors (risk group 2 threshold for phototherapy: \" + pmed_txt + \" mg/dL). <br />&nbsp;<br />The AAP guidelines recommend PHOTOTHERAPY for patients in this group, with repeat measurements of serum bilirubin after the start of therapy. Home phototherapy should not be used for this group.\";}",
"else if((Clinical_Risk_Group == 3) && (Total_Bilirubin >= phigh)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is in the HIGH risk zone, and the patient has other clinical risk factors (risk group 3 threshold for phototherapy: \" + phigh_txt + \" mg/dL). <br />&nbsp;<br />The AAP guidelines recommend PHOTOTHERAPY for patients in this group, with repeat measurements of serum bilirubin after the start of therapy. Home phototherapy should not be used for this group.\";}",
"else if((Clinical_Risk_Group == 1) && (Total_Bilirubin >= p95th)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is above the 95th percentile for this patient's age (\" + p95th_txt + \" mg/dL), but the other clinical risk factors are low. <br />&nbsp;<br />Monitoring of bilirubin (either by serum or transcutaneous measurement) is recommended as these infants are at a high to intermediate risk that future bilirubin levels will rise above the 95th percentile. The threshold for starting phototherapy is \" +  plow_txt + \" mg/dL at the patient's current age.\";}",
"else if((Clinical_Risk_Group == 2) && (Total_Bilirubin >= p95th)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is above the 95th percentile for this patient's age (\" + p95th_txt + \" mg/dL), but still below the phototherapy threshold. <br />&nbsp;<br />Monitoring of bilirubin (either by serum or transcutaneous measurement) is recommended as these infants are at a high to intermediate risk that future bilirubin levels will reach the threshold for starting phototherapy (\" +  pmed_txt + \" mg/dL at the patient's current age.)\";}",
"else if((Clinical_Risk_Group == 1) && (Total_Bilirubin >= p75th) && (Total_Bilirubin < p95th)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is in the HIGH-INTERMEDIATE RISK zone (between the 75th and 95th percentiles for this age: \" + p75th_txt + \"-\" + p95th_txt + \" mg/dL); other clinical risk factors are low (risk group 1) <br />&nbsp;<br />Monitoring of bilirubin (either by serum or transcutaneous measurement) is recommended as these infants are at a high to intermediate risk that future bilirubin levels will rise above the 95th percentile. The threshold for starting phototherapy is \" + plow_txt + \" mg/dL at the patient's current age.\";}",
"else if((Clinical_Risk_Group == 2) && (Total_Bilirubin >= p75th) && (Total_Bilirubin < p95th)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is in the HIGH-INTERMEDIATE RISK zone (between the 75th and 95th percentiles for this age: \" + p75th_txt + \"-\" + p95th_txt + \" mg/dL), and the patient has other clinical risk factors (risk group 2). <br />&nbsp;<br />Monitoring of bilirubin (either by serum or transcutaneous measurement) is recommended as these infants are at a high to intermediate risk that future bilirubin levels will rise above the 95th percentile. The threshold for starting phototherapy is \" + pmed_txt + \" mg/dL at the patient's current age.\";}",
"else if((Clinical_Risk_Group == 3) && (Total_Bilirubin >= p75th) && (Total_Bilirubin < p95th)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is in the HIGH-INTERMEDIATE RISK zone (between the 75th and 95th percentiles for this age: \" + p75th_txt + \"-\" + p95th_txt + \" mg/dL), and the patient has other clinical risk factors (risk group 3) <br />&nbsp;<br />Monitoring of bilirubin (either by serum or transcutaneous measurement) is recommended as these infants are at a high to intermediate risk that future bilirubin levels will rise above the 95th percentile. The threshold for starting phototherapy is \" + phigh_txt + \" mg/dL at the patient's current age.\";}",
"else if((Total_Bilirubin >= p40th) && (Total_Bilirubin < p75th)){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is in the LOW-INTERMEDIATE RISK zone (between the 40th and 75th percentiles for this age: \" + p40th_txt + \"-\" + p75th_txt + \" mg/dL) <br />&nbsp;<br />Phototherapy is not recommended at this time because there is low to intermediate risk that future bilirubin levels will rise above the 95th percentile.\";}",
"else if(Total_Bilirubin < p40th){ document.getElementById('ttxt').innerHTML = \"The bilirubin level is in the LOW  RISK zone (less than the 40th percentile for this age: \" + p40th_txt + \" mg/dL). <br />&nbsp;<br />Phototherapy is not recommended at this time because there is low risk that future bilirubin levels will rise above the 95th percentile.\";}",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.NewbornHyperbili_form){",
"",
"if (Infant_Age_param.value && isNaN(Infant_Age_param.value)){ Infant_Age_param.value = ''; alertNaN(); }",
"if (Infant_Age_param.value && Infant_Age < 12) {",
"Infant_Age = 0;",
"Infant_Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Infant Age is 12 Hours.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Infant_Age_param.value && Infant_Age > 147.99) {",
"Infant_Age_param.value = \"\";",
"clrResults();",
"Infant_Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Infant Age is 147.99 Hours.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Total_Bilirubin_param.value && isNaN(Total_Bilirubin_param.value)){ Total_Bilirubin_param.value = ''; alertNaN(); }",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.NewbornHyperbili_form){",
"",
"document.getElementById('ttxt').innerHTML = '';",
"",
"",
"}",
"",
"}",
"",
"n1_40th = new Array;",
"n1_75th = new Array;",
"n1_95th = new Array;",
"",
"n1_40th[0] = 4.0; n1_75th[0] = 5.0; n1_95th[0] = 7.0; ",
"n1_40th[1] = 4.4; n1_75th[1] = 5.5; n1_95th[1] = 7.2; ",
"n1_40th[2] = 4.7; n1_75th[2] = 5.9; n1_95th[2] = 7.4; ",
"n1_40th[3] = 4.9; n1_75th[3] = 6.1; n1_95th[3] = 7.8; ",
"n1_40th[4] = 5.5; n1_75th[4] = 7.0; n1_95th[4] = 8.9; ",
"n1_40th[5] = 6.3; n1_75th[5] = 8.0; n1_95th[5] = 10.0; ",
"n1_40th[6] = 7.0; n1_75th[6] = 8.9; n1_95th[6] = 11.1; ",
"n1_40th[7] = 7.7; n1_75th[7] = 9.9; n1_95th[7] = 12.2; ",
"n1_40th[8] = 8.2; n1_75th[8] = 10.3; n1_95th[8] = 12.5; ",
"n1_40th[9] = 8.6; n1_75th[9] = 10.8; n1_95th[9] = 13.2; ",
"n1_40th[10] = 9.0; n1_75th[10] = 11.3; n1_95th[10] = 13.8; ",
"n1_40th[11] = 9.3; n1_75th[11] = 12.0; n1_95th[11] = 14.4; ",
"n1_40th[12] = 9.6; n1_75th[12] = 12.6; n1_95th[12] = 15.2; ",
"n1_40th[13] = 10.2; n1_75th[13] = 12.9; n1_95th[13] = 15.4; ",
"n1_40th[14] = 10.7; n1_75th[14] = 13.1; n1_95th[14] = 15.6; ",
"n1_40th[15] = 11.2; n1_75th[15] = 13.4; n1_95th[15] = 15.9; ",
"n1_40th[16] = 11.3; n1_75th[16] = 13.8; n1_95th[16] = 16.2; ",
"n1_40th[17] = 11.4; n1_75th[17] = 14.3; n1_95th[17] = 16.4; ",
"n1_40th[18] = 11.6; n1_75th[18] = 14.7; n1_95th[18] = 16.7; ",
"n1_40th[19] = 11.8; n1_75th[19] = 14.7; n1_95th[19] = 17.0; ",
"n1_40th[20] = 12.2; n1_75th[20] = 15.0; n1_95th[20] = 17.2; ",
"n1_40th[21] = 12.3; n1_75th[21] = 15.2; n1_95th[21] = 17.4; ",
"n1_40th[22] = 12.5; n1_75th[22] = 15.3; n1_95th[22] = 17.4; ",
"n1_40th[23] = 12.7; n1_75th[23] = 15.4; n1_95th[23] = 17.5; ",
"n1_40th[24] = 12.8; n1_75th[24] = 15.5; n1_95th[24] = 17.5; ",
"n1_40th[25] = 13.0; n1_75th[25] = 15.6; n1_95th[25] = 17.5; ",
"n1_40th[26] = 13.1; n1_75th[26] = 15.7; n1_95th[26] = 17.6; ",
"n1_40th[27] = 13.2; n1_75th[27] = 15.8; n1_95th[27] = 17.7; ",
"n1_40th[28] = 13.2; n1_75th[28] = 15.7; n1_95th[28] = 17.6; ",
"n1_40th[29] = 13.2; n1_75th[29] = 15.6; n1_95th[29] = 17.5; ",
"n1_40th[30] = 13.2; n1_75th[30] = 15.5; n1_95th[30] = 17.4; ",
"n1_40th[31] = 13.2; n1_75th[31] = 15.4; n1_95th[31] = 17.4; ",
"n1_40th[32] = 13.2; n1_75th[32] = 15.3; n1_95th[32] = 17.3; ",
"n1_40th[33] = 13.2; n1_75th[33] = 15.2; n1_95th[33] = 17.3; ",
"n1_40th[34] = 13.2; n1_75th[34] = 15.3; n1_95th[34] = 17.4; ",
"",
"function interpN1(thisp, thisx){",
"var xconv = (thisx - 12) / 4;",
"x1 = Math.floor(xconv);  ",
"x2 = x1 + 1;",
"xfrac = xconv - x1;",
"return xfrac * (thisp[x2] - thisp[x1]) + thisp[x1];",
"}",
"",
"n2_high = new Array;",
"n2_med = new Array;",
"n2_low = new Array;",
"",
"n2_high[0] = 5.8; n2_med[0] = 7.6; n2_low[0] = 9.0; ",
"n2_high[1] = 6.5; n2_med[1] = 8.2; n2_low[1] = 9.8; ",
"n2_high[2] = 7.1; n2_med[2] = 9.0; n2_low[2] = 10.7; ",
"n2_high[3] = 7.8; n2_med[3] = 9.8; n2_low[3] = 11.6; ",
"n2_high[4] = 8.3; n2_med[4] = 10.2; n2_low[4] = 12.2; ",
"n2_high[5] = 8.9; n2_med[5] = 11.0; n2_low[5] = 12.9; ",
"n2_high[6] = 9.4; n2_med[6] = 11.7; n2_low[6] = 13.5; ",
"n2_high[7] = 10.0; n2_med[7] = 12.0; n2_low[7] = 14.1; ",
"n2_high[8] = 10.7; n2_med[8] = 12.5; n2_low[8] = 14.8; ",
"n2_high[9] = 11.2; n2_med[9] = 13.0; n2_low[9] = 15.1; ",
"n2_high[10] = 11.7; n2_med[10] = 13.5; n2_low[10] = 15.8; ",
"n2_high[11] = 12.0; n2_med[11] = 14.1; n2_low[11] = 16.0; ",
"n2_high[12] = 12.4; n2_med[12] = 14.6; n2_low[12] = 16.5; ",
"n2_high[13] = 12.8; n2_med[13] = 14.9; n2_low[13] = 16.9; ",
"n2_high[14] = 13.1; n2_med[14] = 15.0; n2_low[14] = 17.2; ",
"n2_high[15] = 13.4; n2_med[15] = 15.3; n2_low[15] = 17.7; ",
"n2_high[16] = 13.7; n2_med[16] = 15.9; n2_low[16] = 18.0; ",
"n2_high[17] = 13.9; n2_med[17] = 16.1; n2_low[17] = 18.3; ",
"n2_high[18] = 14.0; n2_med[18] = 16.4; n2_low[18] = 18.8; ",
"n2_high[19] = 14.1; n2_med[19] = 16.8; n2_low[19] = 19.0; ",
"n2_high[20] = 14.3; n2_med[20] = 17.0; n2_low[20] = 19.5; ",
"n2_high[21] = 14.5; n2_med[21] = 17.2; n2_low[21] = 19.8; ",
"n2_high[22] = 14.7; n2_med[22] = 17.5; n2_low[22] = 20.0; ",
"n2_high[23] = 14.8; n2_med[23] = 17.8; n2_low[23] = 20.1; ",
"n2_high[24] = 14.9; n2_med[24] = 18.0; n2_low[24] = 20.4; ",
"n2_high[25] = 15.0; n2_med[25] = 18.0; n2_low[25] = 20.7; ",
"n2_high[26] = 15.0; n2_med[26] = 18.1; n2_low[26] = 20.9; ",
"n2_high[27] = 15.0; n2_med[27] = 18.1; n2_low[27] = 21.0; ",
"n2_high[28] = 15.0; n2_med[28] = 18.1; n2_low[28] = 21.0; ",
"n2_high[29] = 15.0; n2_med[29] = 18.1; n2_low[29] = 21.0; ",
"n2_high[30] = 15.0; n2_med[30] = 18.1; n2_low[30] = 21.0; ",
"n2_high[31] = 15.0; n2_med[31] = 18.1; n2_low[31] = 21.0; ",
"n2_high[32] = 15.0; n2_med[32] = 18.1; n2_low[32] = 21.0; ",
"n2_high[33] = 15.0; n2_med[33] = 18.1; n2_low[33] = 21.0; ",
"n2_high[34] = 15.0; n2_med[34] = 18.1; n2_low[34] = 21.0; ",
"",
"function interpN2(thisp, thisx){",
"var xconv = (thisx - 12) / 4;",
"x1 = Math.floor(xconv);  ",
"x2 = x1 + 1;",
"xfrac = xconv - x1;",
"return xfrac * (thisp[x2] - thisp[x1]) + thisp[x1];",
"}",
"",
"n3_high = new Array;",
"n3_med = new Array;",
"n3_low = new Array;",
"",
"n3_high[0] = 13.4; n3_med[0] = 15.1; n3_low[0] = 17.7; ",
"n3_high[1] = 14.0; n3_med[1] = 15.6; n3_low[1] = 18.0; ",
"n3_high[2] = 14.5; n3_med[2] = 16.1; n3_low[2] = 18.5; ",
"n3_high[3] = 15.0; n3_med[3] = 16.6; n3_low[3] = 19.0; ",
"n3_high[4] = 15.3; n3_med[4] = 17.0; n3_low[4] = 19.6; ",
"n3_high[5] = 15.7; n3_med[5] = 17.4; n3_low[5] = 20.1; ",
"n3_high[6] = 16.0; n3_med[6] = 18.0; n3_low[6] = 20.9; ",
"n3_high[7] = 16.3; n3_med[7] = 18.3; n3_low[7] = 21.2; ",
"n3_high[8] = 16.8; n3_med[8] = 18.8; n3_low[8] = 21.8; ",
"n3_high[9] = 17.1; n3_med[9] = 19.0; n3_low[9] = 22.1; ",
"n3_high[10] = 17.4; n3_med[10] = 19.5; n3_low[10] = 22.4; ",
"n3_high[11] = 17.7; n3_med[11] = 19.9; n3_low[11] = 22.8; ",
"n3_high[12] = 18.0; n3_med[12] = 20.1; n3_low[12] = 23.0; ",
"n3_high[13] = 18.2; n3_med[13] = 20.5; n3_low[13] = 23.3; ",
"n3_high[14] = 18.4; n3_med[14] = 21.0; n3_low[14] = 23.7; ",
"n3_high[15] = 18.6; n3_med[15] = 21.2; n3_low[15] = 24.0; ",
"n3_high[16] = 18.7; n3_med[16] = 21.7; n3_low[16] = 24.1; ",
"n3_high[17] = 18.8; n3_med[17] = 21.9; n3_low[17] = 24.3; ",
"n3_high[18] = 18.9; n3_med[18] = 22.0; n3_low[18] = 24.4; ",
"n3_high[19] = 18.9; n3_med[19] = 22.1; n3_low[19] = 24.5; ",
"n3_high[20] = 19.0; n3_med[20] = 22.3; n3_low[20] = 24.8; ",
"n3_high[21] = 19.0; n3_med[21] = 22.4; n3_low[21] = 25.0; ",
"n3_high[22] = 19.0; n3_med[22] = 22.4; n3_low[22] = 25.0; ",
"n3_high[23] = 19.0; n3_med[23] = 22.4; n3_low[23] = 25.0; ",
"n3_high[24] = 19.0; n3_med[24] = 22.4; n3_low[24] = 25.0; ",
"n3_high[25] = 19.0; n3_med[25] = 22.4; n3_low[25] = 25.0; ",
"n3_high[26] = 19.0; n3_med[26] = 22.4; n3_low[26] = 25.0; ",
"n3_high[27] = 19.0; n3_med[27] = 22.4; n3_low[27] = 25.0; ",
"n3_high[28] = 19.0; n3_med[28] = 22.4; n3_low[28] = 25.0; ",
"n3_high[29] = 19.0; n3_med[29] = 22.4; n3_low[29] = 25.0; ",
"n3_high[30] = 19.0; n3_med[30] = 22.4; n3_low[30] = 25.0; ",
"n3_high[31] = 19.0; n3_med[31] = 22.4; n3_low[31] = 25.0; ",
"n3_high[32] = 19.0; n3_med[32] = 22.4; n3_low[32] = 25.0; ",
"n3_high[33] = 19.0; n3_med[33] = 22.4; n3_low[33] = 25.0; ",
"n3_high[34] = 19.0; n3_med[34] = 22.4; n3_low[34] = 25.0; ",
"",
"function interpN3(thisp, thisx){",
"var xconv = (thisx - 12) / 4;",
"x1 = Math.floor(xconv);  ",
"x2 = x1 + 1;",
"xfrac = xconv - x1;",
"return xfrac * (thisp[x2] - thisp[x1]) + thisp[x1];",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f4_63_5109=null;
var title_f4_63_5110="Anatomy VIII cranial nerve";
var content_f4_63_5110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Anatomy of the auditory nerve (cranial nerve VIII)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5110=[""].join("\n");
var outline_f4_63_5110=null;
var title_f4_63_5111="Dermatitis herpetiformis AGA";
var content_f4_63_5111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74915%7EALLRG%2F70783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74915%7EALLRG%2F70783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A skin blister on the elbow of a subject with dermatitis herpetiformis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Ciclitira PJ. Gastroenterology 2001; 120:1526.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Herpetiform clusters of vesicles on an erythematous, edamatous base with crusts and postinflammatory pigmentation on the upper back and shoulder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Skin signs of immune, autoimmune, and rheumatic diseases. In: Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, Fitzpatrick TB, Johnson RA, Wolff K (Eds), McGraw-Hill, New York 1997. p.327. Copyright &copy; 1997 McGraw Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5111=[""].join("\n");
var outline_f4_63_5111=null;
var title_f4_63_5112="Overview of genetic variation";
var content_f4_63_5112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of genetic variation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5112/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5112/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5112/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5112/contributors\">",
"     Anne Slavotinek, MBBS, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5112/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5112/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/63/5112/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human genome is rich in variation. Until recently, only a handful of common variants, termed polymorphisms (chromosome variants found in more than 1 percent of the population), have been implicated in common disease, although the majority of heritable phenotypic variation is due to alterations in DNA sequence. In contrast, the genetics of Mendelian conditions caused by rare mutations that occur sporadically or that are inherited have been better characterized.",
"   </p>",
"   <p>",
"    The Human Genome Project, completed in 2003, elucidated the complete sequence of the human reference genome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/1\">",
"     1",
"    </a>",
"    ]. This sequence, together with the availability of DNA genotyping and sequencing methods capable of surveying variation in large numbers of subjects on a genome-wide scale, has led to rapid expansion of the list of common genetic variants that contribute to disease susceptibility, disease progression, and variability in treatment response.",
"   </p>",
"   <p>",
"    This topic will review the types of genetic variation implicated in health and disease, with a particular focus on common genetic variants, including short tandem repeats (STRs), single nucleotide polymorphisms (SNPs), and copy number variants (CNVs). A glossary of genetic terms is available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RARE CHROMOSOMAL ABERRATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal abnormalities that are visible using light microscopy can be classified into those due to aberrant chromosome number and those due to abnormal chromosome structure. These variants can result in well-characterized syndromes, although many structural abnormalities are rare or unique. Chromosome aberrations typically result from either chromosome recombination errors during meiosis (for germ-line mutations) or aberrant chromosomal segregation during meiosis or mitosis. Large-scale variants can be evaluated using a variety of cytogenetic approaches, including karyotyping, fluorescence in-situ hybridization (FISH), and array comparative genome hybridization (array CGH) applications. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Aneuploidy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Structural chromosome abnormalities'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Numerical chromosome abnormalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Aneuploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneuploidy refers to an abnormal copy number of one chromosome. This is thought to result during cell division, either through non-disjunction of paired chromosomes in meiosis (",
"    <a class=\"graphic graphic_figure graphicRef52882 graphicRef81597 \" href=\"UTD.htm?41/6/42088\">",
"     figure 1A-B",
"    </a>",
"    ) or through anaphase lag. Monosomy refers to loss of chromosomal material. Trisomy refers to gain of chromosomal material.",
"   </p>",
"   <p>",
"    All autosomal monosomies (loss of an autosomal [chromosomes 1 to 22] or non-sex linked chromosome) are lethal in the embryonic period, unless they are accompanied by a second, karyotypically normal cell line. The co-occurrence of two cytogenetically or molecularly distinct cell lines is called mosaicism.",
"   </p>",
"   <p>",
"    Females with only one X chromosome (monosomy X or XO) have Turner syndrome and can have normal life spans. Turner syndrome occurs in approximately one in every 2500 female births and is characterized by short stature, webbed neck, and gonadal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional manifestations may include congenital heart disease (coarctation of the aorta), renal anomalies, lymphedema of the hands and feet, and hypothyroidism. Overall intellect is considered to be normal, although there may be individual specific strengths (for example, verbal skills) and challenges (for example, tasks that require visuospatial or math skills). Management guidelines for females with Turner syndrome have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) are caused by one additional copy of chromosome 18 and 13, respectively. Although babies with both of these autosomal trisomies have been reported to survive to term, there is a significantly shortened life expectancy. Trisomy 21, also known as Down syndrome, is often compatible with survival well into adulthood. Down syndrome is characterized by variable expression of a range of clinical manifestations, including cognitive impairment, muscle hypotonia, congenital heart disease, and characteristic facial features (round facies, upslanting eye fissures, flattened nasal bridge, and macroglossia) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sex-linked aneuploidies (47,XXY, 47,XYY, and 47,XXX).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      47,XXY, also known as Klinefelter syndrome, occurs in approximately 1 out of every 500 to 1 in 1000 male births. 47,XXY males are infertile due to hypogonadism, although residual foci of spermatogonia and testicular sperm extraction in combination with intracytoplasmic sperm injection may allow some men with Klinefelter syndrome to father children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/5\">",
"       5",
"      </a>",
"      ]. Other manifestations include cognitive or behavioral problems, microorchidism, and gynecomastia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of primary hypogonadism in males\", section on 'Klinefelter's syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of an extra Y chromosome (47,XYY), in contrast, is usually of little clinical consequence, other than increased growth velocity in early childhood. Males who are 47,XYY generally have normal physical attributes and are fertile. The diagnosis is usually only made when genetic testing is performed for other reasons. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10073?source=see_link&amp;anchor=H21#H21\">",
"       \"The child with tall stature or abnormally rapid growth\", section on 'XYY syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Triple X syndrome (47,XXX) occurs in one in 1000 female births. 47,XXX females, similar to 47,XXY males, display increased growth velocity but are usually otherwise asymptomatic, although mild learning disabilities with difficulties with motor coordination and auditory processing disorders have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Polyploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyploidy refers to abnormal copy number of all chromosomes, typically manifesting as triploidy (69,XXX, 69,XXY, or 69,XYY) resulting from ovum fertilization by two spermatozoa (dispermy). Approximately 1 to 3 percent of pregnancies are triploid, which results in spontaneous abortion in early to mid-pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Structural chromosome abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of different categories of structural chromosomal abnormalities that include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosomal translocations &mdash; As observed in chronic myeloid leukemia (CML) (",
"      <a class=\"graphic graphic_figure graphicRef70807 \" href=\"UTD.htm?21/21/21855\">",
"       figure 2",
"      </a>",
"      ). The Philadelphia chromosome results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)], causing a fusion gene and predisposing to CML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link\">",
"       \"Cellular and molecular biology of chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chromosome deletions &mdash; When disease-causing genes are deleted, the resultant haploinsufficiency can cause clinical effects, for example deletion of the peripheral myelin protein 22 or",
"      <em>",
"       PMP22",
"      </em>",
"      gene causes hereditary neuropathy with liability to pressure palsies.",
"     </li>",
"     <li>",
"      Chromosome duplications &mdash; When disease-causing genes are duplicated, the resultant increase in copy number can cause clinical effects. For example, duplication of the peripheral myelin protein 22 or",
"      <em>",
"       PMP22",
"      </em>",
"      gene can cause Charcot-Marie-Tooth disease type IA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"       \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chromosome inversions &mdash; Inversions of disease-causing genes can interrupt transcripts or change their regulation, for example a gene inversion associated with factor VIII deficiency has been identified in 40 percent of patients with hemophilia A [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=see_link\">",
"       \"Genetics of the hemophilias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ring chromosome formation &mdash; Ring chromosomes commonly result from breakage and loss of chromosome material at the ends of both &lsquo;p&rsquo; and &lsquo;q&rsquo; arms of the same chromosome, with subsequent rejoining of the ends of the arms to form a ring structure. Ring chromosomes are often unstable and frequently associated with deleterious phenotypic effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other structural chromosome differences (acentric or dicentric chromosomes, or isochromosomes) result through abnormal chromosome breakage repair or non-homologous recombination errors (",
"    <a class=\"graphic graphic_figure graphicRef67644 \" href=\"UTD.htm?40/28/41412\">",
"     figure 3",
"    </a>",
"    ). Non-homologous recombination &ldquo;hotspots&rdquo; are thought to contribute to several disorders, including Duchenne muscular dystrophy and osteogenesis imperfecta [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Gene inversions related to factor VIII deficiency may result from mechanisms related to abnormal chromatin folding patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link\">",
"     \"Inherited syndromes associated with cardiac disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Structural abnormalities influence gene function in several ways, including deletion or duplication of phenotypically relevant genes, or gene fusion to create a novel gene and transcript. Fusion may result in an inappropriate regulatory sequence and aberrant gene expression, or juxtaposition of two coding sequences to produce novel fusion proteins (",
"    <a class=\"graphic graphic_figure graphicRef65092 \" href=\"UTD.htm?18/63/19441\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene fusion is the cause of CML and the idiopathic hypereosinophilic syndrome. CML results from fusion of the",
"    <em>",
"     BCR",
"    </em>",
"    and",
"    <em>",
"     ABL",
"    </em>",
"    genes. Idiopathic hypereosinophilic syndrome is caused by the fusion of the FIP1-like-1 (",
"    <em>",
"     FIP1L1",
"    </em>",
"    ) and platelet-derived growth factor receptor alpha (",
"    <em>",
"     PDGFRA",
"    </em>",
"    ) genes. Interestingly, the resulting fusion proteins in both cases are hyperfunctional tyrosine kinases whose uncontrolled activity leads to dysregulated clonal cellular expansion. The activity of both kinases can be blocked by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , resulting in clinical and molecular remission of both conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMMON GENETIC VARIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large chromosomal aberrations can dramatically impact clinical phenotype and are frequently implicated in rare genetic syndromes. Smaller sized variants, however, are far more abundant and frequent, and are responsible for most of the genetic variance for heritable traits in general populations. These variants include short tandem repeats, single nucleotide substitutions (mutations or single nucleotide polymorphisms), insertions and deletions (indels), and copy number variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Short tandem repeat markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short tandem repeats (STRs) are sequences of two to six base pairs that repeat in tandem and are flanked by non-repetitive sequence. Genetic variation is conferred by the variable length of the sequence due to variation in the number of tandem repeats (",
"    <a class=\"graphic graphic_figure graphicRef82363 \" href=\"UTD.htm?29/17/29971\">",
"     figure 5",
"    </a>",
"    ). This polymorphism is generated by slip-mispairing during DNA replication, with formation of DNA loops and back priming of the leading strand [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The longer the length of a segment of repetitive DNA, the more susceptible it is to slip-mispairing. Thus, mutation rates for STRs are substantially higher than for single-base pair mutations. Although previously widely used, STRs have largely been replaced by single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) as markers of genetic variation.",
"   </p>",
"   <p>",
"    Disease-causing expansions of tandem repeat sequences (trinucleotide repeats) have been described in coding regions of genes, intronic sequences, and 5' untranslated regions (5&rsquo;UTR) of sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/16-18\">",
"     16-18",
"    </a>",
"    ] and are mutated in several neurogenetic conditions. These include Fragile X syndrome (due to expansion of a CGG repeat sequence in the 5'UTR of the",
"    <em>",
"     FMR1",
"    </em>",
"    gene), myotonic dystrophy (due to expansion of a CTG repeat in the 3'UTR of the",
"    <em>",
"     DMPK",
"    </em>",
"    gene) (",
"    <a class=\"graphic graphic_figure graphicRef82363 \" href=\"UTD.htm?29/17/29971\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/19-21\">",
"     19-21",
"    </a>",
"    ], and Huntington disease (due to CAG expansion within the coding region of the",
"    <em>",
"     HD",
"    </em>",
"    gene that encodes Huntingtin) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=see_link\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A unique clinical feature often associated with disease due to expanded trinucleotide repeats is that of genetic anticipation, whereby disease severity worsens or age of symptom onset decreases in subsequent generations. As an example, in myotonic dystrophy, mild manifestations of the disease in an older adult patient may only be recognized following diagnosis of the condition in a severely affected grandchild. This phenomenon reflects increasing expansion of the number of trinucleotide repeats with subsequent generations. The converse phenomenon of repeat length contraction has also been observed, and may explain variable penetrance observed in myotonic dystrophy, although this phenomenon is very rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/20\">",
"     20",
"    </a>",
"    ]. Parent of origin biases have also been observed in several of these conditions, likely due to gender-related differences in repeat expansion rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Microsatellite markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;As tens of thousands of common and highly polymorphic STR loci have been identified throughout the genome, and because they are readily amenable to polymerase chain reaction (PCR)-based genotyping, STRs (otherwise known as microsatellite markers) were previously used as genetic markers for genome mapping and family-based linkage analysis studies. In linkage analysis, a panel of 300 to 600 densely spaced markers is genotyped in large pedigrees that are ascertained because of multiple affected subjects. Chromosome recombination rates are tracked across families at a genome-wide level to identify chromosomal segments that segregate with disease status through multiple generations (",
"    <a class=\"graphic graphic_figure graphicRef75378 graphicRef57437 \" href=\"UTD.htm?39/53/40785\">",
"     figure 6A-B",
"    </a>",
"    ). The markers themselves are rarely the disease-causing variation, but the markers that are most strongly linked with disease can be used to delineate the genomic region harboring the causative mutation. An example of the successful use of linkage for gene mapping was the location of the",
"    <em>",
"     CFTR",
"    </em>",
"    gene on chromosome 7 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hundreds of disease-causing traits have since been identified by this methodology. Similar approaches for mapping complex common diseases such as diabetes, cancer, asthma, and hypertension, have been less reliably successful, and it has become more common to perform SNP analysis, array comparative genomic hybridization (array CGH), or next-generation sequencing for gene identification in both rare and common inherited disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nucleotide substitutions and single nucleotide polymorphisms (SNPs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single nucleotide substitutions represent the most abundant form of genetic variation and are responsible for much of the heritable phenotypic variation observed in human populations. Estimates based on whole genome sequencing efforts suggest that individuals carry between 2.8 and 3.9 million single-base pair variants, with higher estimates observed in individuals of African descent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates suggest that unrelated haploid genomes differ every 185 to 2000 nucleotides. This wide range is due in part to the variable rate of polymorphism across the genome, with some regions demonstrating high heterozygosity (such as the MHC cluster on chromosome 6), while others display more restricted variation. It has been proposed that this is likely to do evolutionary constraint of critical functional elements [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Local heterozygosity rates within genes also differ substantially, with lower rates of base substitution in coding regions of genes compared to untranslated (noncoding) regions, upstream promoter sequences, or exon-intron boundaries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By convention, single-base pair changes that achieve a population frequency of at least 1 percent are referred to as single nucleotide polymorphisms (SNPs). Less frequent substitutions that interrupt gene function, or that have clinical consequences, are labeled as mutations. The distinction between a SNP and a mutation is largely semantic. Differences in the frequency distribution of SNPs result from the combination of effects of natural selection, genetic drift, and other population genetic effects. The functional impact of a variant is not determined by its frequency, but rather by its location within genes or non-genic regulatory regions. Single-base substitutions resulting in SNPs or mutations arise through shared mechanisms, primarily single-base slip mispairing during DNA replication and CpG-mediated cytosine deamination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Monogenic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 50 percent of mutations known to cause disease are single nucleotide substitutions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/30\">",
"     30",
"    </a>",
"    ]. The majority of such loci identified to date represent highly penetrant rare coding variants that alter the amino acid composition of proteins, resulting in deleterious phenotypic consequences such as sickle cell anemia, alpha-1 antitrypsin deficiency, and hemochromatosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Genetic basis of complex disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of common variation that confers susceptibility to common, complex diseases, such as hypertension, has been more challenging. These common variants typically confer much weaker effects than variants associated with monogenic diseases and must interact with other genes and environmental triggers to establish disease. Mapping of these variants has been facilitated by advances in high-throughput genotyping with SNPs and next-generation sequencing.",
"   </p>",
"   <p>",
"    It is anticipated that the number of proven disease susceptibility variants will grow exponentially over the next few years. Genome-wide association studies, also known as GWAS, have emerged as a powerful means of identifying common disease-susceptibility variants and have been applied across a wide range of conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/31\">",
"     31",
"    </a>",
"    ]. Such studies are supported by the availability of large, well-characterized populations; robust microarray technology enabling genotyping of hundreds of thousands of variants; and the development of powerful analytic tools and statistical methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, GWAS has now been joined by other gene identification strategies, such as next-generation sequencing and systems biology approaches, as it has been recognized that susceptibility loci identified by GWAS account for only a small proportion of the estimated heritability of common, complex traits",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/31-33\">",
"      31-33",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Insertion/deletion polymorphism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion/deletion",
"    (or indel) polymorphisms are polymorphic sites of gains or losses of one or more nucleotides (",
"    <a class=\"graphic graphic_figure graphicRef69699 \" href=\"UTD.htm?17/43/18111\">",
"     figure 7",
"    </a>",
"    ). Most indels range in length between one and four nucleotides; the vast majority are one nucleotide.",
"   </p>",
"   <p>",
"    Indels are distributed throughout the genome and represent approximately 10 percent of human DNA variation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/24\">",
"     24",
"    </a>",
"    ]. Though less common than single-base pair substitutions (~350,000 per individual,",
"    <span class=\"nowrap\">",
"     ~1/10",
"     <sup>",
"      th",
"     </sup>",
"    </span>",
"    of the number of SNPs), indels represent a considerable proportion of sequence variation in human populations. Like single-base substitutions, most indels (particularly insertions) arise through slip-mispairing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. When situated in the coding sequence of a gene, indels typically result in frameshift mutations that can alter protein structure and function (",
"    <a class=\"graphic graphic_figure graphicRef69699 \" href=\"UTD.htm?17/43/18111\">",
"     figure 7",
"    </a>",
"    ). If a frameshift mutation causes a premature stop codon, the transcript may undergo nonsense mediated decay, leading to loss of an allele. Indels constitute a substantial proportion of variation contributing to disease pathogenesis, representing more than 25 percent of the disease-associated variants in the Human Gene Mutation Database [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most pathogenic indels are frameshift mutations. However, insertions or deletions of three or six nucleotides can have pathogenic consequences despite maintaining normal reading frames. As an example, a 3-nucleotide (CTT) deletion at codon 508 (phenylalanine) of the",
"    <em>",
"     CFTR",
"    </em>",
"    gene (DeltaF508) is responsible for 70 percent of cystic fibrosis cases in Caucasian populations. This mutation prevents normal trafficking of mature CFTR protein to the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Larger indels have also been implicated in human disease, including a 32 base pair deletion in the coding region of chemokine-receptor 5 (",
"    <em>",
"     CCR5",
"    </em>",
"    ), observed in 16 percent of Caucasians.",
"    <em>",
"     CCR5",
"    </em>",
"    Delta32 substantially impairs HIV infection of T cells by impairing normal CCR5 function, a T-cell surface receptor, which serves as a co-receptor for HIV transfection. Thus, homozygotes for this indel are protected from HIV infection, and the rate of disease progression is slowed among heterozygote carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5112/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Copy number variations (CNVs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural genetic variation refers to a class of sequence alterations spanning more than 1000 base pairs (one kilobase or kb). This class includes quantitative variations such as copy number variations (CNVs) (",
"    <a class=\"graphic graphic_figure graphicRef67644 \" href=\"UTD.htm?40/28/41412\">",
"     figure 3",
"    </a>",
"    ), sequence rearrangements (such as those observed among immunoglobulins), and other less common variations including chromosome inversions or translocations described above.",
"   </p>",
"   <p>",
"    CNVs, another prevalent type of structural variation, are DNA segments spanning thousands to millions of bases whose copy number varies between different individuals. These submicroscopic genomic differences in the number of copies of one or more sections of DNA result in DNA gains or losses. CNVs may or may not be associated with phenotypic effects. An extensive discussion of CNVs is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=see_link&amp;anchor=H16722199#H16722199\">",
"     \"Genomic disorders: An overview\", section on 'Copy number variations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large chromosomal abnormalities involve changes in chromosome number or structure. Aneuploidy is an abnormal copy number of one chromosome. Autosomal monosomies (loss of a non-sex linked chromosome), are non-viable unless accompanied by a normal cell line (termed mosaicism). Turner syndrome is the loss of one X chromosome. Trisomy 21 (Down syndrome) is the only trisomy for a whole human autosome in which affected individuals frequently survive into adulthood. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Aneuploidy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Structural chromosome abnormalities include chromosomal translocations, deletions, duplications, and inversions. Gene fusion caused by a structural chromosome aberration may result in a novel protein. Both chronic myeloid leukemia and idiopathic hypereosinophilia syndrome are related to a hyperfunctional tyrosine kinase fusion protein. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Structural chromosome abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smaller chromosome abnormalities (single nucleotide polymorphisms, short tandem repeats, indels, and copy number variants) are responsible for most genetic variation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Common genetic variation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short tandem repeats (STRs) are sequences of two to six base pairs that repeat in tandem and are flanked by non-repetitive sequences. When used as markers of genetic loci for genome mapping and linkage analysis studies, STRs are known as microsatellites. Trinucleotide repeats, a type of STR, have been identified in several neurogenetic conditions (for example, Fragile X, myotonic dystrophy, and Huntington disease) and may be associated with genetic anticipation (increasing disease severity and earlier age of onset over subsequent generations). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Short tandem repeat markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Single nucleotide substitutions are responsible for much of the heritable phenotypic variation in human populations. Single nucleotide polymorphisms (SNPs) are single-base pair changes that achieve a population frequency of at least 1 percent. More than 60 percent of the currently-identified mutations that cause disease are highly penetrant single nucleotide substitutions, resulting in amino acid substitutions and abnormal proteins. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nucleotide substitutions and single nucleotide polymorphisms (SNPs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genome-wide association studies have facilitated the identification of susceptibility loci for more complex diseases. These gene variations with low penetrance can result in phenotypic expression, depending on interaction with other genes and environmental triggers. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Genetic basis of complex disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Insertion/deletion",
"      </span>",
"      (or indel) polymorphisms are polymorphic sites of gains or losses of one or more nucleotides. Most pathogenic indels are frameshift mutations. For example a 32 base pair deletion (",
"      <em>",
"       CCR5",
"      </em>",
"      Delta32) conveys protection against HIV transfection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Insertion/deletion polymorphism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Copy number variants (CNVs) are the most prevalent structural genetic variation, with DNA segments multiple kilobases in length varying between individuals. CNVs are particularly common in gene families related to immune and inflammatory responses, cell signaling and cell adhesion, structural proteins and olfactory receptors. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Copy number variations (CNVs)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=see_link&amp;anchor=H16722199#H16722199\">",
"       \"Genomic disorders: An overview\", section on 'Copy number variations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/1\">",
"      Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research. Nature 2003; 422:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/2\">",
"      Kesler SR. Turner syndrome. Child Adolesc Psychiatr Clin N Am 2007; 16:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/3\">",
"      Hjerrild BE, Mortensen KH, Gravholt CH. Turner syndrome and clinical treatment. Br Med Bull 2008; 86:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/4\">",
"      Ranweiler R. Assessment and care of the newborn with Down syndrome. Adv Neonatal Care 2009; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/5\">",
"      Wikstr&ouml;m AM, Dunkel L. Klinefelter syndrome. Best Pract Res Clin Endocrinol Metab 2011; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/6\">",
"      Otter M, Schrander-Stumpel CT, Curfs LM. Triple X syndrome: a review of the literature. Eur J Hum Genet 2010; 18:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/7\">",
"      Higuchi M, Kazazian HH Jr, Kasch L, et al. Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci U S A 1991; 88:7405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/8\">",
"      Hu XY, Ray PN, Worton RG. Mechanisms of tandem duplication in the Duchenne muscular dystrophy gene include both homologous and nonhomologous intrachromosomal recombination. EMBO J 1991; 10:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/9\">",
"      Lau YL, Srivastava G, Wong V, et al. Deletions, duplications and novel restriction fragment length polymorphism in Duchenne and Becker muscular dystrophies. Clin Genet 1992; 41:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/10\">",
"      Cohn DH, Zhang X, Byers PH. Homology-mediated recombination between type I collagen gene exons results in an internal tandem duplication and lethal osteogenesis imperfecta. Hum Mutat 1993; 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/11\">",
"      Jennings MW, Jones RW, Wood WG, Weatherall DJ. Analysis of an inversion within the human beta globin gene cluster. Nucleic Acids Res 1985; 13:2897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/12\">",
"      Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/13\">",
"      Van den Berghe H. Letter: The Ph1-chromosome: translocation to chromosome 9. Lancet 1973; 302:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/14\">",
"      Schl&ouml;tterer C. Evolutionary dynamics of microsatellite DNA. Chromosoma 2000; 109:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/15\">",
"      Ellegren H. Microsatellite mutations in the germline: implications for evolutionary inference. Trends Genet 2000; 16:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/16\">",
"      A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993; 72:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/17\">",
"      Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997; 386:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/18\">",
"      Muragaki Y, Mundlos S, Upton J, Olsen BR. Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13. Science 1996; 272:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/19\">",
"      Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/20\">",
"      Buxton J, Shelbourne P, Davies J, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992; 355:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/21\">",
"      Harley HG, Brook JD, Rundle SA, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992; 355:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/22\">",
"      Iannuzzi MC, Collins FS. Reverse genetics and cystic fibrosis. Am J Respir Cell Mol Biol 1990; 2:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/23\">",
"      Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010; 362:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/24\">",
"      1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/25\">",
"      Chakravarti A. It's raining SNPs, hallelujah? Nat Genet 1998; 19:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/26\">",
"      Li WH, Sadler LA. Low nucleotide diversity in man. Genetics 1991; 129:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/27\">",
"      Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/28\">",
"      Halushka MK, Fan JB, Bentley K, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/29\">",
"      Rideout WM 3rd, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990; 249:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/30\">",
"      Cooper DN, Krawczak M. Human Gene Mutation Database. Hum Genet 1996; 98:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/31\">",
"      Prins BP, Lagou V, Asselbergs FW, et al. Genetics of coronary artery disease: genome-wide association studies and beyond. Atherosclerosis 2012; 225:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/32\">",
"      Guerra SG, Vyse TJ, Cunninghame Graham DS. The genetics of lupus: a functional perspective. Arthritis Res Ther 2012; 14:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/33\">",
"      Marian AJ. Elements of 'missing heritability'. Curr Opin Cardiol 2012; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/34\">",
"      Krawczak M, Cooper DN. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet 1991; 86:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/35\">",
"      Taylor MS, Ponting CP, Copley RR. Occurrence and consequences of coding sequence insertions and deletions in Mammalian genomes. Genome Res 2004; 14:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/36\">",
"      Antonarakis SE, Krawczak M, Cooper DN. Disease-causing mutations in the human genome. Eur J Pediatr 2000; 159 Suppl 3:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/37\">",
"      Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/38\">",
"      Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/39\">",
"      Rommens JM, Zengerling S, Burns J, et al. Identification and regional localization of DNA markers on chromosome 7 for the cloning of the cystic fibrosis gene. Am J Hum Genet 1988; 43:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/40\">",
"      Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/41\">",
"      Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5112/abstract/42\">",
"      Eugen-Olsen J, Iversen AK, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2895 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5112=[""].join("\n");
var outline_f4_63_5112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RARE CHROMOSOMAL ABERRATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Numerical chromosome abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Polyploidy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Structural chromosome abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMMON GENETIC VARIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Short tandem repeat markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Microsatellite markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nucleotide substitutions and single nucleotide polymorphisms (SNPs)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Monogenic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Genetic basis of complex disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Insertion/deletion polymorphism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Copy number variations (CNVs)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2895|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/62/16356\" title=\"figure 1A\">",
"      Normal assortment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/16/34051\" title=\"figure 1B\">",
"      Non-disjunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/21/21855\" title=\"figure 2\">",
"      Translocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/28/41412\" title=\"figure 3\">",
"      Nonhomologous recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/63/19441\" title=\"figure 4\">",
"      Gene fusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/17/29971\" title=\"figure 5\">",
"      Short tandem repeats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/47/1789\" title=\"figure 6A\">",
"      Linkage one pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/48/39680\" title=\"figure 6B\">",
"      Link disease gene location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/43/18111\" title=\"figure 7\">",
"      Pathogenic indel",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=related_link\">",
"      Genetics of the hemophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=related_link\">",
"      Genomic disorders: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=related_link\">",
"      Huntington disease: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=related_link\">",
"      Prenatal screening and diagnosis for fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10073?source=related_link\">",
"      The child with tall stature or abnormally rapid growth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_63_5113="Pharmacologic management of cancer anorexia/cachexia";
var content_f4_63_5113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic management of cancer anorexia/cachexia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5113/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5113/contributors\">",
"     Charles L Loprinzi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5113/contributors\">",
"     Aminah Jatoi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5113/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5113/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5113/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/63/5113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cancer-related",
"    <span class=\"nowrap\">",
"     anorexia/cachexia",
"    </span>",
"    syndrome (CACS) is a hypercatabolic state characterized by anorexia and loss of body weight associated with reduced muscle mass and adipose tissue. In addition to a variable contribution from decreased energy intake, resting energy expenditure can be elevated in CACS in association with increases in both muscle protein breakdown and lipolysis. These changes appear to be due in part to an inflammatory response with the elaboration of cytokines including tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1 beta. Tumor-elaborated factors such as proteolysis-inducing factor and lipid-mobilizing factor also may play an important role. Unlike starvation, weight loss in cancer arises both from loss of muscle and fat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CACS is frequently seen in patients with advanced cancer. One study evaluated 644 consecutive, mostly ambulatory cancer patients: decreased appetite, decreased food intake, and weight loss in excess of 5 percent of premorbid weight were present in more than one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, 54 percent were underweight when compared with the calculated ideal body weight.",
"   </p>",
"   <p>",
"    Weight loss in CACS is a marker for both progression of the syndrome and for prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/2\">",
"     2",
"    </a>",
"    ]. In a multi-institutional, retrospective review of 3047 clinical protocol cancer patients from the Eastern Cooperative Oncology Group, weight loss of more than 5 percent of premorbid weight prior to the initiation of chemotherapy was predictive of early mortality. Weight loss was independent of disease stage, tumor histology, and patient performance status in its predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/2\">",
"     2",
"    </a>",
"    ]. There was also a trend towards lower response rates with the use of chemotherapy among weight-losing patients. This trend reached statistical significance only among patients with breast cancer.",
"   </p>",
"   <p>",
"    There is no convincing evidence that nutritional counseling has any benefit in CACS, although it is frequently recommended and may provide some helpful information for patients; nutritional supplementation with parenteral or enteral feeding has only limited efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This finding is not surprising since increased protein catabolism is thought to be a sentinel feature in this syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations have provided the rationale for drug therapy aimed at reversing some aspects of CACS. Primary pharmacologic management of cancer cachexia has included the administration of orexigenic (appetite stimulants), anticatabolic (antimetabolic and anticytokine), and anabolic agents (primarily hormonal).",
"   </p>",
"   <p>",
"    A major focus has been on the palliation of anorexia, and the two classes of drugs that have been shown to be effective in phase III clinical trials are corticosteroids and progestational agents. These drugs do not appear to improve survival, nor have they been demonstrated to improve global quality of life in the majority of studies that have examined such parameters. Nonetheless, improvement in appetite",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight gain in selected patients with the CACS appears beneficial, because anorexia is a prevalent and distressing symptom suffered by cancer patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPETITE STIMULANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the orexigenic agents that have been evaluated in CACS are corticosteroids, progesterone analogs, and serotonin antagonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of corticosteroids in CACS has not been established. Euphorigenic and antiinflammatory effects, and perhaps stimulation of orexigenic hormones within the hypothalamus, may be responsible for an increase in appetite.",
"   </p>",
"   <p>",
"    At one time, corticosteroids were first-line therapy for appetite stimulation in CACS. In the first placebo-controlled trial in CACS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    alleviated cancer anorexia on a short-term basis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/5\">",
"     5",
"    </a>",
"    ]. This finding has subsequently been replicated by other studies, and both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    have also been shown to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A reasonable dose of dexamethasone in this setting is 4",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    although lower doses may also be effective.",
"   </p>",
"   <p>",
"    Many patients treated with corticosteroids experience an increase in appetite and sense of well being but not weight gain, compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, the duration of appetite stimulation is often short-lived. Furthermore, prolonged steroid therapy produces myopathy and a wide variety of other side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Progesterone analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of prospective controlled randomized trials and a meta-analysis of the Cochrane database have confirmed the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (MPA) for palliation of CACS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The effectiveness of megestrol acetate and its potential superiority to other classes of agents are illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 133 patients with CACS were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      (800",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/8\">",
"       8",
"      </a>",
"      ]. There was a significant increase in both appetite and weight in patients treated with megestrol acetate, and eleven of 67 patients treated with megestrol acetate gained at least 15 lbs, compared with just 1 of 66 receiving a placebo. The only side effect was mild edema.",
"     </li>",
"     <li>",
"      The advantages of progesterone analogs over corticosteroids and anabolic agents were demonstrated in a trial in which 475 patients with CACS were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      (800",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (4",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/34/41508?source=see_link\">",
"       fluoxymesterone",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/9\">",
"       9",
"      </a>",
"      ]. The megestrol acetate and dexamethasone had similar efficacy in terms of appetite stimulation and weight gain, and both were superior to fluoxymesterone. However, toxicity was more common with dexamethasone and included myopathy, cushingoid body habitus, and peptic acid disease. These side effects led some patients to discontinue treatment. There was no difference between the treatment groups in survival or quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dose of megestrol acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have addressed the optimal dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The best balance between effectiveness and toxicity is between 480 to 800",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    This was demonstrated in a dose-response trial, in which there was a positive relationship between appetite stimulation and increasing megestrol acetate doses ranging from 160 to 800 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/12\">",
"     12",
"    </a>",
"    ]. A higher dose, 1280 mg per day, was not more effective.",
"   </p>",
"   <p>",
"    Most published studies tested",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    tablets rather than the oral suspension. However, the liquid form is associated with good compliance, lower expense, and possibly better bioavailability. Our practice is to begin with liquid megestrol acetate at a dose of 400",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    A high-potency liquid formulation is available, which contains 625 mg in 5 ml.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    is usually well tolerated. There may be a slight increase in the risk of deep vein thrombosis, particularly in patients receiving concomitant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/16\">",
"     16",
"    </a>",
"    ]. Megestrol may cause symptomatic suppression of the hypothalamic pituitary adrenal axis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In the presence of serious infection, surgery, or trauma, this complication may be life threatening if not anticipated and treated. In male patients with cancer, treatment with megestrol may also suppress the gonadal axis, resulting in symptomatic androgen deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=see_link\">",
"     \"Causes of secondary and tertiary adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Use in prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of these agents in the treatment of CACS has led investigators to study their role in prophylaxis. The benefit of prophylactic progesterone analogs remains unclear despite several prospective randomized clinical trials, as is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 243 patients with newly diagnosed, extensive-stage small cell lung cancer were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      (800",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/16\">",
"       16",
"      </a>",
"      ]. Although megestrol reduced nausea somewhat, there was no improvement in tumor response rate, survival, or quality of life. An increased incidence of thromboembolic events was observed in patients treated with megestrol acetate.",
"     </li>",
"     <li>",
"      A second trial randomly assigned 134 patients with advanced, incurable, non-hormone-sensitive cancer to MPA (500 mg BID) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/20\">",
"       20",
"      </a>",
"      ]. At 12 weeks, MPA was associated with improved appetite and a mean weight gain of 0.6 &plusmn; 4.4 kg compared to a mean weight loss of 1.4 &plusmn; 4.6 kg in the placebo-treated group (p = 0.04 for the between group difference). However, there was no improvement in global quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cannabinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal reports and small studies suggest that marijuana stimulates appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/21\">",
"     21",
"    </a>",
"    ], prompting interest in the use of cannabinoids in patients with CACS.",
"   </p>",
"   <p>",
"    Unfortunately, synthetic cannabinoids have not been demonstrated to have activity against CACS in patients advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], despite their activity in patients with advanced HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cooperative group trial, 469 evaluable patients with anorexia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weight loss were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      or both agents [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/22\">",
"       22",
"      </a>",
"      ]. Significantly more patients had appetite improvement with megestrol acetate (73 versus 47 percent, compared to dronabinol) and weight gain of &ge;10 percent over baseline (13 versus 5 percent). Combined therapy with both megestrol acetate and dronabinol had no benefit beyond that obtained with megestrol acetate alone.",
"     </li>",
"     <li>",
"      Similarly, benefit could not be shown in a European trial, in which 243 adults with advanced cancer and CACS were randomly assigned to a standardized cannabis extract,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      , or a placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/23\">",
"       23",
"      </a>",
"      ]. No differences were observed between the groups in terms of appetite, quality of life, or cannabinoid-related toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no data on the efficacy of inhaled marijuana for patients with CACS, and, like synthetic cannabinoids, its use cannot be recommended in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cyproheptadine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     Cyproheptadine",
"    </a>",
"    is a histamine and serotonin antagonist that has been observed to cause weight gain in observational studies of patients with advanced cancer. In a large placebo-controlled trial that included 295 patients with the CACS, cyproheptadine (8 mg three times daily) had a mild stimulatory effect on appetite but failed to prevent weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     Cyproheptadine",
"    </a>",
"    appears to be effective in patients with carcinoid syndrome who have",
"    <span class=\"nowrap\">",
"     anorexia/cachexia.",
"    </span>",
"    In these patients, cyproheptadine presumably acts by directly counteracting increased serotonin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANABOLIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anabolic steroid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/34/41508?source=see_link\">",
"     fluoxymesterone",
"    </a>",
"    was shown to be less effective than either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    as an appetite stimulant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Progesterone analogs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, anabolic steroids may have a selective effect that induces an increase in lean body mass, even while body fat decreases and there is a decrease in overall weight. In a randomized trial presented at the 2008 ASCO meeting, 155 patients receiving chemotherapy were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     oxandrolone",
"    </a>",
"    (10 mg twice a day for 12 weeks) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 12 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/28\">",
"     28",
"    </a>",
"    ]. Total weight and lean body mass were assessed at the end of the 12-week treatment course and again four weeks later after a washout period. Treatment with oxandrolone was associated with perhaps a slight nonstatistically significant increase in lean body mass at 12 weeks (2.67 versus 0.82 pounds with megestrol, p = 0.12), but a decrease in overall weight as compared with megestrol (-3.3 versus +5.8 pounds, respectively). The potential benefit in lean body mass did not persist at the end of the washout period.",
"   </p>",
"   <p>",
"    Interpretation of the trial results is limited by the fact that more patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     oxandrolone",
"    </a>",
"    dropped out prior to completing the planned 12 weeks of therapy (63 versus 39 percent with megestrol). In addition, the results of this trial have not been published in a peer-reviewed journal to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     Recombinant human growth hormone",
"    </a>",
"    in conjunction with protein restriction increased skeletal muscle mass at the expense of the tumor when used in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the use of recombinant growth hormone in critically ill adults has been associated with high mortality rates, perhaps because of a diversion of amino acids and energy to skeletal muscle and away from the acute phase response, thus blunting host defenses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative approach has been the use of ghrelin, which is a ligand for growth hormone secretagogue receptor and can induce release of growth hormone. Preliminary studies have shown that multiple doses of parenteral ghrelin therapy can be safely administered to patients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, additional research is required to determine whether this approach has any beneficial effect in patients with cancer cachexia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=see_link\">",
"     \"Ghrelin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CYTOKINE AND METABOLIC INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, cytokines (eg, tumor necrosis factor-alpha (TNF-alpha), IL-6, and IL-1 beta) and tumor-elaborated factors (eg, proteolysis-inducing factor and lipid-mobilizing factor) are thought to play an important role in CACS. As a result, several agents have been evaluated for anti-CACS effects because of their ability to modulate these mediators. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Eicosapentaenoic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eicosapentaenoic acid (EPA) is an alpha-3 omega fatty acid, which is found in marine products, such as fish oil. In vitro studies have shown that EPA can attenuate the stimulation of adenylate cyclase activity and lipolysis produced by tumor-derived lipid-mobilizing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/34\">",
"     34",
"    </a>",
"    ]. It may also suppress IL-6 production in patients with pancreatic cancer cachexia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of EPA has been assessed in a number of randomized trials, without consistent evidence of a beneficial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. A 2007 Cochrane database meta-analysis concluded that there were insufficient data to establish that EPA was better than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Targeting TNF",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the catabolic state of CACS is characterized by anorexia and loss of body weight associated with reduced muscle mass and adipose tissue and increases in both muscle protein breakdown and lipolysis. These changes appear to be due in part to an inflammatory response with the elaboration of cytokines including tumor necrosis factor-alpha (TNF-alpha). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and pathogenesis of cancer cachexia\", section on 'Cytokines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic strategies targeting TNF that have been explored for treatment of CACS include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , a methylxanthine derivative that can inhibit TNF-alpha production by monocytes and T lymphocytes in vitro and can reduce plasma concentrations and mRNA expression of this cytokine in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , both monoclonal antibodies that block TNF-alpha. Despite the compelling rationale underlying their use, small, placebo-controlled trials that have tested these three agents individually have failed to demonstrate benefit, reporting no positive effect on appetite or body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains possible that blockade of multiple cytokines could benefit cancer patients who suffer from anorexia and weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , a potent inhibitor of TNF-alpha production, has been associated with weight gain in patients with tuberculosis or HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. A possible role in cancer patients has also been suggested. As an example, a small placebo-controlled trial in patients with advanced pancreatic cancer suggested modest benefits in preventing weight loss using thalidomide 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/50\">",
"     50",
"    </a>",
"    ]. However, other endpoints such as survival and quality of life showed no differences between groups. A Cochrane review concluded that there is insufficient evidence to support or refute the use of thalidomide for the management of cachexia in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/51\">",
"     51",
"    </a>",
"    ]. Larger, more definitive studies are needed to clarify the role of this agent in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hydrazine sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrazine sulfate, an inhibitor of phosphoenolpyruvate kinase, an enzyme involved in gluconeogenesis, was widely touted for the treatment of CACS. However, three placebo-controlled clinical trials failed to demonstrate any benefit in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Central and peripheral neurotoxicity has been described with hydrazine, which is similar to that observed with the hydrazine-derived drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    . A fatal case of hepatorenal failure has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other therapies have been tried in patients with CACS, including insulin, adenosine triphosphate (ATP) infusions, melatonin, the prokinetic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , and branched chain amino acids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with low doses of insulin has been assessed in patients with advanced cancer in an effort to limit the progression of weight loss and improve physical functioning. In a trial in patients with advanced cancer, 138 patients were randomly assigned to intensive supportive care with or without insulin (0.11",
"    <span class=\"nowrap\">",
"     units/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/56\">",
"     56",
"    </a>",
"    ]. There was a suggestion of improvement based upon multiple metabolic parameters and overall survival, and there was no evidence to suggest that the insulin stimulated tumor growth.",
"   </p>",
"   <p>",
"    Additional clinical trials are required to further assess potential benefits and toxicity of insulin in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     ATP infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preliminary study suggested infusions of ATP helped lung cancer patients regain their appetite and maintain weight. In an unblinded controlled trial, 58 patients with advanced non-small cell lung cancer were randomly assigned to ATP (ten intravenous 30 hour infusions of up to 75",
"    <span class=\"nowrap\">",
"     &micro;g/minute,",
"    </span>",
"    as tolerated, every two to four weeks) or to no ATP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Body composition, appetite and dietary intake stabilized among the ATP-treated patients, while the non-ATP group had an erosion of lean tissue and fat, a dwindling appetite, and a drop in dietary intake. Although these data are intriguing, the absolute benefits were marginal and further confirmatory trials are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Melatonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin has been recommended to correct disturbances in the circadian rhythm and it also downregulates production of TNF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/31\">",
"     31",
"    </a>",
"    ]. One study compared supportive care with the administration of melatonin (20 mg per night for three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/59\">",
"     59",
"    </a>",
"    ]. Although there was no difference in food intake, weight loss was significantly less in the melatonin-treated group. In a subsequent study, 70 consecutive patients with advanced non-small cell lung cancer were randomized to receive chemotherapy with cisplatin and etoposide either alone or with melatonin (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/60\">",
"     60",
"    </a>",
"    ]. The degree of cachexia and frequency of myelosuppression and neuropathy were significantly lower in those treated with melatonin, and the one-year survival of this group was increased (15 of 34 versus 7 of 36). These results require confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mirtazapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;At standard doses, the tetracyclic antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    induces weight gain and increases food intake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benefit in CACS was suggested in a phase II trial in which 17 non-depressed patients with cancer-related CACS received an eight-week course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    (15 to 30 mg by mouth daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/61\">",
"     61",
"    </a>",
"    ]. Four of 17 patients gained 1 kg or more, and 24 percent reported improved appetite. Definitive proof of benefit will require a randomized, placebo-controlled trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Serotonin antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antagonists to the serotonin type 3 receptor are under evaluation as appetite stimulants because serotonin is associated with anorexia in cachectic animals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/31\">",
"     31",
"    </a>",
"    ]. In one study of patients with metastatic cancer who were not receiving chemotherapy or radiation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    improved appetite but did not reverse weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Metoclopramide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    increases gastrointestinal motility, thereby speeding gastric emptying and potentially decreasing nausea and increasing appetite. In a placebo-controlled trial, metoclopramide resulted in a significant decrease in nausea but did not improve caloric intake [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Amino acid supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information from pilot studies suggests that specific amino acid nutritional formulations with branched chain amino acids, arginine and glutamine, might have some efficacy in alleviating cancer",
"    <span class=\"nowrap\">",
"     anorexia/cachexia",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/64\">",
"     64",
"    </a>",
"    ]. However, placebo-controlled clinical trials have yet to be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link&amp;anchor=H8#H8\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'Immunonutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H375560115\">",
"    <span class=\"h2\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least some data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    may add to the already-established (but certainly less than ideal) benefits of megestrol appetite in reducing the severity of cancer-associated anorexia and increasing non-fluid weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/65\">",
"     65",
"    </a>",
"    ]. In a pilot study, 80 patients with advanced gastrointestinal or lung cancer were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    alone at a dose of 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or the same dose of megestrol plus olanzapine 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for eight weeks. The MD Anderson Symptom Inventory was used to objectively assess appetite. Patients receiving combined therapy had a significantly higher rate of improved appetite (64 versus 5 percent).",
"   </p>",
"   <p>",
"    Although these results suggest that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    to megestrol may provide a substantial degree of appetite stimulation compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    alone in patients with advanced cancer, these results cannot yet be considered definitive because this single-institution study was only pilot in nature and the megestrol appetite arm appeared to underperform compared to historical controls. Olanzapine should be further tested as a palliative agent for cancer-associated anorexia. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized Italian trial attempted to address the role of combination therapy in patients with advanced stage cancer and cancer-related",
"    <span class=\"nowrap\">",
"     anorexia/cachexia.",
"    </span>",
"    In this five-arm study, 332 patients were randomly assigned to a four-month course of a progestational agent (medroxyprogesterone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    ), an eicosapentaenoic acid (EPA)-enriched nutritional supplement,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     l-carnitine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , or a combination of all four interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5113/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination arm appeared to have provided improved clinical outcomes, thereby suggesting that combination therapy (and single agent treatment with some of the individual study arms of this trial) merits further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       \"Patient information: Managing loss of appetite and weight loss with cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many agents have been evaluated for the treatment of CACS, only corticosteroids and progesterone analogs have proven benefit in palliation of the anorexia associated with this syndrome.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    can be considered when treatment for days to weeks is anticipated. For patients with longer life expectancies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    is more appropriate.",
"   </p>",
"   <p>",
"    The primary benefits associated with these drugs are increased appetite and weight gain, not improved survival or quality of life. For this reason, the use of corticosteroids or progesterone analogs should be undertaken only after a detailed discussion of risks and potential benefits in the symptomatic cancer patient.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/1\">",
"      Hashida H, Takabayashi A, Tokuhara T, et al. Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. Int J Cancer 2002; 97:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/2\">",
"      Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/3\">",
"      Ovesen L, Allingstrup L, Hannibal J, et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993; 11:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/4\">",
"      Barber MD, Fearon KC, Delmore G, Loprinzi CL. Should cancer patients with incurable disease receive parenteral or enteral nutritional support? Eur J Cancer 1998; 34:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/5\">",
"      Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/6\">",
"      Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/7\">",
"      Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989; 25:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/8\">",
"      Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/9\">",
"      Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17:3299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/10\">",
"      Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005; :CD004310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/11\">",
"      Yavuzsen T, Davis MP, Walsh D, et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005; 23:8500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/12\">",
"      Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/13\">",
"      Vadell C, Segu&iacute; MA, Gim&eacute;nez-Arnau JM, et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 1998; 21:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/14\">",
"      Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/15\">",
"      Pardo J, Mena AM, Motnsech L, et al. Megestrol acetate for anorexia in lung cancer patients undergoing radiation therapy. A randomized trial comparing the efficacy of two different doses in 130 patients (abstract). Proc Am Soc Clin Oncol 2003; 22:765a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/16\">",
"      Rowland KM Jr, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996; 14:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/17\">",
"      Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995; 122:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/18\">",
"      Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/19\">",
"      Dev R, Del Fabbro E, Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 2007; 110:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/20\">",
"      Simons JP, Aaronson NK, Vansteenkiste JF, et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 1996; 14:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/21\">",
"      Abel EL. Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971; 231:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/22\">",
"      Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/23\">",
"      Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24:3394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/24\">",
"      Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/25\">",
"      Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/26\">",
"      Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990; 65:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/27\">",
"      Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991; 67:33.",
"     </a>",
"    </li>",
"    <li>",
"     Lesser GJ, Case D, Ottery F, et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy (abstract). J Clin Oncol 2008; 505:s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/29\">",
"      Bartlett DL, Stein TP, Torosian MH. Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery 1995; 117:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/30\">",
"      Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/31\">",
"      Kotler DP. Cachexia. Ann Intern Med 2000; 133:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/32\">",
"      Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008; 98:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/33\">",
"      Lundholm K, Gunnebo L, K&ouml;rner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 2010; 116:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/34\">",
"      Price SA, Tisdale MJ. Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Res 1998; 58:4827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/35\">",
"      Wigmore SJ, Fearon KC, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 1997; 92:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/36\">",
"      Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/37\">",
"      Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003; 21:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/38\">",
"      Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/39\">",
"      Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006; 24:3401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/40\">",
"      Murphy RA, Mourtzakis M, Chu QS, et al. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011; 117:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/41\">",
"      Dewey A, Baughan C, Dean T, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007; :CD004597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/42\">",
"      Lissoni P, Ardizzoia A, Perego MS, et al. Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha. J Biol Regul Homeost Agents 1993; 7:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/43\">",
"      Dezube BJ, Sherman ML, Fridovich-Keil JL, et al. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993; 36:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/44\">",
"      Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995; 13:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/45\">",
"      Jatoi A, Dakhil SR, Nguyen PL, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007; 110:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/46\">",
"      Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010; 68:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/47\">",
"      Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/48\">",
"      Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/49\">",
"      Reyes-Ter&aacute;n G, Sierra-Madero JG, Mart&iacute;nez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/50\">",
"      Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/51\">",
"      Reid J, Mills M, Cantwell M, et al. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev 2012; 4:CD008664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/52\">",
"      Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994; 12:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/53\">",
"      Loprinzi CL, Kuross SA, O'Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994; 12:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/54\">",
"      Kosty MP, Fleishman SB, Herndon JE 2nd, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994; 12:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/55\">",
"      Hainer MI, Tsai N, Komura ST, Chiu CL. Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med 2000; 133:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/56\">",
"      Lundholm K, K&ouml;rner U, Gunnebo L, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007; 13:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/57\">",
"      Agteresch HJ, Dagnelie PC, van der Gaast A, et al. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/58\">",
"      Agteresch HJ, Rietveld T, Kerkhofs LG, et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002; 20:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/59\">",
"      Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/60\">",
"      Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 1997; 23:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/61\">",
"      Riechelmann RP, Burman D, Tannock IF, et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care 2010; 27:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/62\">",
"      Edelman MJ, Gandara DR, Meyers FJ, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 1999; 86:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/63\">",
"      Bruera E, Belzile M, Neumann C, et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000; 19:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/64\">",
"      Pisters PW, Pearlstone DB. Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci 1993; 30:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/65\">",
"      Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 2010; 18:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5113/abstract/66\">",
"      Mantovani G, Macci&ograve; A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010; 15:200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2816 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-9D0B6BF364-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5113=[""].join("\n");
var outline_f4_63_5113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPETITE STIMULANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Progesterone analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dose of megestrol acetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Use in prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cannabinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cyproheptadine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANABOLIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Growth hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CYTOKINE AND METABOLIC INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Eicosapentaenoic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Targeting TNF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hydrazine sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MISCELLANEOUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ATP infusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Melatonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mirtazapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Serotonin antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Metoclopramide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Amino acid supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H375560115\">",
"      Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=related_link\">",
"      Causes of secondary and tertiary adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=related_link\">",
"      Ghrelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_63_5114="Headache in pregnancy";
var content_f4_63_5114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Headache in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Men-Jean Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Debra Guinn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Susan Hickenbottom, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/63/5114/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/63/5114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches are common among women in their childbearing years: in the Norwegian Head-HUNT study, 60 percent of women &le;40 years of age reported experiencing a headache within the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/1\">",
"     1",
"    </a>",
"    ]. Tension-type headache and migraine are most common, while cluster headache is much less common [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women with a history of headaches, the effect of pregnancy on the frequency and severity of their headaches, the effect of their headaches on pregnancy, and the safety of maternal headache treatment for the fetus are major concerns. When headaches first present during pregnancy or postpartum, a diagnostic evaluation is indicated and should consider the possibility that the headache is related to a complication of pregnancy; severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    always needs to be excluded in women over 20 weeks of gestation.",
"   </p>",
"   <p>",
"    This topic will discuss issues specific to diagnosis and management of headache in pregnant and postpartum women. The diagnosis and treatment of headaches in the general population are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3624?source=see_link\">",
"     \"Headache syndromes other than migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31147023\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, pregnant women with primary headache syndromes (tension-type headache, migraine headache, cluster headache) have been diagnosed before pregnancy, but as many as 10 percent initially present or are first diagnosed during gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/3\">",
"     3",
"    </a>",
"    ]. Among pregnant women with the onset of new or atypical headache, one third have migraine, one third have",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia-related",
"    </span>",
"    headache, and the remaining one third have a variety of other causes of headache (",
"    <a class=\"graphic graphic_table graphicRef71620 \" href=\"UTD.htm?23/15/23803\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnant women presenting with headache complaints should be evaluated initially with a detailed history and physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/6\">",
"     6",
"    </a>",
"    ]. A woman with a prior history of headaches may continue to suffer from them during pregnancy; pursuing a complicated duplication of diagnostic testing is not necessary if her characteristic symptoms have not changed.",
"   </p>",
"   <p>",
"    When indicated, the diagnostic evaluation of headache in pregnant women is similar to that in nonpregnant adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    .) Migraine, tension-type, and cluster headaches are primary causes of headache and diagnosed by specific clinical criteria (",
"    <a class=\"graphic graphic_table graphicRef68064 \" href=\"UTD.htm?40/58/41899\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the following worrisome",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    may have a secondary cause of headache. They should be evaluated promptly and have a complete neurological evaluation since these characteristics increase the probability of a serious underlying disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden onset of severe headache (&ldquo;worst headache of my life&rdquo;)",
"     </li>",
"     <li>",
"      New-onset migrainous headaches",
"     </li>",
"     <li>",
"      Headache in immunosuppressed women",
"     </li>",
"     <li>",
"      Worsening headaches",
"     </li>",
"     <li>",
"      Headache characteristic (eg, pain, pattern) different from usual headaches",
"     </li>",
"     <li>",
"      Headache related to exertion",
"     </li>",
"     <li>",
"      Headache with fever (",
"      <a class=\"graphic graphic_table graphicRef80966 \" href=\"UTD.htm?31/19/32059\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Headache with altered mental status, seizures, papilledema, changes in vision, stiff neck, or focal neurological",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"     </li>",
"     <li>",
"      Headache unrelieved by pain medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for neuroimaging and lumbar puncture are similar to those in nonpregnant adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of headache in adults\", section on 'Indications for imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of headache in adults\", section on 'Indications for lumbar puncture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of imaging modality should be determined by the suspected pathology, with the following considerations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnetic resonance imaging (MRI) does not expose the fetus to ionizing radiation and has not been associated with adverse fetal effects. Use of gadolinium is typically avoided because of limited experience with its use in pregnancy, but no adverse effects have been reported. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H26#H26\">",
"       \"Diagnostic imaging procedures during pregnancy\", section on 'Magnetic resonance imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Computed tomography (CT) involves ionizing radiation, but fetal radiation exposure from scatter is minimal during maternal head CT [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/7\">",
"       7",
"      </a>",
"      ]. Iodinated contrast materials cross the placenta and can produce transient effects on the developing fetal thyroid gland; however, clinical sequelae from brief exposures have not been reported. Iodinated contrast materials should be used in pregnancy, when clinically indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H17#H17\">",
"       \"Diagnostic imaging procedures during pregnancy\", section on 'Computed tomography'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, MRI is preferable to CT for assessing nontraumatic or nonhemorrhagic craniospinal pathology, such as edema, vascular disease, mass lesions, or local infection. Suspected arterial vascular lesions can be detected by MR angiography without gadolinium contrast. MR venogram is the standard for detecting venous thrombosis and can be performed without the use of gadolinium.",
"   </p>",
"   <p>",
"    Lumbar puncture is not contraindicated during pregnancy and should be performed following neuroimaging if increased intracranial pressure or infection is suspected. Neuroimaging is performed to exclude the presence of a large space-occupying lesion, which would be a contraindication to performing a lumbar puncture in the setting of increased intracranial pressure.",
"   </p>",
"   <p>",
"    An algorithm to guide the evaluation of adults with severe headache in the emergency department is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef71604 graphicRef51917 \" href=\"UTD.htm?25/39/26230\">",
"     algorithm 1A-B",
"    </a>",
"    ), and can be used by obstetrical providers evaluating pregnant women. However, blood pressure measurement is critical in pregnant women over 20 weeks of gestation. If blood pressure is elevated, urine protein should be determined to evaluate for preeclampsia.",
"   </p>",
"   <p>",
"    No large trials of headache therapy in pregnant women are available to provide data on which to base therapeutic recommendations. The major consideration is to \"do no harm\" since a history of headaches does not appear to adversely affect pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Drugs known to be teratogenic or otherwise harmful in pregnancy (eg, uterotonic agents, vasoconstrictors) should be avoided. Treatment decisions are made according to recommendations for nonpregnant adults, but choosing those drugs with the best safety profile for the fetus and limiting the number of medications and dosages to the minimum needed to control symptoms adequately. Treatment is also guided by the patient's prior treatment successes and failures, co-morbid conditions, and gestational age (first trimester versus later in pregnancy [ie, after the major period of organogenesis]). Patients should have realistic expectations regarding the limits of therapy and physicians should be willing to treat headache pain aggressively when the patient requests aggressive treatment after a discussion of the available information about potential fetal risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10723790\">",
"    <span class=\"h1\">",
"     COURSE AND MANAGEMENT OF PRIMARY HEADACHE SYNDROMES IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine typically becomes less frequent during pregnancy, while the frequency of other types of primary headache does not appear to be affected. Treatment of headaches is indicated for maternal comfort; the headaches themselves are not harmful to the",
"    <span class=\"nowrap\">",
"     pregnancy/fetus",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is often, but not always, unilateral and tends to have a throbbing or pulsatile quality. Accompanying features may include nausea, vomiting, and photophobia or phonophobia during attacks. Triggering factors include stress, visual stimuli, weather changes, nitrates, fasting, sleep disturbances, and certain foods. A migraine occurring during pregnancy can generally be differentiated from a preeclampsia headache by assessment of the patient&rsquo;s blood pressure, urine protein, gestational age, and whether she reports similar headaches prior to pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H21674085#H21674085\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H203275744#H203275744\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of migraine is higher in women than in men and peaks during the childbearing years. Approximately 18 percent of American women suffer from severe migraine headaches; many others have mild to moderate interference with their usual activities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/10\">",
"     10",
"    </a>",
"    ]. Approximately 2 percent of women develop their first migraine during pregnancy, usually in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of migraine is modulated by fluctuations in estrogen levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=see_link&amp;anchor=H2#H2\">",
"     \"Estrogen-associated migraine\", section on 'Pathophysiology'",
"    </a>",
"    .) Most women (60 to 70 percent) with a history of migraine report improvement over the course of pregnancy, approximately 5 percent describe worsening, and the remainder report no change [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/2\">",
"     2",
"    </a>",
"    ]. Improvement is most likely in women with menstrual migraine, migraine without aura, and women who experience improvement in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/2\">",
"     2",
"    </a>",
"    ]. Improvement has been defined as absence of attacks, less severe attacks, decreased frequency of attacks, or shorter duration of symptoms.",
"   </p>",
"   <p>",
"    The most common time for recurrence is during the postpartum period. In a study of postpartum women with a history of migraine, migraine recurred during the first week postpartum in 34 percent and during the first postpartum month in 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/12\">",
"     12",
"    </a>",
"    ]. Women with menstrual migraine are most likely to experience postpartum migraine, and women who breastfeed are less likely to experience migraine postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. In the same study, the prevalence of migraine in women who breastfed and bottle-fed was 43 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/12\">",
"     12",
"    </a>",
"    ]. The protective effect of breastfeeding has been attributed to more stable levels of estrogen in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reviews of studies evaluating pregnancy outcome in migraineurs generally conclude that migraine, treated or untreated, probably has no effect on most pregnancy outcomes, including risk of congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. There may, however, be an increased risk of developing",
"    <span class=\"nowrap\">",
"     preeclampsia/gestational",
"    </span>",
"    hypertension, which are associated with an increased risk of low birthweight (preterm birth, small for gestational age infant) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. As an example, a prospective cohort study found that the risk of developing hypertensive disorders of pregnancy was almost three-fold higher in migraineurs than in non-migraineurs (9.1 versus 3.1 percent; adjusted OR 2.85, 95% CI 1.40-5.81) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=see_link\">",
"     \"Gestational hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There appears to be an increased risk of stroke associated with migraine, particularly in women who have migraine with aura. However, the absolute increase in the risk of stroke is small and the effect of pregnancy is unclear as stroke is rare in",
"    <span class=\"nowrap\">",
"     pregnant/postpartum",
"    </span>",
"    women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In a study that used discharge codes to evaluate risk factors for stroke in pregnancy and the puerperium, there appeared to be a strong association (OR 16) between migraine and",
"    <span class=\"nowrap\">",
"     pregnancy/postpartum",
"    </span>",
"    stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The strong association may reflect the increased likelihood of accurately coding migraine in women who have had a stroke and in the minority of women whose migraines have been particularly active during pregnancy or postpartum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link&amp;anchor=H20#H20\">",
"     \"Headache, migraine, and stroke\", section on 'Women'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24458?source=see_link\">",
"     \"Cerebrovascular disorders complicating pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Treatment of migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of migraine in pregnant women differs somewhat from treatment of nonpregnant women because of concerns about adverse fetal drug effects. We begin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    because it has the best maternal-fetal safety profile. If ineffective, we move on to other drugs in the order listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314478\">",
"    <span class=\"h4\">",
"     Acetaminophen alone or combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We initiate therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . Acetaminophen (1000 mg) can be an effective treatment of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/24\">",
"     24",
"    </a>",
"    ] and extensive evidence from large case series suggests that it does not increase the risk of adverse effects on pregnancy or the fetus (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H394093#H394093\">",
"     \"Initial prenatal assessment and patient education\", section on 'Acetaminophen'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Migraine that does not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    alone may be relieved with combination therapy such as acetaminophen (650 to 1000 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (10 mg);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10328?source=see_link\">",
"     acetaminophen-codeine",
"    </a>",
"    ; or acetaminophen-caffeine-butalbital. Women with migraine that has not responded to these drugs after several days should be evaluated for provoking factors and treated more aggressively (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Treatment of refractory migraine'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    These medications are generally safe for the fetus. Caffeine doses range from 40 to 50 mg in medications for migraine; daily caffeine intake less than 200 mg from all sources is unlikely to be associated with adverse pregnancy effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20026?source=see_link&amp;anchor=H16#H16\">",
"     \"The effects of caffeine on reproductive outcomes in women\", section on 'Effects of caffeine on reproductive outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged use of butalbital or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    near term can cause neonatal withdrawal in the neonate, but neither of these drugs has been associated with an increased risk of congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"     25",
"    </a>",
"    ]. Prolonged use of barbiturates can also cause vitamin K responsive bleeding in the neonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314485\">",
"    <span class=\"h4\">",
"     NSAIDs and aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , are a second-line option, and safest in the second trimester. In the first trimester, an association with miscarriage and some birth defects (ventricular septal defect, gastroschisis) has been suggested, but available evidence is limited and weak. In the third trimester, their use should be limited to fewer than 48 hours due to concerns about premature ductal closure, platelet inhibition, and oligohydramnios. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H20#H20\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Third trimester use of NSAIDs and aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Minimal fetal or maternal risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Information on use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    early in pregnancy is more limited than for other NSAIDs and not associated with an increased risk of congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/26\">",
"     26",
"    </a>",
"    ]. It has been used as a tocolytic in laboring women without adverse",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    effects.",
"   </p>",
"   <p>",
"    Although salicylates readily cross the placenta, a 2002 meta-analysis did not find clear evidence of an overall increase in risk of congenital defects associated with first trimester use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/27\">",
"     27",
"    </a>",
"    ]. Some case-control studies have reported associations between human congenital malformations and aspirin use early in gestation, but no consistent adverse outcome attributable to aspirin use has been observed. Aspirin is generally avoided in the third trimester because of its effects on maternal and fetal platelets and risk of premature closure of the ductus arteriosus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314499\">",
"    <span class=\"h4\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) are a third-tier option. Because they can be given by rectal, intravenous, or intramuscular administration, opioids can be useful for treatment in women with nausea and vomiting.",
"   </p>",
"   <p>",
"    These drugs should not be used on a chronic basis since they are habit-forming and can contribute to the development of medication overuse and chronic daily headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. They may also worsen the",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    and constipation associated with pregnancy. All opioids have potential for maternal addiction and neonatal withdrawal; thus, they should not be used for prolonged periods of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314506\">",
"    <span class=\"h4\">",
"     Triptans",
"    </span>",
"    &nbsp;&mdash;&nbsp;For moderate to severe symptoms in patients who do not respond to other drugs, triptans can be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     Sumatriptan",
"    </a>",
"    (100 mg orally, 4 to 6 mg subcutaneously, or 5 to 25 mg intranasally),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"     rizatriptan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"     naratriptan",
"    </a>",
"    are selective serotonin agonists that are highly effective in treating migraine headaches. They selectively vasoconstrict brain vessels, but there is a theoretic possibility of vasoconstriction of uteroplacental vessels and increased uterotonic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/30\">",
"     30",
"    </a>",
"    ]. Human experience with triptan exposure during pregnancy primarily involves sumatriptan and has been generally reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"     25",
"    </a>",
"    ]. A pregnancy registry for sumatriptan exposure during pregnancy did not find an increased risk of birth defects or miscarriage in 600 exposed women, including 514 first trimester exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"     25",
"    </a>",
"    ]; however, one study reported an increase in low birth",
"    <span class=\"nowrap\">",
"     weight/preterm",
"    </span>",
"    birth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/31\">",
"     31",
"    </a>",
"    ]. Information on triptans other than sumatriptan is limited. The Norwegian Mother and Child Cohort Study found no significant association between triptan therapy during the first trimester and major congenital malformations compared to the general obstetric population of Norway (3 percent versus 2.9 percent in controls [women with migraine but no triptan use and women without migraine]; adjusted OR (aOR) 1.0, 95% CI 0.7-1.2; n = 1387 exposures, 47 percent were to sumatriptan) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/32\">",
"     32",
"    </a>",
"    ]. Women who used triptans in the second and third trimesters had a slightly increased risk of uterine atony (aOR 1.4, 95% CI 1.1-1.8) and blood loss at delivery, but the authors hypothesized that this was related to persistent migraine rather than its treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=see_link\">",
"     Frovatriptan",
"    </a>",
"    is less desirable than other triptans because of its longer half-life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314513\">",
"    <span class=\"h4\">",
"     Drugs to reduce nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The H1 antagonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    (25 mg orally),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (25 to 50 mg orally), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    (12.5 to 25 mg orally, per rectum, or intramuscularly) are preferred in pregnancy to relieve nausea and vomiting associated with migraine or migraine therapy. Dopamine antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (10 mg intravenously, intramuscularly, or orally) or phenothiazines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    (10 mg intravenously, intramuscularly, or orally) are effective, but acute dystonic reactions sometimes occur in the mother. As an alternative,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    (4 to 8 mg orally or intravenously), a 5HT3 antagonist, may be used to treat severe nausea and vomiting associated with severe migraine headaches. The safety profiles of all of these drugs and other anti-emetics used in pregnant women are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=see_link\">",
"     \"Treatment and outcome of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314520\">",
"    <span class=\"h4\">",
"     Other drugs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       Ergotamine",
"      </a>",
"      is",
"      <strong>",
"       absolutely contraindicated",
"      </strong>",
"      <strong>",
"       during pregnancy",
"      </strong>",
"      because of the potential to induce hypertonic uterine contractions and",
"      <span class=\"nowrap\">",
"       vasospasm/vasoconstriction,",
"      </span>",
"      which could cause adverse fetal effects. Postpartum use is reasonable; contraindications are the same as for nonpregnant women (eg, hypertension; concurrent use of protease inhibitors, azole antifungals, and some macrolide antibiotics).",
"     </li>",
"     <li>",
"      Isometheptene is a sympathomimetic amine that is used for relief of migraine and tension-type headaches. It is sold in combination with dichloralphenazone and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . There is no information on its use in pregnancy and other alpha adrenergic agents have been shown to compromise uterine blood flow; therefore, it should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314527\">",
"    <span class=\"h4\">",
"     Nonpharmacologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapies, such as hydration, massage, ice packs, relaxation, biofeedback, and lifestyle changes (rest, sleep, regular meals, avoidance of triggers) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H23#H23\">",
"     \"Preventive treatment of migraine in adults\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Treatment of refractory migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;For severe, refractory migraine, our preference is intravenous hydration, an antiemetic, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (1 gram intravenously over 15 minutes) or an intravenous opioid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. If unsuccessful, combination therapy with a triptan and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    (2.5 mg intravenously every 30 minutes up to 3 doses) appears to be effective, but can be associated with extrapyramidal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/35\">",
"     35",
"    </a>",
"    ]. Droperidol has no proven teratogenic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"     25",
"    </a>",
"    ]. However, droperidol has been associated with QTc prolongation and the development of torsades de pointes in at least 20 cases reported to the United States Food and Drug Administration (FDA), prompting it to issue a",
"    <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173778.htm\">",
"     black box warning",
"    </a>",
"    in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids may be useful in intractable cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    (20 mg orally four times daily for two days) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (4 mg orally, 21 tablets over six days) are the preferred glucocorticoids because they are metabolized by the placenta and have minimal fetal effects, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    readily cross the placenta and are more metabolically active in the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/38\">",
"     38",
"    </a>",
"    ]. Use of glucocorticoids in the first trimester may increase the risk of oral clefts.",
"   </p>",
"   <p>",
"    Medication overuse headaches may develop with frequent (daily) use of analgesics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , in women with recurrent headaches. Medication overuse headaches may be confused with migraine and can develop in patients with migraine; the diagnosis should be suspected in patients who have persistent daily headaches despite the regular use of analgesic medications. The only treatment is cessation of the offending drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3624?source=see_link&amp;anchor=H8#H8\">",
"     \"Headache syndromes other than migraine\", section on 'Medication overuse headache'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Prophylactic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with frequent migraine headaches often benefit from preventative therapy. This may include daily use of beta-blockers and calcium channel blockers in the lowest effective dose, and cognitive and behavioral therapy. Co-management with a neurologist is essential in these difficult cases. The preventive treatment of migraine is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Beta-blockers",
"      </strong>",
"      such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      are not teratogens, but",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      effects from beta-blockade are possible with prolonged use and include: mild fetal growth restriction; mild transient neonatal bradycardia, respiratory depression, hyperbilirubinemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypoglycemia. Growth restriction may be more of an issue with atenolol than with other beta-blockers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"       \"Management of hypertension in pregnant and postpartum women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short and long acting",
"      <strong>",
"       calcium channel blockers",
"      </strong>",
"      are commonly used in the third trimester for treatment of hypertension and preterm labor, without adverse",
"      <span class=\"nowrap\">",
"       fetal/pregnancy",
"      </span>",
"      effects. Congenital anomalies have been observed in animal reproduction studies, but may not have been a direct effect. An increase in congenital anomalies has not been reported in humans, although information is limited [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      is the preferred agent because it is relatively safe, and has good tolerability and ease of use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"       \"Preventive treatment of migraine in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low dose antidepressants, such as selective serotonin reuptake inhibitors (SSRI), serotonin&ndash;norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants (TCA), may be considered in refractory patients, particularly those with suspected underlying chronic depressive illness or postpartum depression. Antidepressants have not been clearly associated with an increased risk of congenital anomalies, but can have neonatal effects when taken in the third trimester. The risks of these drugs in pregnant and breastfeeding women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link&amp;anchor=H4#H4\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Effect of antiepileptic drugs on the fetus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H7#H7\">",
"     \"Depression in pregnant women: Management\", section on 'SSRIs and SNRIs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H22#H22\">",
"     \"Depression in pregnant women: Management\", section on 'Tricyclic antidepressants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11736?source=see_link\">",
"     \"Infants with antenatal exposure to serotonin reuptake inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For refractory patients without a history of depression,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is an option. Some anticonvulsants, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , are teratogenic and should be avoided.",
"   </p>",
"   <p>",
"    Although there are no studies reviewing their use in pregnancy, nutraceuticals may be considered for migraine prophylaxis. The most commonly used are magnesium 400 to 800 mg daily, riboflavin 400 mg daily, or extract of butterbur root 50 to 100 mg twice daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H13#H13\">",
"     \"Preventive treatment of migraine in adults\", section on 'Other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tension-type headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headaches are the most common type of headache. They are characterized by feelings of pressure or tightness all around the head, and have a tendency to wax and wane in intensity. Gastrointestinal upset and heightened sensitivity to light, sound, and smell may occur, but are more typical of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/39\">",
"     39",
"    </a>",
"    ]. Tension-type headaches had been attributed to muscle aches from psychological stress. The trigeminal neurovascular system and unstable serotonergic neurotransmission likely play an important role in the pathogenesis of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link&amp;anchor=H3#H3\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to migraine, the frequency of tension-type headaches usually does not change during pregnancy since these headaches are not hormonally mediated. In one study where migraine and tension-type headaches were ascertained by a clinical interview and examination, 48 percent of migraine patients improved during pregnancy compared with only 28 percent of patients with tension-type headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/40\">",
"     40",
"    </a>",
"    ]. In this study, primigravida had fewer headaches during pregnancy, while multiparous women had no significant change in headache frequency.",
"   </p>",
"   <p>",
"    One prospective cohort study reported an increased risk of preterm birth &lt;37 weeks in women with tension-type headaches compared with women without headaches (8.7 versus 2.9 percent), but this was likely due to chance given the unusually low rate of preterm birth in the controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment of tension-type headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute treatment of tension-type headache in adults is similar in pregnant and nonpregnant women, and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=see_link\">",
"     \"Tension-type headache in adults: Acute treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is the first-line analgesic for treatment of tension-type headaches during pregnancy and NSAIDs are a second-line medical therapy, with the caveats described above (see",
"    <a class=\"local\" href=\"#H314478\">",
"     'Acetaminophen alone or combination therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H314485\">",
"     'NSAIDs and aspirin'",
"    </a>",
"    above). &nbsp;",
"   </p>",
"   <p>",
"    If monotherapy is ineffective, a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    500 mg and caffeine 100 mg is a reasonable third tier. The use of butalbital and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    may be considered when other drugs have been ineffective or NSAIDS are contraindicated (eg, the third trimester of pregnancy), but prolonged use should be avoided due to the potential for drug dependency and medication overuse headaches. Butalbital should be limited to only four to five days per month and codeine to no more than nine days per month to avoid development of medication overuse headaches.",
"   </p>",
"   <p>",
"    Nonpharmacologic interventions include heat, ice, massage, rest, and biofeedback (eg, psychotherapy, relaxation therapy, and biofeedback) and are useful in managing chronic tension-type headaches. Physical therapy also may reduce the frequency of headaches in some women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cluster headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headaches are repetitive headaches that occur for weeks to months at a time, followed by periods of remission. The pain of cluster headache begins quickly, reaches a crescendo within a few minutes, and is usually excruciating. It is always unilateral and associated with cranial autonomic symptoms (eg, nasal stuffiness, lacrimation, facial sweating, eyelid edema). Men are affected more commonly than women; the peak age of onset is 25 to 50 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cluster headaches are probably not affected by reproductive events [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In a study that examined the clinical features of headache and the physiologic events related to reproductive life in 82 women with these headaches compared to a control group, the course of cluster headache was not altered by menstruation, pregnancy, or the puerperium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/42\">",
"     42",
"    </a>",
"    ]. However, others have reported improvement. In one study, six of eight women with a history of cluster headaches who became pregnant reported remission during their nine pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/45\">",
"     45",
"    </a>",
"    ] and another noted that 3 of 58 women with a history of cluster headaches commented that they were due for a bout of headaches when they became pregnant, but missed the bout [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/46\">",
"     46",
"    </a>",
"    ]. In one subject, the bout started postpartum after two pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment of cluster headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;First- and second-line therapies (oxygen, triptans) are similar to those in nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=see_link\">",
"     \"Cluster headache: Acute and preventive treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abortive therapy of cluster headaches can be difficult because of the short duration of each episode. In most patients, acute cluster headaches can be aborted by inhalation of 100 percent oxygen. If this is unsuccessful, subcutaneous or intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    is a reasonable option. As discussed above (see",
"    <a class=\"local\" href=\"#H314506\">",
"     'Triptans'",
"    </a>",
"    above), human experience with sumatriptan exposure in several hundred pregnancies has been reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If response to these therapies is suboptimal, 0.5 mL",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    4% can be placed inside the nostril on the affected side of the head; extensive experience with local anesthesia in pregnancy suggests that it is not associated with significant adverse reproductive or teratogenic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     Ergotamine",
"    </a>",
"    is effective but",
"    <strong>",
"     absolutely contraindicated",
"    </strong>",
"    <strong>",
"     during pregnancy",
"    </strong>",
"    because of the potential to induce hypertonic uterine contractions and",
"    <span class=\"nowrap\">",
"     vasospasm/vasoconstriction,",
"    </span>",
"    which could cause adverse fetal effects. Postpartum use is reasonable; contraindications are the same as for nonpregnant women (eg, hypertension; concurrent use of protease inhibitors, azole antifungals, and some macrolide antibiotics).",
"   </p>",
"   <p>",
"    When preventive therapy is indicated, the two best options during pregnancy are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/47\">",
"     47",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Treatment of refractory migraine'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Prophylactic treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Alternative treatments after the first trimester of pregnancy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    (first trimester exposure has been associated with Ebstein's anomaly in the fetus and third trimester exposure has been associated with signs of lithium toxicity in neonates) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    (first trimester exposure has been associated with cleft lip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palate) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"     25",
"    </a>",
"    ]. Third-line agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/15/40181?source=see_link\">",
"     pizotifen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , intranasal application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , and oral melatonin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/47\">",
"     47",
"    </a>",
"    ]. Pizotifen, gabapentin, and valproate should not be used in the first trimester because valproate has been associated with fetal congenital anomalies and other adverse effects and there is only sparse information on gabapentin and pizotifen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/25\">",
"     25",
"    </a>",
"    ]. There is minimal information on use of capsaicin and melatonin in pregnancy, but they are unlikely to be harmful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link&amp;anchor=H1561534#H1561534\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Lithium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link&amp;anchor=H4#H4\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Effect of antiepileptic drugs on the fetus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTPARTUM HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postpartum period is characterized by hormonal and other physiological changes, sleep deprivation, irregular food intake, psychological stress, and fatigue. In addition, many women have had a neuraxial anesthetic for labor and delivery. These are all risk factors for development of headache.",
"   </p>",
"   <p>",
"    Although headache is common postpartum, the prevalence across studies varies widely depending on the definitions used, method of ascertainment (eg, discharge diagnosis, postal survey, patient evaluation), timing (two to four days postpartum to one year after delivery), and patient population (eg, breastfeeding status).",
"   </p>",
"   <p>",
"    In a prospective cohort study in which most of the 381 postpartum patients had mild or moderate headache pain, the most common etiologies were tension-type, migraine, and",
"    <span class=\"nowrap\">",
"     musculoskeletal/cervicogenic",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/49\">",
"     49",
"    </a>",
"    ]. In a retrospective study of 95 women with severe unrelenting headache greater than 24 hours and less than 42 days from the time of delivery, the types and frequencies of headache were tension-type (39 percent),",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    (24 percent), postdural puncture (16 percent), migraine (11 percent), pituitary",
"    <span class=\"nowrap\">",
"     hemorrhage/mass",
"    </span>",
"    (3 percent), cerebral venous sinus thrombosis (3 percent), and other (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/50\">",
"     50",
"    </a>",
"    ]. The authors suggested the following basic guidelines and evaluation of postpartum headache:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preeclampsia should be the initial consideration in women with hypertension and proteinuria. Although seizure is the key finding of eclampsia, it also occurs with other intracranial pathology, including cerebral venous sinus thrombosis, hemorrhage, and tumor. (See",
"      <a class=\"local\" href=\"#H314967\">",
"       'Evaluation for preeclampsia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The presence of worrisome",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H31147023\">",
"       'General approach'",
"      </a>",
"      above), such as new focal neurologic findings or sudden onset of severe headache, always requires neurologic imaging and consultation with a neurologist to rule out migraine with aura and intracranial pathology, such as a stroke, pituitary lesion, cerebral venous thrombosis, subarachnoid hemorrhage, vascular malformation or dissection, meningitis, encephalitis, vasculitis, benign intracranial hypertension, brain tumor, or multifocal segmental vasoconstriction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24458?source=see_link\">",
"       \"Cerebrovascular disorders complicating pregnancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Reversible cerebral vasoconstrictive syndrome is often caused by use of vasoconstrictive drugs (eg, ergots, cocaine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/51\">",
"       51",
"      </a>",
"      ]. The headache is diffuse, sudden and severe, may occur in multiple attacks, and may be associated with confusion, agitation, or focal neurologic signs.",
"     </li>",
"     <li>",
"      If the woman is normotensive and had neuraxial anesthesia for",
"      <span class=\"nowrap\">",
"       labor/delivery,",
"      </span>",
"      an anesthesiologist or neurologist should be consulted for evaluation and treatment of postdural puncture headache (PDPH). The pain in PDPH typically develops within 48 hours of the procedure and is worse on standing or raising the head from the bed and characteristically improves with rest in a supine position; tinnitus, nausea, vomiting, and cranial nerve dysfunction rarely occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link\">",
"       \"Post-lumbar puncture headache\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tension-type headache is the likely diagnosis in women in whom there are no focal neurologic deficits or findings consistent with preeclampsia. Migraine headache with or without aura is also common in this setting, especially in women with a history of migraine (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Migraine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Tension-type headache'",
"      </a>",
"      above). Cluster headache is rare (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Cluster headache'",
"      </a>",
"      above). These headaches are diagnosed according to standard criteria from the International Classification for Headache Disorders (ICHD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H308673\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is guided by the underlying cause of the headache. Non-breastfeeding postpartum women are treated with the same drugs as nonpregnant women. In breastfeeding mothers, medications that are transferred into breast milk and considered potentially harmful to the infant are avoided (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    may cause vomiting, diarrhea, weakness, and unstable blood pressure in the nursing infant). The safety of medication use in breastfeeding mothers can be checked by searching on the drug name in UpToDate and reading the lactation section of the drug information topic, or by searching on the drug name in other resources, such as",
"    <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\">",
"     LactMed",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Postdural puncture headache is often treated with a blood patch; breastfeeding is not a contraindication. Prophylactic epidural blood patch after unintentional dural puncture has been performed for the prevention of postdural puncture headache [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link&amp;anchor=H10#H10\">",
"     \"Post-lumbar puncture headache\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314967\">",
"    <span class=\"h1\">",
"     EVALUATION FOR PREECLAMPSIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia must be considered in every pregnant woman over 20 weeks of gestation with headache. The gradual development of hypertension and proteinuria in pregnancy is most often due to preeclampsia, particularly in a primigravida. These findings typically become apparent in the latter part of the third trimester and progress until delivery. In some patients, however, symptoms begin in the latter half of the second trimester, while other women have onset during delivery or the early postpartum period. The absence of hypertension and the absence of proteinuria in a woman with headache are reasonable criteria for excluding the diagnosis of preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Headache is considered a manifestation of severe preeclampsia and a potential precursor of eclampsia (preeclampsia with seizure) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/53\">",
"     53",
"    </a>",
"    ]. The headache is typically diffuse, constant, and mild to severe in intensity. The diagnosis of preeclampsia-related headache is supported by the presence of scotomata or other visual problems (eg, blurred vision, double vision, photophobia, amaurosis, hemianopsia), epigastric pain, or laboratory findings of thrombocytopenia, elevated liver function tests, hemolysis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated creatinine (",
"    <a class=\"graphic graphic_table graphicRef60502 \" href=\"UTD.htm?17/15/17659\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The cause of headache in severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    is not known, but may be related to increased cerebral perfusion pressure (eg, hypertensive encephalopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], cerebral ischemia from vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/54\">",
"     54",
"    </a>",
"    ], posterior reversible encephalopathy syndrome (PRES) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/56\">",
"     56",
"    </a>",
"    ], cerebral edema, or microhemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/57\">",
"     57",
"    </a>",
"    ]. PRES is characterized by a headache of acute onset, possibly with seizures, altered mental status (confusion), restlessness, and a spectrum of cortical visual disturbances. It is considered a variant of hypertensive encephalopathy, although an elevation of blood pressure is not required for the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24458?source=see_link\">",
"     \"Cerebrovascular disorders complicating pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neurologic examination is normal if the etiology of headache is uncomplicated severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia.",
"    </span>",
"    Cerebral venous thrombosis should be considered in any woman with severe preeclampsia or eclampsia who complains of unremitting headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\"",
"    </a>",
"    .) Lateralizing neurologic signs and symptoms suggest stroke, but severe headache is not a common symptom of stroke. Women with focal neurologic symptoms, including hemiplegia, dysphasia, hemisensory loss,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scotoma, may have migraine with aura, which can first present during pregnancy and is more likely to occur in women with a preexisting migraine history than in those with other types of headaches or no headache history [",
"    <a class=\"abstract\" href=\"UTD.htm?4/63/5114/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis of migraine with aura can be challenging and should be made by a neurologist.",
"   </p>",
"   <p>",
"    Neuroimaging studies are indicated in women with a severe headache and:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of an acute cerebral vascular hemorrhage that occurred during pregnancy",
"     </li>",
"     <li>",
"      Malignant hypertension",
"     </li>",
"     <li>",
"      Severe preeclampsia in the setting of preexisting cerebral aneurysm or cerebrovascular arteriovenous malformation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A neurologist or neurosurgeon should be consulted if intracranial pathology is suspected during the work-up, and for evaluation of severe headaches that persist after preeclampsia has been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315088\">",
"    <span class=\"h2\">",
"     Management of preeclampsia/eclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive treatment of",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    is delivery to prevent development of maternal or fetal complications from disease progression. Antihypertensive therapy should be initiated to reduce severe blood pressure elevation (eg, systolic pressure &ge;160 mmHg, diastolic pressure &ge;105 to 110 mmHg) and prevent stroke.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is administered to prevent initial or recurrent eclamptic seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link&amp;anchor=H16#H16\">",
"     \"Preeclampsia: Management and prognosis\", section on 'Seizure prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link&amp;anchor=H12#H12\">",
"     \"Eclampsia\", section on 'Treatment of convulsions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preeclampsia must be ruled in or out in every pregnant woman over 20 weeks of gestation with headache. (See",
"      <a class=\"local\" href=\"#H314967\">",
"       'Evaluation for preeclampsia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New headaches or headaches different from the woman&rsquo;s usual pattern during pregnancy may be due to migraine or tension-type headaches, but many other conditions can present with headache at this time (",
"      <a class=\"graphic graphic_table graphicRef71620 \" href=\"UTD.htm?23/15/23803\">",
"       table 1",
"      </a>",
"      ). A pregnant woman complaining of a headache of sudden onset and intense severity (\"worst headache of my life\"), especially if not typical of her usual headaches, should be evaluated immediately for preeclampsia or an acute neurovascular event. The presence of new focal neurological signs is also an indication for an in-depth evaluation. (See",
"      <a class=\"local\" href=\"#H31147023\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most women with migraine headaches report improvement during pregnancy. For women who request drug therapy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      as first-line acute (abortive) therapy, given its safety profile (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women who do not respond to acetaminophen alone, we suggest acetaminophen combination therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Options include acetaminophen (650 to 1000 mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      (10 mg);",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10328?source=see_link\">",
"       acetaminophen-codeine",
"      </a>",
"      (30 to 60 mg); or acetaminophen (325 mg), caffeine (40 mg), and butalbital (50 mg). If this is unsuccessful, we would try a nonsteroidal anti-inflammatory drug, followed by an opioid and then",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Migraine'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Tension-type headaches are not likely to improve during pregnancy since they are not hormonally mediated. We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      as first-line drug therapy, given its safety profile (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <span class=\"nowrap\">",
"       Non-pharmacologic/behavioral",
"      </span>",
"      interventions are also useful. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tension-type headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The postpartum period is characterized by multiple changes that increase the risk of developing headache. Differential diagnosis includes primary headache (almost always tension-type or migraine) and secondary causes of headache, including",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia,",
"      </span>",
"      postdural puncture headache, and cerebral venous thrombosis. The presence of focal neurologic signs usually requires neurologic imaging and consultation with a neurologist to rule out intracranial pathology. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Postpartum headache'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/1\">",
"      Aegidius K, Zwart JA, Hagen K, Stovner L. The effect of pregnancy and parity on headache prevalence: the Head-HUNT study. Headache 2009; 49:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/2\">",
"      MacGregor EA. Headache in pregnancy. Neurol Clin 2012; 30:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/3\">",
"      Melhado EM, Maciel JA Jr, Guerreiro CA. Headache during gestation: evaluation of 1101 women. Can J Neurol Sci 2007; 34:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/4\">",
"      Contag SA, Bushnell C. Contemporary management of migrainous disorders in pregnancy. Curr Opin Obstet Gynecol 2010; 22:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/5\">",
"      Marcus DA. Managing headache during pregnancy and lactation. Expert Rev Neurother 2008; 8:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/6\">",
"      Silberstein SD. Evaluation and emergency treatment of headache. Headache 1992; 32:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/7\">",
"      Goldberg-Stein SA, Liu B, Hahn PF, Lee SI. Radiation dose management: part 2, estimating fetal radiation risk from CT during pregnancy. AJR Am J Roentgenol 2012; 198:W352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/8\">",
"      Aromaa M, Rautava P, Helenius H, Sillanp&auml;&auml; ML. Prepregnancy headache and the well-being of mother and newborn. Headache 1996; 36:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/9\">",
"      Dixit A, Bhardwaj M, Sharma B. Headache in pregnancy: a nuisance or a new sense? Obstet Gynecol Int 2012; 2012:697697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/10\">",
"      Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993; 43:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/11\">",
"      Ertresv&aring;g JM, Zwart JA, Helde G, et al. Headache and transient focal neurological symptoms during pregnancy, a prospective cohort. Acta Neurol Scand 2005; 111:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/12\">",
"      Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/13\">",
"      Silberstein SD. Headaches in pregnancy. Neurol Clin 2004; 22:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/14\">",
"      Wall VR. Breastfeeding and migraine headaches. J Hum Lact 1992; 8:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/15\">",
"      Marcus DA, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache 1999; 39:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/16\">",
"      Menon R, Bushnell CD. Headache and pregnancy. Neurologist 2008; 14:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/17\">",
"      Adeney KL, Williams MA, Miller RS, et al. Risk of preeclampsia in relation to maternal history of migraine headaches. J Matern Fetal Neonatal Med 2005; 18:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/18\">",
"      Simbar M, Karimian Z, Afrakhteh M, et al. Increased risk of pre-eclampsia (PE) among women with the history of migraine. Clin Exp Hypertens 2010; 32:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/19\">",
"      Facchinetti F, Allais G, Nappi RE, et al. Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study. Cephalalgia 2009; 29:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/20\">",
"      Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/21\">",
"      Sharshar T, Lamy C, Mas JL. Incidence and causes of strokes associated with pregnancy and puerperium. A study in public hospitals of Ile de France. Stroke in Pregnancy Study Group. Stroke 1995; 26:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/22\">",
"      James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/23\">",
"      Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ 2009; 338:b664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/24\">",
"      Lipton RB, Baggish JS, Stewart WF, et al. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000; 160:3486.",
"     </a>",
"    </li>",
"    <li>",
"     www.reprotox.org (Accessed on October 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/26\">",
"      Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin 1997; 15:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/27\">",
"      Kozer E, Nikfar S, Costei A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002; 187:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/28\">",
"      Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/29\">",
"      Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother 2008; 42:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/30\">",
"      Olesen C, Steffensen FH, Sorensen HT, et al. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/31\">",
"      Soldin OP, Dahlin J, O'Mara DM. Triptans in pregnancy. Ther Drug Monit 2008; 30:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/32\">",
"      Nezvalov&aacute;-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Headache 2010; 50:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/33\">",
"      Demirkaya S, Vural O, Dora B, Top&ccedil;uolu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 2001; 41:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/34\">",
"      Rozen TD. Aborting a prolonged migrainous aura with intravenous prochlorperazine and magnesium sulfate. Headache 2003; 43:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/35\">",
"      Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache 1997; 37:377.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173778.htm (Accessed on June 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/37\">",
"      Lucas S. Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep 2009; 13:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/38\">",
"      Solomon GD, Cady RK, Klapper JA, Ryan RE Jr. Standards of care for treating headache in primary care practice. National Headache Foundation. Cleve Clin J Med 1997; 64:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/39\">",
"      Paulson GW. Headaches in women, including women who are pregnant. Am J Obstet Gynecol 1995; 173:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/40\">",
"      Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/41\">",
"      Marozio L, Facchinetti F, Allais G, et al. Headache and adverse pregnancy outcomes: a prospective study. Eur J Obstet Gynecol Reprod Biol 2012; 161:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/42\">",
"      Manzoni GC, Micieli G, Granella F, et al. Cluster headache in women: clinical findings and relationship with reproductive life. Cephalalgia 1988; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/43\">",
"      van Vliet JA, Favier I, Helmerhorst FM, et al. Cluster headache in women: relation with menstruation, use of oral contraceptives, pregnancy, and menopause. J Neurol Neurosurg Psychiatry 2006; 77:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/44\">",
"      Calhoun AH, Peterlin BL. Treatment of cluster headache in pregnancy and lactation. Curr Pain Headache Rep 2010; 14:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/45\">",
"      Ekbom K, Waldenlind E. Cluster headache in women: evidence of hypofertility(?) Headaches in relation to menstruation and pregnancy. Cephalalgia 1981; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/46\">",
"      Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002; 58:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/47\">",
"      J&uuml;rgens TP, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia 2009; 29:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/48\">",
"      Giraud P, Chauvet S. Cluster headache during pregnancy: case report and literature review. Headache 2009; 49:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/49\">",
"      Goldszmidt E, Kern R, Chaput A, Macarthur A. The incidence and etiology of postpartum headaches: a prospective cohort study. Can J Anaesth 2005; 52:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/50\">",
"      Stella CL, Jodicke CD, How HY, et al. Postpartum headache: is your work-up complete? Am J Obstet Gynecol 2007; 196:318.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/51\">",
"      Ducros A, Boukobza M, Porcher R, et al. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007; 130:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/52\">",
"      Agerson AN, Scavone BM. Prophylactic epidural blood patch after unintentional dural puncture for the prevention of postdural puncture headache in parturients. Anesth Analg 2012; 115:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/53\">",
"      Witlin AG, Saade GR, Mattar F, Sibai BM. Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia. Am J Obstet Gynecol 1999; 180:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/54\">",
"      Belfort MA, Saade GR, Grunewald C, et al. Association of cerebral perfusion pressure with headache in women with pre-eclampsia. Br J Obstet Gynaecol 1999; 106:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/55\">",
"      Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992; 159:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/56\">",
"      Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/63/5114/abstract/57\">",
"      Cunningham FG, Twickler D. Cerebral edema complicating eclampsia. Am J Obstet Gynecol 2000; 182:94.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4797 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5114=[""].join("\n");
var outline_f4_63_5114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31147023\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10723790\">",
"      COURSE AND MANAGEMENT OF PRIMARY HEADACHE SYNDROMES IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Treatment of migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H314478\">",
"      Acetaminophen alone or combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H314485\">",
"      NSAIDs and aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H314499\">",
"      Opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H314506\">",
"      Triptans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H314513\">",
"      Drugs to reduce nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H314520\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H314527\">",
"      Nonpharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Treatment of refractory migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Prophylactic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tension-type headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment of tension-type headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cluster headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment of cluster headaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTPARTUM HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H308673\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H314967\">",
"      EVALUATION FOR PREECLAMPSIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H315088\">",
"      Management of preeclampsia/eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4797|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?17/44/18112\" title=\"algorithm 1A\">",
"      Headache in ER I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/42/10914\" title=\"algorithm 1B\">",
"      Headache in ER II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/15/23803\" title=\"table 1\">",
"      Causes of headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/58/41899\" title=\"table 2\">",
"      Common headache syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/19/32059\" title=\"table 3\">",
"      Diff dx headache with fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/15/17659\" title=\"table 4\">",
"      Findings that increase the certainty of dx of preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24458?source=related_link\">",
"      Cerebrovascular disorders complicating pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=related_link\">",
"      Cluster headache: Acute and preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=related_link\">",
"      Estrogen-associated migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=related_link\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11736?source=related_link\">",
"      Infants with antenatal exposure to serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=related_link\">",
"      Post-lumbar puncture headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=related_link\">",
"      Tension-type headache in adults: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20026?source=related_link\">",
"      The effects of caffeine on reproductive outcomes in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=related_link\">",
"      Treatment and outcome of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=related_link\">",
"      Treatment and prognosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_63_5115="Concentrations from osmolal gap";
var content_f4_63_5115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated osmolal concentration of common organic intoxicants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Solvent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration (mg/dL) per 1 mosmol/kg elevation in osmolal gap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methanol",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetone",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isopropanol",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kulig, K, Duffy, JP, Linden, CH, et al. Top Emerg Med 1984; 6:16.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5115=[""].join("\n");
var outline_f4_63_5115=null;
var title_f4_63_5116="WHO immunologic classification for HIV";
var content_f4_63_5116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO immunological classification for established HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        HIV-associated immunodeficiency",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Age-related CD4 values",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;11 months (CD4 percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        12-35 months (CD4 percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        36-59 months (CD4 percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        &gt;5 years (absolute number per mm",
"        <sup>",
"         3",
"        </sup>",
"        or CD4 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None or not significant",
"       </td>",
"       <td>",
"        &gt;35",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &gt;25",
"       </td>",
"       <td>",
"        &gt;500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        30-35",
"       </td>",
"       <td>",
"        25-30",
"       </td>",
"       <td>",
"        20-25",
"       </td>",
"       <td>",
"        350-499",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        25-29",
"       </td>",
"       <td>",
"        20-24",
"       </td>",
"       <td>",
"        15-19",
"       </td>",
"       <td>",
"        200-349",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        &lt;20",
"       </td>",
"       <td>",
"        &lt;15",
"       </td>",
"       <td>",
"        &lt;200 or &lt;15 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    CD4 cells expressed as number of cells per mm",
"    <sup>",
"     3",
"    </sup>",
"    or percentage of total lymphocytes.",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization; HIV: human immunodeficiency virus.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization, Geneva, Switzerland, 2007. Copyright &copy; 2007 World Health Organization.",
"     <a href=\"file://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf\">",
"      file://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5116=[""].join("\n");
var outline_f4_63_5116=null;
var title_f4_63_5117="CAP diagnostic testing";
var content_f4_63_5117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical indications for diagnostic testing for community-acquired pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Indication",
"      </td>",
"      <td class=\"subtitle1\">",
"       Blood culture",
"      </td>",
"      <td class=\"subtitle1\">",
"       Sputum culture",
"      </td>",
"      <td class=\"subtitle1\">",
"       Legionella UAT",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pneumococcal UAT",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intensive care unit admission",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Failure of outpatient antibiotic therapy",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cavitary infiltrates",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leukopenia",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Active alcohol abuse",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic severe liver disease",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe obstructive/structural lung disease",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asplenia (anatomic or functional)",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recent travel (within past 2 weeks)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Positive Legionella UAT result",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X&loz;",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Positive pneumococcal UAT result",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pleural effusion",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X&sect;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable; UAT: urinary antigen test.",
"     <br>",
"      * Endotracheal aspirate if intubated, possibly bronchoscopy or nonbronchoscopic bronchoalveolar lavage.",
"      <br>",
"       &bull; Fungal and tuberculosis cultures.",
"       <br>",
"        &Delta; See \"Risk factors pathogens CAP\" for details.",
"        <br>",
"         &loz; Special media for Legionella. See \"Dx Legionella\".",
"         <br>",
"          &sect; Thoracentesis and pleural fluid cultures.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mandell, LA, Wunderink, RG, Anzueto, A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007; 44 (Suppl 2):S27. Copyright &copy;2007 University of Chicago.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5117=[""].join("\n");
var outline_f4_63_5117=null;
var title_f4_63_5118="VO2 DO2 relationships";
var content_f4_63_5118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oxygen delivery (DO2) and consumption (VO2)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the normal state (blue line), oxygen consumption is constant over a range of DO2, and decreases only when DO2 falls below a critical level (critical DO2). Pathologic changes caused by sepsis or systemic inflammatory responses (red line) cause increased VO2 and impaired peripheral oxygen utilization, resulting in an elevation in critical DO2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5118=[""].join("\n");
var outline_f4_63_5118=null;
var title_f4_63_5119="Pulmonary osteoarthropathy I";
var content_f4_63_5119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary osteoarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain film of the hand in a 41-year-old woman who presented with severe hand and ankle pain demonstrates marked periosteal new bone formation adjacent to the first metacarpal bone (arrows). A chest radiograph revealed a large, solitary mass subsequently shown to represent an adenocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_63_5119=[""].join("\n");
var outline_f4_63_5119=null;
